Hepatitis B core evolution and cellular localisation by Jazayeri, Seyed Mohammed
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
HEPATITIS B CORE EVOLUTION 
AND CELLULAR LOCALISATION
BY 
SEYED MOHAMMED JAZAYERI
A thesis presented for the degree of Doctor of Philosophy,
IBLS
University of Glasgow
Division of Virology 
Church Street 
Glasgow
October 2003
ProQuest Number: 10800572
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10800572
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
GLASGOW ) 
UNIVERSITY
.LIBRARY: ,
I2>3zs 
CO?V t
To my dear wife and daughters,
Reihaneh and Sepideh 
that really without whose affection, love, support and patience, 
this thesis would not have been possible
Finally, last but not least, without the support of my wife I would never have started the 
work towards this thesis. Also, I wish to thank my parents for relentlessly begging the 
question "Have you finished it yet?"
-The author was in receipt of Islamic Republic of Iran student scholarship. I thank The 
Ministry of Health and Medical Education for generous financial support. Unless 
otherwise stated, all work presented in this thesis was carried out by the author.
Seyed Mohammed Jazayeri October 2003
II
Summary
HBV core gene has attracted a resurgence of interest recently because it influences the 
outcome of hepatitis B infection. The aims of this study were: to characterise the core 
gene variability in diverse geographic regions and ethnic groups; to determine 
subtype/genotype-specific variants; to specify country/ethnic-specific variants; and to 
identify any relationship between intracellular HBcAg and chronic HB disease.
The current work can be divided into three main parts. In chapter 3, in the first and 
second sections, HBV DNA in 139 sera samples from 12 diverse geographic origins was 
analyzed by sequencing the core gene. We found that certain residues allow definition of 
subtypes and genotypes. Further, specific nucleotide motifs were defined for particular 
countries. We also found, intriguingly, a set of amino acid variants in a majority of 
sequences from South-east Asian patients and also for Western populations. In the second 
section of chapter 3, core gene variability in the Pacific region, the nucleotide diversity of 
the genotype C samples was significantly greater than that of genotype D samples, which 
is consistent with a longer history of HBV infection in genotype C predominant islands. 
Results obtained from this chapter confirm that HBV strains spread within constrained 
ethnic groups and that selection pressure defined the sequence variability within each 
genotype (and subtype). It may be that specific T cell epitopes are specific for particular 
geographic regions, and thus ethnic groups, which may affect the design of 
immunomodulatory therapies, including therapeutic vaccines.
The third section of this thesis (chapter 4) deals with in vitro biological effects of HBV C 
gene variability. Confocal microscopy was used to visualise HBcAg cellular expression 
in 40 clones (including mutagenised samples) from various stages of HB disease from
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patients with different HBeAg/anti-HBe status.. This was correlated with sequence 
variation within B cell epitopes and at the C-terminus. Using site-directed mutagenesis to 
revert C-terminus and B-cell epitope mutated sequences with cytoplasmic expression to 
the original (wild type) sequences led to a shift back to predominantly nuclear and both 
nuclear and cytoplasmic distribution, respectively.
In conclusion, we showed that HBcAg reflects the genotype of the whole genome and 
there are certain residues that are distinct for the HBV genotypes. Moreover, we 
demonstrate that the pattern of HBcAg localisation in vitro is dependent on sequence and 
correlates with the serology of chronic HBV infection. It supports the hypotheses that 
such variants may play a biological role including antigenic expression. This study not 
only has an impact on the design of the therapeutic and prophylactic vaccines, but on our 
understanding of the immune response to different HBVs.
Chapter 5 is composed of a preliminary study on FT09.1 cell line infectivity by HBV. 
This cell line which is transfected with a construct containing human-Annexin V, showed 
propagation of virus in primary and transfer experiments. Due to some difficulties using 
the Cat III laboratory, this project stopped after the first six months of the research 
course. The results obtained during that period have therefore been included in a separate 
chapter (chapter 5).
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Chapter 1 Introduction
CHAPTER 1 GENERAL INRODUCTION
1.1 HBV STRUCTURE AND GENOME ORGANIZATION
Hepadnaviruses are small hepatotropic DNA viruses that can produce persistent 
infections of liver cells, leading to chronic hepatitis and, in some cases, to 
hepatocellular carcinoma. The prototype hepadnavirus is the human hepatitis B virus 
(HBV), but related viruses have also been isolated from several other vertebrate 
species including squirrels, woodchucks, and ducks. Electron microscopy examination 
of partially purified serum derived preparations of HBV revealed the presence of three 
kinds of particles. Complete infectious virions of about 42-nm in diameter which 
consist of a 36-nm icosahedral nucleocapsid of the hepatitis B core antigen (HBcAg) 
and a 7nm lipoprotein bilayer derived from the endoplasmic reticulum (ER) 
membrane of the host (Dane et al., 1970; Patzer et al., 1986; Crowther et al., 1994). 
Three HBV surface proteins of varying sizes (see section 1.3.2) are inserted into this 
lipoprotein bilayer. The viral DNA, a virus encoded RNA-dependent DNA 
polymerase, a protein kinase which phosphorylates HBcAg (see section 1.3.IB) and a 
genome bound protein, covalently linked to the negative strand of HBV DNA, are all 
contained in the nucleocapsid (Albin and Robinson, 1980; Gerlich and Robinson, 
1980).
Small spherical and filamentous forms of non-infectious subviral particles of 20-nm 
diameter are composed of S protein with variable amounts of M and L protein in 
addition to the host derived lipids (Ganem et al., 1996). Although they do not contain 
viral DNA or nucleocapsid, they are highly immunogenic and elicit a strong antibody 
response in most individuals. The concentration of subviral particles often exceeds the 
virion concentration by at least three fold.
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Figure 1.1: Genom ic organisation of HBV.
The outer lines represent the different classes of transcripts. The four major ORFs (S, P, C and 
X) are indicated in the centre. The partially double stranded circle represents the viral genom e, 
showing the prom oters (SIP , S2P, XP and CP), the enhancers (Enhl and Enh II) and direct 
repeats (DR1 and DR2). Taken from Caselm ann, 1996.
Within the core is the 3 to 3.3-kb viral genome and a polymerase activity known to be 
central to its replication. The virion DNA of these viruses is a relaxed circular species 
that is only partially duplex (Fig 1.1). Although the minus strand is full length, its plus 
strand complement is less than unit length, being variably truncated at its 3 ’ end. The 
result is a single stranded gap o f varying extent (20-80% o f the genome). It has been 
shown that host DNA polymerase fills in this gap (reviewed by Kann et al., 1998). 
The most important features o f the genomic DNA, however, are found at its termini: 
the minus DNA strand has a protein covalently attached to its 5 ’ end, whereas the 5 ’ 
end o f the plus strand is covalently linked to a capped oligoribonucleotide. The coding 
organization o f the viral DNA is also summarized in Fig 1.1. The coding organization 
is highly compact, i.e. every nucleotide is within a coding region, and over half o f  the 
sequence is translated in more than one frame. As shown in figure 1.1, there are four
2
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major open reading frames (ORFs), all encoded by minus-strand DNA (Ganem et al., 
1987), these are the surface (S), core (C), polymerase (P), and X protein ORFs. These 
proteins are translated from a series of viral transcripts whose extents are also 
summarized in fig. 1.1 (see below).
1.2 HBV life cycle
Little is known about the early molecular events regarding the nature of the virus- 
receptor interaction, viral uptake or uncoating. However, considerably more is known 
about viral replication, virion release and later events in viral replication. The narrow 
host range of HBV and lack of suitable cell lines for infection are major limitations to 
such studies (for details see chapter 5).
1.2A Attachment to the cell membrane
To date the exact mechanism of attachment and penetration of HBV into human 
hepatocytes is not fully identified. Binding of a viral particle to the human hepatocyte 
plasma membrane is an important step in viral entry and replication of HBV. In this 
interaction, the envelope proteins of HBV are thought to play a crucial role. Although 
there have been many reports during the last two decades of putative receptors, the 
identity of the HBV receptor remains elusive.
It has been suggested that the pre-Sl domain, amino acid residues 21-47, is probably 
the most important attachment site to liver cells (De Meyer et al., 1997; reviewed by 
Cooper, 2003). Besides hepatocytes, many cells of non hepatic origin including 
hemopoetic cells of the B lymphocyte lineage, peripheral blood lymphocytes and even 
some non-human, simian virus 40 transformed cell lines have receptors for the pre-S 1 
(21 to 47) region (Budkowska et a 1., 1993). Several receptors on the liver cell 
membrane have been proposed (Table 1.1). Viral pre-Sl interacts with several 
proteins, which have therefore been suggested as receptor candidates. 
Asialoglycoprotein receptor (ASGPR), a transmembrane molecule specifically
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expressed on the hepatocellular membrane (Treichel et al., 1997), human interleukin-6 
(Neurath et al., 1992), and transferrin (Franco et al., 1992), are all proposed to contain 
recognition sites for the HBV pre-Sl domain. Also, peptides of molecular weight of 
31 kd (Dash et al., 1992), which interact with pre-S2 (Budkowska et al., 1993) have 
been proposed as possible receptors for HBsAg, a finding which questioned the role
Table 1.1 Proposed HBV-binding receptors.
Binding Protein Function Mediator
Albumin receptor 
Transferrin receptor 
IgA receptor 
LDL receptor
Asialoglycoprotein receptor 
Interleukin-6 receptor 
Annexin V
Endocytosis
Endocytosis
Endocytosis
Endocytosis
Endocytosis
Signal transduction
Cell adhesion
Polymerised albumin
Not known
IgA
Apolipoprotein H 
Not known 
Not known 
Direct
GAPD Metabolism Direct
of IgA receptors as an HBV binding site, previously proposed by Pontisso et al., 1992. 
Apolipoprotein H, found on lipoproteins and taken into hepatocytes after binding to 
small HBsAg, has been also suggested (Mehdi et al., 1994; 1996). Furthermore, in an 
attempt to identify cell surface receptor(s) for hepadnaviruses, several proteins which 
have binding sites for the HBV pre-S region have been proposed, including 
glycoproteins of 170-180 kd (Kuroki et al., 1994; Tong et al., 1999), 120 kd (Li et al., 
1996), 80 kd (Ryu et al., 2000) and 44 kd (De Falco et al., 2001).
Among studies performed for identification of receptor(s) in the initiation of infection 
by HBV, the role of Annexin-V has been supported by several observations (De Bruin 
et al., 1995, 1996). Annexin-V, previously referred to as Endonexin II, is a member of
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the family of Ca2+ dependent phospholipid-binding proteins present on human 
hepatocyte plasma membranes (Neurath et al., 1994; Gong et ah, 1999). Annexins 
have also been found to be involved in the initial step of cytomegalovirus and of 
influenza virus (Gong et ah, 1999) and possibly hepatitis Delta virus attachment (De 
Bruin et ah, 1994). Others have argued an important role for human Annexin-V (hA- 
V) in the cell nucleus (Mohiti et ah, 1997). In addition, species-specific distribution of 
the HBsAg binding annexin V apparently correlates with the species tropism of HBV 
(De Bruin et ah, 1996).
The receptor-ligand relationship between hA-V and small HBsAg has been studied by 
using antibodies against hA-V which inhibit the binding of HBsAg to intact human 
hepatocytes (De Meyer et ah, 1997). Spontaneous development of anti-idiotype (and, 
thus, anti-HBsAg) antibodies in rabbits immunised with hA-V and in chickens 
immunised with the F(ab)2 fragment of rabbit anti-hA-V IgG, are able to compete 
with hA-V for the binding to HBsAg (De Bruin et ah, 1995). Neurath and colleagues 
(1994) assumed that hA-V and apolipoprotein H bind sHBsAg via the lipid 
component of HBsAg and not HBV protein specifically.
1.2B Viral entry and uncoating
Although the exact post-binding steps are still unclear, several mechanisms have been 
suggested for viral entry. There is evidence from DHBV that entry proceeds by a pH- 
dependent mechanism (Rigg and Schaller, 1992). Endocytosis has also been described 
(Offensperger et ah, 1991; de Bruin et ah, 1995). Additionally, Lu et ah (1996) 
showed that HepG2 cells internalized HBV after proteolytic cleavage of the preS 
domain by V8 protease. This exposed a fusion domain within the envelope protein of 
HBV that enabled the viral fusion with host cell membranes. It is also not clear in 
what form the viral genome is transported into the cell nucleus since the diameter of 
core particles is at the maximal limit for transport through the nuclear pore (this issue
5
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will be discussed in detail in section 1.3.IB). The HBV genome, once in the nucleus is 
repaired to form its covalently closed circular (ccc) DNA conformation. This process 
requires the following modifications: the removal of its terminal structures (from both 
strands); repair of the single-stranded gap region (by completion of the plus-strand); 
and covalent ligation of the DNA termini. Host cell enzymes are most likely 
responsible for all of these reactions (Kock and Schlicht, 1993).
1.2C Transcription and transcription regulation
Viral ccc HBV DNA is transcribed by host RNA polymerase II. It creates both an 
RNA template for HBV replication and leads to the synthesis of all viral mRNA 
transcripts (Summers and Mason, 1982). There are at least four groups of mRNA 
species produced in hepatocytes (reviewed by Seeger and Mason, 2000) (Fig 1.1). 
These are exported into the cytoplasm where translation of viral proteins, assembly of 
viral particles and genome replication occurs. The largest, 3.5-kb, which is greater 
than genome length, and is termed the pregenome RNA (pgRNA), covers the entire 
genome and is terminally redundant. It is reverse transcribed to DNA. It also acts as a 
message for HBcAg and polymerase protein synthesis. The second, the pre-core 
mRNA, is used to translate HBeAg. Pre-core mRNA consists of longer and shorter 
mRNAs, with start sites separated by~18 nucleotides (Fig 1.2). For HBeAg synthesis 
and secretion, pre-core mRNA needs to be transcribed followed by translation of the 
pre-core and core regions (reviewed by Okamoto et al., 1997). The third set of 
mRNAs, produce the large, middle, and small S proteins. They are initiated at 
different initiation sites. It is unclear if the fourth (0.7kb) makes HBx protein; it may 
be that the pregenome message is also used in this capacity.
It is known that each gene of HBV has one or more promoters regulating its activity 
and that these promoters are in turn regulated by one or both of the viral enhancer 
elements, Enhl (nt 970-1240) and Enh2 (1627-1774), that are located upstream of the
6
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' 8^ '8 Pregenom a'C-P mRNA
1789-1791 Shorter PreC mRNA
Longer PreC mRNA
PreC C
1814 11901 2449
DR2 (1S90-1600) DR1 (1H24-1834)
_z_______ z_______________ HBV DNA
Enhancer II (nt 1685-1773) 
Basic Core Promoter (nt 1742-1849)
I
Core Upstream Regulatory Sequence (nt 1643-174?)
Target Sequence
Fig 1.2. Pregenome and pre-C mRNAs of HBV. Start positions of mRNAs are indicated in 
relation to various genes and elements regulating transcription. Positions of DR1 and DR2 are 
indicated. Taken from Okamoto et al, 1997.
core promoter (Fig 1.2) (reviewed by Seeger and Mason, 2000). To date, four 
promoters (Slpromoter (SIP), S2 promoter (S2P), C promoter (CP), and X promoter 
(XP)) have been identified to be responsible for the transcription of the HBV mRNAs 
(Siddiqui et al., 1986; Treinin and Laub 1987; Honigwachs et al., 1989). Of these four 
promoters, S2P (nt 3045-3180) is the least liver specific. On the other hand, SIP (nt 
2710-2800) and CP are highly liver specific and cells in which CP is inactive can’t 
support HBV DNA replication, as the production of pgRNA which is the template for 
reverse transcription is mostly under the control of this promoter (Seeger et al., 1989). 
XP is partly overlapped with Enhl. In addition to the cellular factors that are 
important for X gene transcription, HBx was shown to have a role in enhancing XP 
activity by binding a 20bp element at its 5’ end (Takada et al., 1996).
A problem of particular importance with a circular DNA template is termination of 
transcription, especially for the pregenome and precore mRNAs. For these, 
transcription must pass through the polyadenylation signal on the first pass in order to 
make a full-size, terminally redundant RNA. Studies with DHBV indicated that this
7
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termination of transcription is facilitated by a sequence on cccDNA, named PET 
(positive effector of transcription), located between the transcription initiation site and 
the poly (A) signal (Huang and Summers, 1994). PET somehow facilitates passage of 
transcription complexes through the termination site on the first but not the second 
passage. A second signal sequence, NET (negative effector of transcription), which is 
needed for termination, is suppressed by PET. If NET is deleted, longer transcripts 
accumulate due to additional transits around the cccDNA template (Beckel-Mitchener 
and Summers, 1997).
Apart from transcription regulation, regulation of viral gene expression also occurs at 
the level of translation. The pregenome serves as the mRNA not only for the viral 
core protein but also for the viral polymerase, which initiates from an AUG located in 
the distal portion of the core gene, although not in the same open reading frame as 
core. However, since core particles are assembled from 240 core protein subunits 
(Crowther et al., 1994), pgRNA may serve as an mRNA for translation, on average, of 
approximately 200 to 300 core polypeptides before allowing the translation of a 
polymerase polypeptide. Since the polymerase preferentially binds to the 5’ end of its 
own mRNA to initiate reverse transcription and packaging (Bartenschlager et al., 
1990; Wang and Seeger, 1993), synthesis of the polymerase is sufficient to stop 
further translation of the pregenome.
Spliced transcripts have also sometimes been detected, but there is so far no evidence 
that RNA splicing plays an important role in HBV gene expression.
1.2D DNA replication
Viral DNA replication is accomplished by reverse transcription of an RNA 
intermediate, after encapsidation of RNA template. Of many viral transcripts 
produced in infected cells, only pregenomic RNA is encapsidated. Encapsidation of 
RNA template with the viral polymerase into the core is followed by sequential
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synthesis of two viral DNA strands. Minus-strand is made first from the RNA 
template, accompanied by degradation of the latter, followed by the plus-strand 
synthesis using the newly synthesized minus-strand as a template.
1.2D-I RNA encapsidation
The sequences of pgRNA required for encapsidation have now been defined. For 
HBV, the 5’ 100 nucleotides suffice to confer efficient encapsidation upon 
heterologous transcripts; this region is termed e. As shown in figure 1.3, this region 
contains several inverted repeats that can be folded into a stem loop structure that 
appears to be phylogenetically conserved (review by Ganem et al., 1994). Extensive 
mutational studies have suggested that this region of the structure is functionally 
important for encapsidation (see section 1.7.3B), as in the loop region at the top of the 
structure, even minimal base substitutions are strongly deleterious to encapsidation 
(Pollack and Ganem, 1993).
1.2D-II DNA synthesis
DNA replication starts with the binding of the viral polymerase to the c bulge at the 5’ 
end of pgRNA (Figure 1.4). The polymerase then primes DNA synthesis, using a 
tyrosine in its own aminoterminal protein domain (TP) as a primer and s as a 
template. After three or four nucleotides the DNA synthesis is arrested. Further DNA 
synthesis requires three switches; one during minus-strand synthesis and two during 
plus-strand synthesis. The first template switch occurs shortly after the priming
reaction. The primed 5’ ---- ► 3’ pgRNA-Pol complex is translocated to a
complementary sequence (UUAC) near the 3’ end of the pgRNA (Fig 1.4B) where the 
synthesis of minus-strand DNA resumes. The minus-strand is then extended to the 5’ 
end of the pgRNA (Fig 1.4C and D). An active role for the polymerase in minus- 
strand DNA transfer has been recently described in DHBV as deletion of aa 79-88 in
9
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Fig 1.3. Predicted stem loop structure of pregenome encapsidation sequence (b) and location of 
the common pre-C HBV mutants. Taken from Lok et al, 1997.
the terminal protein domain specifically inhibited the minus-strand transfer 
reaction(Gong et al, 2000). Accompanying or shortly following the minus-strand 
synthesis, the pgRNA template is degraded by the RnaseH activity of Pol with the 
exception of a short terminal oligoribonucleotide (Fig 1.4D). This oligoribonucleotide 
is then translocated, in the second switch, to DR2 near the 5’ end of minus-strand 
DNA where it serves as the primer for plus-strand DNA synthesis (Lien et al., 1986; 
Loeb et al., 1991). Following this second transfer, the plus-strand DNA synthesis 
continues to the 5’ end of the minus-strand DNA (Fig 1.4H). However, in 
approximately 10% of cases the second switch from DR1 to DR2 does not occur, 
leading to an in situ priming reaction (Staprans et al., 1991) (Fig 1.4E). Thus a double 
strand linear DNA genome rather than relaxed circular DNA (rcDNA) is produced. A 
third template switch occurs once the plus-strand DNA synthesis reaches the 5’ end of 
minus-strand DNA. The minus-strand DNA template contains a 7-9 nt terminal 
redundancy (r). This redundancy is required for the third template switch in which the 
3’ end of the nascent plus-strand is translocated to the 3’ end of minus strand (Loeb et
Chapter 1 Introduction
al., 1997) (Fig 1.41) to circularize the genome and permit resumption of the plus- 
strand synthesis. The synthesis of plus-strand is only partially completed resulting in a 
noncovalently closed, partially double stranded, circular DNA genome (rcDNA).
1.2E Viral assembly
Nucleocapsids containing rcDNA, can be then either enveloped at an internal cellular 
membrane and be actively secreted as mature virions or transported back into the 
nucleus, where the genome is repaired to yield cccDNA, to amplify the intracellular 
genome pool (Tuttleman et al., 1986). Thus, cccDNA amplification is caused not only 
by a reinfection of the cells but by re-entry of the viral genomes (similar to artificial 
transfection) from the mature core particles (Seifer et al., 1993, 1998; reviewed by 
Nassal, 1999) which assemble in the cytosol. Persistence of the virus in infected cells 
during chronic HBV may therefore be dependent on this intracellular conversion 
pathway which generates, maintains, and regulates the pool size of transcriptionally 
active cccDNA molecules (Tuttleman et al., 1986; Serinoz et al., 2003). It is likely 
that these nuclear levels of cccDNA are specifically regulated to maintain amounts 
that are sufficient for virus production but are not toxic to the cells. This amplification 
could be regulated by either a cell-directed mechanism or virus-directed negative 
feedback inhibition (Fig 1.5). Negative control over the conversion of rcDNA would 
be effected through production of viral gene products at both transcription and 
translation levels, whose concentration in the cell is dependent on the size of the 
cccDNA pool (reviewed by Seeger and Mason, 2000). These gene products would 
then block further synthesis of cccDNA directly, or would direct assembly of 
cytoplasmic nucleocapsid exclusively into mature virus (Tuttleman et al., 1986). 
Other authors showed that high amounts of L protein in the ER lumen blocked viral 
maturation (Bock et al., 1999).
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Fig 1.4. HBV genome replication.
The thin line stands for pgRNA, dashed line for the plus strand and the bold line for the m inus 
strand. The direct repeats are presented as boxes labeled DR1 and DR2. The UUAC involved in 
the minus strand tem plate switch are shown. The dashed circle represents the viral P protein, 
which binds the s bulge at the 5' end of pgRNA. The sequences o f the terminal redundancy of 
minus strand DNA are shown as 5'r and 3'r. Basepairing is shown as hatch marks. B, M inus 
strand tem plate switch. C, Elongation of the minus strand. D, com pletion o f minus strand  
synthesis and generation o f the plus strand prim er. E, generation of duplex linear genom e. F, 
plus strand prim er translocation. G, initiation of plus strand synthesis. H, plus strand synthesis 
continues to the 5' terminus of the minus strand DNA. I, circularization tem plate sw itch. J, 
generation of a relaxed circular DNA genom e. Taken from Harvet and Loeb, 1997.
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1.2E-I Surface-gene Regulation
L protein, in addition to S protein, is also required for the assembly and production of 
mature virions; however, most of the preS region is dispensable for this process. The 
L polypeptide when synthesised in an in vitro system, bound firmly to HBeAg, 
indicating that interaction between HBeAg and the pre-S region of the L polypeptide 
is important for virus morphogenesis (Dyson et al., 1995). Using electron microscopy, 
Kamimura et al, (1981) demonstrated that in the presence of L and S proteins, cores 
could bud into the intermediate compartment between the endoplasmic reticulum and 
the Golgi complex, and exit the cell as enveloped virions through the secretary 
pathway.
It has long been known that maturation of HBV virions requires interaction between 
HBV S and core proteins on the ER. This interaction also appears to regulate the 
nuclear transport of HBeAg: Yeh et al, (1994) described that nuclear transport was 
inhibited to an undetectable level in COS-7 cells when S proteins were co-expressed 
with core protein. Further analysis revealed that L but not S protein reduced the 
amount of the core protein in the nucleus and was crucial for this inhibitory effect. 
This effect was attributed to the amino-terminal sequence of L which interacted with 
core protein (Yeh et al., 1994) and specifically to aa positions between 19-24 and 63- 
65 aa in the pre-S domain which are essential in mediating interaction with the 
nucleocapsid (Dyson et al., 1995).
There is an assumption that the pre-S proteins regulate viral cccDNA levels via 
negative feedback (Summers et al., 1990). It is known that overexpression of the L 
protein can block secretion of subviral particles as well as virions (Hadziyannis et al., 
1987; Bock et al., 1999). These authors therefore suggested that early in infection, 
when there are low amounts of surface proteins, mature nucleocapsids are shunted
13
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into the nucleus and the newly synthesised viral genome converted into cccDNA. The 
number of cccDNA molecules increases as infection progresses, leading to an 
increase of viral RNA synthesis. The viral envelope proteins are subsequently 
produced at high levels and exert a negative feedback on cccDNA amplification by 
redirecting the nucleocapsids into the virion formation pathway (Bartholomeusz and 
Locamini, 2001). Failure of regulation of the cccDNA copy number by the envelope 
proteins results in hepatocyte death (Lenhoff et al., 1994). On the other hand, in the 
late stage of infection, when the L protein levels increase, export of core particles (as 
the mature virions) occurs (Yeh et al., 1994).
1.2E-II Cell cycle Regulation
The effect of cell cycle regulation on intracellular core protein has been studied 
extensively by Yeh and co-workers. They showed in transfected cell lines as well as 
human hepatocytes that the core protein localization was largely in the nucleus in the 
Gl/0 phase but in the cytoplasm in the S phase (Yeh et al., 1993, 1995, and 1998). 
They also found that nuclear localization of HBV DNA (RC form) occurred only in 
the G1 phase and that prolonged aphidicolin treatment was required for cccDNA 
formation. Further, they showed that when cells were grown to confluence and 
arrested in the G0/G1 phase, the nuclear transport of core protein was significantly 
increased. These results revealed that hepatocytes in different cell cycle phases are 
associated with different directions of viral DNA traffic. In the G1 phase, the nuclear
14
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Figure 1.5: cccDNA pool formation during the early stages of HBV 
infection. Dotted lines indicate the inhibitory effects of viral gene products 
on cccDNA formation. Taken from Tuttleman 1986.
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RC viral DNA is processed (excision of polymerase, ligation, DNA repair, etc) to 
cccDNA. HBV DNA is recycled into the nucleus to form cccDNA, so only a small 
amount is destined for viral maturation. This small but constant out-flow of virions 
will eventually result in a high concentration of serum HBV DNA. The accumulation 
of cccDNA clearly also results in an increase of total intracellular HBV DNA, which 
can be used for virion maturation. In contrast, in the S phase, nuclear entry of HBV 
DNA does not occur, so the majority of the viral DNA is destined for virion 
maturation. Of note is that a prolonged G1 phase is not the only requirement for 
cccDNA formation, and other cellular factors (which are species specific) must be 
involved (Yeh et al., 1998). This assumption was based on the observation that, in 
transgenic mice, no cccDNA could be found in nuclei, although most hepatocytes 
were in the Gl/0 phase (Guidotti et al., 1994a). Conversely, a constantly regenerating 
liver (as seen in aggressive hepatitis) is unfavorable for HBV replication because the 
G1 phase may not be long enough for ccc DNA accumulation. This explained a 
recent observation that HBV DNA replication is enhanced in quiescent hepatocytes 
(Chu et al., 1997). On the other hand, Guidotti et al (1994, 1997) demonstrated that in 
the absence of certain cytokines, HBV can efficiently replicate in dividing 
hepatocytes, suggesting that HBV gene expression is relatively resistant to signals that 
upregulate or downregulate the expression of cellular genes during liver cell 
regeneration. They also claimed that the nuclear membrane allows translocation of 
only the non-particulate core protein. Further, in separate studies carried out by Yeh 
et al (1990, 1993) and Eckhardt et al (1991), it was suggested that this translocation 
which was dependent on NLS (nuclear localization signal) at the C-terminus (as will 
be discussed next), was regulated through differential phosphorylation of the serine on 
the SPRRR motifs at different cell cycle stages (see below).
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1.3 HBV viral proteins
1.3.1 C protein
1.3.1 A Structure
The regular display o f multiple identical structural features on the HBV core particle 
surface is crucial for its exceptional immunogenicity and ability to act as a T cell 
independent antigen (Nassal et al, 1992a). Two classes o f the core particle have been 
identified: 120 and 90 dimeric subunits in T =4 and T =3 arrangements.
a
£
*  >
b
Figure 1.6. The Tri-dim ensional model o f the HBV capsid protein dim er on the basis o f crystal 
structure (a) and from electron cryom icroscopy (b). Central a-helices (boxes) and the loop 
covering aa residues 78-83 are shown. C and N indicate C-Term inal and N-Term inal dom ains, 
respectively. Taken from W ynne et al, 1999.
The building block o f the capsid structure is a T-shaped dimer (inverted), the stem o f 
which interfaces with the other dimer and protrudes outwards as a spike; the cross-
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pieces pack together to form the contiguous shell (Conway et a l, 1998a) (Figure 1.6). 
This characteristic folding of core protein has been defined by its crystal structure 
(Wynne et a l, 1999) (Fig 1.6a) and by cryoelectron microscopy (Bottcher et al., 1997; 
Conway et al., 1998b) (Fig 1.6, b). The two dimers run from the inside of the capsid 
to the tip of the spike (Kratz et al., 1999), which consists of a four a-helix bundle. 
Amino acid residues 78-82 form a non-helical loop connection between two alpha- 
helical segments (Bringas et al., 1997) at the tip of the capsid spike (Figure 1.6b). The 
region 128-149 forms an arm-like structure that plays a critical role in capsid 
assembly (Hui et al., 1999). This arm or loop makes a small protrusion on the surface 
of the shell and provides the next most exposed and accessible feature on the surface. 
It is known that the principal antigenic sites of the protein correspond to these 
residues. The interaction between dimers to form the icosahedral shell is mediated by 
the C-terminus. This region is positioned within the shell interacting with nucleic acid 
(Bottcher et al., 1997).
With a 30 or 34-nm diameter, the core encapsidates the circular DNA genome. HBc 
protein packages the pgRNA and the viral polymerase. Early studies indicated that the 
C-gene encoded two polypeptides. Initiation of translation at the first AUG of the pre- 
C region in a “pre-C-mRNA” produces a 25-kd pre-core/core precursor protein 
(p25e), which after removal of the leader sequence at the amino-terminus (first 19 
residues) and the 34 C-terminal aa (Takahashi et al., 1983), is secreted as a soluble 
17-kd protein (pl7e), HBeAg (Fig 1.7). The C-terminus marks the processing site in 
the sequence (146) T V V R R R G (153) (Figure 1.8) that is selectively cleaved 
during HBeAg secretion in vivo, and the 10 amino acids remaining from the pre-C 
sequence are essential for the correct folding of HBeAg (Nassal et al., 1993). Non- 
carboxy-terminally processed pre-core/core gene products comprised of 193 aa from
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position -10 (the site of signal cleavage during HBeAg secretion) to 183, are 
designated p22e (Figure 1.7) (Salfeld et al., 1989).
Initiation at the second AUG in the pgRNA, leads to the synthesis of HBeAg, a 183 
aa, 21 kd, protein (p21c). Icosahedral shells of two sizes are produced, containing 180 
(T=3, where T is the triangulation number and the shell contains 60T subunits), or 
240 (T=4) subunits, which assemble to form the viral core (Wingfield et al., 1995). 
Core protein is 183 or 185 residues long depending on the subtype. Despite pl7e and 
p21c sharing a large stretch of identical primary sequence, HBeAg and HBeAg are 
serologically distinct (see section 1.6). HBeAg is always present in a non-particulate 
state in the serum of HBV infected individuals, whereas HBeAg occurs only in the 
enveloped virus or inside HBV infected hepatocytes (Salfeld et al., 1989). 
Immunofluorescence studies strongly suggest that expression of the pre-C gene 
determines the attachment of the nascent p25e to the membrane of the ER. The 
affinity of the pre-C protein to cellular membrane and its amino terminal sequence 
resembles the properties of signal peptides known to transport proteins through 
cellular membranes, an event which is a pre-condition for acquiring the viral envelope 
and subsequent secretion (Ou et al., 1986; Uy et al., 1986; Ballare et al., 1989; 
reviewed by Okamoto, 1997). This translocation requires the first 19 residues of the 
pre-core protein as a signal peptide to direct it to the ER (Garcia et al., 1988), where 
they are cleaved with the formation of a pre-C protein-derivative, p22e (Ou et al., 
1986; Garcia et al., 1988). P22e is then released in the ER and Golgi apparatus with 
further hydrolysis at the arginine-rich C-terminus prior to secretion (pl7e); some 
p22e, however, is released into the cytoplasm and translocates to the nucleus (Figure 
1.7). For this, it requires the first 10 aa residues as a nuclear localisation signal 
(Garcia et al., 1988; Ou et al., 1989; Yeh et al., 1990).). Thus, the pre-C sequence
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alters profoundly the properties of the viral core protein (Uy et al., 1986); if the 
proximal pre-C sequence is replaced by a random sequence, the resulting mutant 
protein cannot be transported into the nucleus (Yeh et al., 1990). Thus, the 29 aa 
residues preceding the core protein might function as a signal peptide for secretion of 
HBeAg or as a nuclear transportation signal for p22e. (Yeh et a l, 1991; reviewed by 
Okamoto, 1997). Both P22e and core protein (p21c) contain nuclear localisation 
sequences, but in different positions (for core protein nuclear localisation signal see 
section 1.3.IB); there are 10 additional residues at the amino-terminus of P22e and 
therefore, the cellular regulation of nuclear transport of these two proteins may be 
different (Yeh et al., 1996). Therefore, HBeAg expressed without the pre-C sequence 
(p21c) accumulates as a high molecular weight complex in the cytoplasm; in contrast, 
the HBeAg produced with the pre-C sequence can be a nuclear protein. Thus, the fact 
that a significant proportion of p22e is retained within the cell nucleus indicates that 
p22e plays an important role in the HBV life cycle (Ou et al., 1989; Aiba et al., 1997). 
1.3.1B C protein C-terminal domain and its phosphorylation 
The core protein consists of two structurally and functionally separate domains: the 
sequence from the N-terminus to about aa position 149 is by itself sufficient for 
assembly, known as the “assembly” domain, and a “protamine” domain at the C- 
terminus, which is involved in pregenome encapsidation and modulates the activity of 
polymerase for reverse transcription of the RNA pregenome and binding to the 
elongating DNA (Hui et al., 1999). If the C-terminus is truncated (after aa 140), the 
core protein still assembles into a shell, but no longer packages RNA (Bottcher et al.,
1997).
The C-terminus 33 aa of core contains 16 (adr and ayw subtypes) or 17 (adw subtype) 
arginine residues; 14 of them are clustered into 4 arginine repeats, in line with its role
20
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Figure 1.7: Hypothetical model for the assembly of HBV particles.
P22e processed from p25e binds to the ER (membrane-bound core protein). There are 
alternatives: molecules may be transported into the lumen, perhaps processed, and secreted as 
HBeAg (pl7e). HBeAg translated from core-mRNA (p21c) remains in the cytoplasm and 
interacts with pregenomic RNA to form core particles. Some of the p21 exists in the HBeAg form. 
The core particles containing HBV RNA or DNA may then interact with HBeAg and HBsAg and 
become encapsidated, presumably via a budding process, with consequent formation of mature 
viral particles. CmRNA and SmRNA, represent core mRNA and surface mRNA, respectively.
in nucleic acid binding (Figure 1.8) (Nassal et al., 1992b). These regions of 
consecutive basic aa are similar to nuclear localisation sequences identified in several 
nuclear proteins: (Eckhardt et al., 1991); influenza viruses (Greenspan et al., 1988); 
Ela in adenoviruses (Lyon et al., 1987); yeast histone 23 protein (Moreland et al., 
1987); yeast ribosomal protein L29 (Underwood et al., 1990); large-T protein of 
polyoma virus (Richardson et al., 1986); and SV40 large-T Ag (Kalderon et al.,
1984).
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The C-terminal domain seems crucial for HBeAg production. HepG2 cells infected 
with a recombinant vaccinia virus expressing a pre-C protein truncated by 34 aa at the 
HBeAg C-terminus secreted about 20 times less HBeAg than those infected with a 
recombinant expressing the entire precore protein (Schlicht et al., 1991). Thus, low 
secretion efficiencies of C-terminally truncated precore proteins are due to a slow 
down in intracellular transport of the HBeAg precursor (Carlier et al., 1995). Taking 
all the data together, one possible function of the pre-C protein might be to transport 
progeny viral genomes from the cytoplasm into the nucleus, where they can direct the 
synthesis of additional RNA and eventually increase the number of progeny particles 
produced by the infected cells. The relatively higher expression of pre-C over core 
results in translation of a greater amount of pre-C protein. This is then either secreted 
as HBeAg or transported to the nucleus as nuclear HBeAg (Ou et al., 1990). This 
hypothesis is in keeping with the clinical observation of high levels of serum HBV 
DNA/HBeAg and the predominant localization of HBeAg in the nucleus during this 
phase (see section 1.7.3D) (Hadziyannis et al., 1983; Wu et al., 1987; Hsu et al., 1987; 
Akiba et al., 1987; Chu et al., 1997). In contrast, expression of the pre-C protein is 
relatively lower than that of core in the low replicative phase.
HBeAg is a nuclear, cytoplasmic, and membrane-associated phosphoprotein 
(Roossink et al, 1987) that shuttles between cytoplasm and nucleus during the 
different stages of chronic infection (Chu et al., 1987; Hsu et al., 1987; Akiba et al., 
1987). It is generally believed that viral assembly of hepadnaviruses occurs in the 
cytoplasm as the capsid proteins are localised there (Yeh et al., 1996). Since diffusion 
of molecules smaller than 60 kd is allowed through a 9-11 nm aqueous channel, 
transport of large proteins requires one or more of the signal sequences to induce 
opening of the nuclear pore complex up to a diameter of about 26 nm (Pante et al.,
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1993). Thus, the 30-34 nm HBV core particle is excluded (reviewed by Kann, 1997). 
Also, the nuclear membrane itself is a natural barrier for intact core particles in 
transgenic mice, and core particles can only migrate to the cytoplasm during mitosis 
when the nuclear membrane is disintegrated (Guidotti et al., 1994a). This allows core 
protein, which had formed capsid-like particles in the nucleus, to be released back 
into the cytoplasm (Liao et al., 1995). After cytoplasmic disassembly of core particles, 
HBeAg remains associated with the viral genome. This nucleoprotein complex is then 
targeted to the nuclear pore complex (NPC) by the use of the core protein nuclear 
localisation signals, where it is translocated through the pore complex into the nucleus 
(Bock et al., 1996).
During the early phase of infection, because of the quiescent state of hepatocytes, 
nuclear entry of the core will be facilitated. This nuclear localisation may be 
important for transporting the HBV DNA into the nucleus for initiating viral mRNA 
transcription. Also, the nuclear localisation of the core is important for transporting 
the viral DNA into the nucleus for cccDNA amplification. Late during infection, 
production of large viral envelope protein inhibits the former, redirecting viral 
nucleocapsids into enveloped virus particles, which are exported from the cell 
(Summers et al., 1990). Thus, control of cccDNA amplification is necessary for the 
ability of hepadnaviruses to infect cells persistently without cytopathic effects.
Within the last few years, considerable progress has been made in understanding the 
role of the C-terminus arginine-rich clusters of the HBV core protein. HBeAg can be 
phosphorylated in vivo (Roossinck et al., 1987) and in vitro (Albin and Robinson, 
1980; Gerlich et al., 1982; Petit et al., 1985). While the core protein phosphorylation 
may be important for pre-genomic RNA packaging, its dephosphorylation may be 
important for viral DNA replication (Lan et al., 1999). It may even regulate
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maturation of the virion (Pugh et al., 1989), as Gazina et al, (2000) reported that HBV 
core protein was phosphorylated prior to assembly into nucleocapsids. Previous 
studies have shown that core protein contains one or more NLS (Yeh et al., 1990; 
Eckhardt et a l, 1991) which may not be exposed on the surface of the core particles 
(Kann et al., 1999). However, Eckhardt et al, (1991) proposed two nuclear 
localisation sequences (Fig 1.8), suggesting that at least a portion of each of these 
regions might be present on the surface of the protein. Collectively, authors presumed 
that HBeAg can be recognised by the NLS receptor(s) and subsequently transported to 
the nucleus by exposure of NLS(s) (Eckhardt et al., 1991; Kann et al., 1999). 
Numerous studies have shown that core particles, purified from infected liver or 
circulating virions, display protein kinase (PK) activity (Albin and Robinson, 1980; 
Gerlich et al., 1982; Petit et al., 1985). Some suggest a host origin of this PK 
(Lanford et al., 1990). This is supported by the lack of a protein kinase consensus 
sequence in the viral genome (Hanks et al., 1988; Schlicht et al., 1989). Studies on 
E.coli-derived core particles have shown that phosphorylation of the core subunits 
was necessary for exposure of the nuclear binding signal (NLS), and inhibition by 
specific peptides indicates that the COOH-terminus was directly involved (Eckhardt 
et al., 1991; Liao et al., 1995; Kann et al., 1999) through a direct interaction with a 
kinase or cellular factor (Hui et al., 1999).
The COOH-terminal domain of the core protein which is highly positively charged 
overlaps and interferes with the nucleic acid binding domain (Fig 1.8) (Petit et al.,
1985). In unphosphorylated cores, cryoelectronmicroscopy has shown that this 
domain is located inside the cores close to small holes in the capsid wall (Zlotnick et 
al., 1997); it binds to nucleic acid (Petit et al., 1985; Nassal et al., 1992b; Liao et al., 
1995) and also provides the phosphorylation site(s) for the protein kinase trapped in
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the central cavity (Machida et al., 1991; Liao et a l, 1995; Kann et al., 1997). Removal 
of the last 36 C-terminal aa completely abolished phosphorylation and genome 
replication but did not interfere with particle formation or genome packaging 
(Schlicht et al., 1989). Since the phosphorylation sites on core proteins interfere with 
the encapsidation of RNA (Kann et al., 1995), this process is most likely linked with 
DNA synthesis. Thus, core protein phosphorylation may be an essential step during 
the generation of a replication-competent Hepadnavirus capsid (reviewed by Cooper, 
2003).
The three proposed phosphorylation sites in the HBV core protein sequence have 
been mapped exclusively to the 7 serine residues in the arginine-rich C-terminus of 
the core and pre-core proteins, six of them in a highly conserved region (Figure 1.8) 
(Gerlich et al., 1982; Machida et al., 1989; Yeh et al., 1990; Liao et al., 1995). These 
serine residues reside in the three adjacent SPRRR repeats and overlap the nuclear 
localization signal (Figure 1.8). Sequences of other nuclear localisation signals in 
other viruses such as WHV, GSHV (Yeh et al., 1990), and DHBV (Walker and 
Lipkin, 2002) are also rich in arginine or lysine residues or both. Certain serine 
residues at amino acid positions either 155, 162, 168 and 170 (Argos and Fuller, 
1988; Machida et al., 1991) or 145-156 (Eckhardt et al., 1991) were proposed as 
candidates for phosphorylation, being the consensus sites for different kinases (cdc2, 
cdk2, PKC, SRPR1 and SRPR2) (Kann et al., 1994; Liao et al., 1995; Daub et al.,
2002). The requirement for the phospho-acceptor sites to be juxtaposed next to 
proline has been conserved during evolution.
Mutations of three phosphorylation sites (SI 57, S I64, and SI72) to alanine (to mimic 
dephosphorylation) abolished pre-genomic RNA packaging. Conversely, the mutation 
of these three phosphorylation sites to glutamic acid (to mimic phosphorylation), had
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only a slight effect. However, such mutations were not able to support viral DNA 
replication (Lan et al., 1999). In DHBV alanine could functionally replace serine at 
the sites of replacement, but not for the phosphoreceptor function. This defect was 
corrected by aspartic acid substitution (the assumption is that aspartic acid mimics 
phosphoserine rather than serine) (Yu et al., 1994). The same results were obtained 
for S I76 and S I78 after substitution by alanine (Daub et al., 2000). Taken together, it 
seems that phosphorylation of core subunits induces a conformational change. As a 
consequence, the COOH terminus is then exposed on the particle surface and serves 
as a nuclear pore targeting signal (Kann et al., 1999).
In contrast, observations that the phospho-core protein was detected in the cytoplasm 
but not in the nucleus, suggested that phosphorylation of the core protein has a 
negative effect on nuclear localisation and that the cell cycle regulated nuclear 
localisation. The core protein accumulates primarily in the nucleus when entry of the 
cell cycle into S phase is blocked by aphidicolin; removal of the chemical resulted in 
the entry of the cells into S phase and the accumulation of the core protein in the 
cytoplasm. It is assumed that lack of nuclear core protein during the S phase may be 
the result of activation of a cellular kinase at this particular stage of the cell cycle. 
Authors found that this kinase could phosphorylate the core protein in vitro. They also 
suggested the possibility that this kinase and/or its related kinases may negatively 
regulate the nuclear localisation of the core protein during the S phase (Yeh et al., 
1998). Although the data presented here on phosphorylation of recombinant, non­
assembled HBV core protein cannot be necessarily transferred to the genuine 
complete core particle (containing genome, polymerase and kinase), further support is 
lent by similar observations with the DHBV core particle.
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1.3.2 S protein
The principal viral surface antigen (HBsAg) is a protein of 24 kd in virions and 
subviral particles. There are 100 polypeptide monomers per subviral particle, and in 
addition host-derived lipid that comprises approximately 25% of the particle mass 
(Ganem et al., 1987). ORF-S is embedded within the ORF-P (Figure 1.1). It encodes 
the three envelope proteins which are translated by three in frame AUG codons. They 
all share their C-terminus sequence and “a” antigenic determinants (see below) 
(Argos and Fuller, 1988). The three-conserved AUG codons are for large (L; 
containing pre-S 1, pre-S2, and S), middle (M; containing pre-S2, and S), and small 
(S; HBsAg) proteins. LHBs covers the entire open reading frame, MHBs initiates at 
an internal site, and the 226 aa sequence of SHBs starts further downstream. All three 
proteins therefore have the S sequence in common. The pre-S proteins represent a 
minor component of the circulating antigenic pool (generally less than 1-10% of the 
total). All three proteins are inserted into the outer envelope of the virion (Argos and 
Fuller, 1988). These proteins are usually detected serologically as HBsAg (Ganem et 
al., 1996), and they are involved in receptor binding, viral assembly and secretion. 
They are also important targets for immune mediated virus elimination (reviewed by 
Wallace et al., 1997). The S proteins in secreted viral and subviral particles are 
extensively cross-linked by disulphide bridges; such cross-linking has been shown to 
occur concomitantly with the assembly and budding of the particle (Huovila et al.,
1992). Of 14 cysteine residues presumably involved in this process, four are located 
in the first hydrophilic region and eight are located in the second hydrophilic region 
(Mandart et al., 1984; Norder et al., 1992b).
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Fig 1.9. Proposed model o f the major hydrophilic region (M H R). The five proposed antigenic 
regions are labled H B sl through HBs5. Cysteine to cystein disulphide bridges are also shown. 
Taken from  W allace and Carm an, 1997.
The first hydrophilic region, aa 29-79, is on the inner cytoplasmic surface o f the viral 
envelope and thus may facilitate core particle envelopment during maturation o f the 
virion (Prange et al., 1995; Loffler-Mary et al., 2000). Three o f the four cysteine 
residues in this region are conserved among all hepadnaviruses and were shown to be 
essential for secretion.
The second hydrophilic region (aa 99-147) is exposed on the outer surface o f secreted 
viral and subviral particles. It is termed the major hydrophilic region (MHR) (Fig 1.9) 
and most o f the anti-HBs stimulated by vaccine bind this; substitution o f many 
residues results in loss o f immunogenicity to vaccines. This region has a highly 
complex structure and is very cysteine rich; eight o f the 14 cysteine residues in 
HBsAg are located here and all o f them are highly conserved among mammalian 
hepadnaviruses (Mandart et al., 1984; Norder et al., 1992b, 1993a). Epitopes o f  the 
MHR o f HBsAg, cluster into five regions (Fig 1.9): H B sl, upstream of aal21; HBs2, 
between aal21 and 124; HBs3, between aal25 and 137; HBs4, between aa 139 and
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147 or 149 and HBs5, from 148 or 150 downstream to 169. Antigenicity of HBsAg is 
dependent upon this complex structure and variants of this region have been well 
described (Carman et al., 1990a; Protzer-knolle et al., 1998; Esteban et al., 1999). 
Moreover, standard HBV subtyping and genotyping is based on the "a" determinant 
which does not include the entire MHR (see section 1.5)
1.3.3 X Protein
The smallest ORF, the X-gene, encodes a polypeptide of 154 amino acids. HBx is 
highly conserved among mammal-specific members of Hepadnaviridae (Sohn et al., 
2000) and seems to be essential for virus infectivity. HBx has been detected in liver 
tissue from HBV-infected patients with chronic hepatitis, cirrhotic liver and HCC 
(Wang et al., 1991; Zhu et al., 1993; Su et al., 1998).
HBx protein activates a wide range of promoters and transcription factor binding sites 
and multiple functional pathways. It contains the basic core promoter (BCP)/enhancer 
II complex, which activates transcription of genes, interacts with other transcription 
factors and is involved in tumorogenic activity (reviewed by Kann et al., 1998) by 
activation of the P53 tumor suppression protein (Feitelson et al., 1993).
1.3.4 P Protein
The longest ORF encodes the viral polymerase and overlaps the C, S, and X genes 
(Figure 1.1). It shares homology with the polymerase genes of retroviruses (Ganem et 
al., 1987). It contains four functional domains which are arranged from the N to the C 
terminus as follows (Fig 1.10): terminal binding protein (TP), which is covalently 
linked to the 5' end of the minus-strand of the virion DNA and is necessary for 
priming minus-strand synthesis; a spacer, which despite being necessary for 
polymerase function, has no specific function of its own; reverse transcriptase, 
encoding the nucleic acid-dependent polymearse activity and the reverse transcriptase
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activity as it has the conserved YMDD motif.; and RNase H, responsible for digesting 
the pgRNA. Sequence analysis o f the mammalian and avian Polymerase ORF 
revealed that it is highly conserved among hepadnaviruses (Chen et al., 1992, 1994).
TP SPACER RT RNase H
F ig l.10  Functional domain of the polym erase. TP and RT represent term inal binding protein and 
reverse transcriptase, respectively.
1.4 Transmission and Epidemiology of HBV transmission
HBV is transmitted by a number o f routes including transmission from an infected 
mother to her child (perinatal or vertical transmission), or by percutaneous and 
mucous membrane exposure to infectious blood and body fluids that contain blood 
(horizontal transmission). Although hepatitis B surface antigen (HBsAg) has been 
detected in a wide variety o f body fluids, only serum, semen, and saliva have been 
demonstrated to be infectious. Perinatal and sexual transmission o f HBV usually 
results from mucous membrane exposure to infectious blood or serum-derived body 
fluids (Alter et al., 1990), and the risk is greatest for infants bom to women who are 
HBeAg-positive, ranging from 70 to 90% at 6 months o f age; about 90% o f  these 
children remain chronically infected (Xu et al., 1985).
The global prevalence o f chronic HBV infection varies widely (Fig 1.11). The 
prevalence o f chronic HBV infection in different areas has been categorized as o f 
high, intermediate or low endemicity (Fig 1.11). Areas o f high endemicity (prevalence 
>8%) account for a total o f 45% o f the global population and include Africa, Asia and 
the Pacific Basin, the Amazon Basin, the Arctic Rim, the Asian republics previously
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part of the Soviet Union, and parts of the Middle East and the Caribbean. 
Additionally, in parts of Eastern Europe, such as Bulgaria, Romania, Albania and 
Moldavia, the HBV prevalence is 5-10% of the general population. Areas of 
intermediate endemicity have a prevalence of chronic HBV infection of 2-7% (Fig 
1.11), and account for a total of 43% of the global population. Parts of Southern and 
Eastern Europe, the Middle East, Japan, parts of Central and South America, are 
regarded as areas of intermediate endemicity. In most developed parts of the world, 
the prevalence of chronic HBV infection is less than 2% (Fig 1.11), and include most 
of Western Europe, Australia and North America that are generally categorized as 
areas of low endemicity.
The predominant routes of HBV transmission vary according to the prevalence of 
HBV infection. In regions of high endemicity, transmission from an infected mother 
to child is the main mode of transmission (Lau et al., 1991; Alter et al., 1996) In 
regions of intermediate endemicity, individuals of all groups can be infected, although 
chronic infection is generally caused by transmission during infancy or early 
childhood. In regions of low HBV prevalence, transmission is primarily horizontal 
(between individuals). Sexual transmission (either homosexual or heterosexual) in 
high-risk adults is a main mode of transmission in Europe and North America 
(reviewed by Alter, 2003), although needle sharing amongst intravenous drug abusers 
or occupational exposure to contaminated blood and blood products continue to be 
important (Lee et al., 1997).
1.4.1 Prevention
The primary goal of hepatitis B prevention is reduction of chronic HBV infection and 
HBV-related chronic liver disease. A secondary goal is the prevention of acute 
hepatitis B. HBV infection can be prevented by screening blood, plasma, organ tissue
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and semen donors. Although such activities can reduce or eliminate the potential risk 
for HBV transmission, immunization is by far the single most effective prevention 
measure. The HBV vaccine was initially recommended for individuals at high risk of 
exposure to HBV infection (health care workers, parenteral drug users, household 
contacts and infants of infected mothers). However, this strategy had little effect on 
the incidence of new HBV infections. In 1992, the World Health Organization 
recommended that all countries include hepatitis vaccine in their routine infant 
immunization program, especially in areas where hepatitis B is endemic (Kane et al., 
1998). Two types of hepatitis B vaccine have been widely used; a plasma derived 
vaccine (consisting of HBsAg particles and small amounts of LHBs and MHBs) and a 
yeast-derived recombinant vaccine, consisting of the major S gene product. The latter 
is used more than the former (McAleer et al., 1984); however, both vaccines are 
equally efficacious (Andre et al., 1989). Additionally, new recombinant vaccines 
containing both preS and S antigens are developed to circumvent the non-response to 
conventional vaccines (Clements et al., 1994; Jones et al., 1998).
Passive immunoprophylaxis is mainly used in the following situations with 
vaccination: in neonates bom to HBeAg-positive mothers (Reesink et al., 1979); after 
needle-stick exposure (Grady et al., 1978); after sexual exposure (Perrillo et al., 
1984); and after liver transplantation (Muller et al., 1991; Samuel et al., 1991).
1.4.2 Treatment of HBV infection
Although mass vaccination programs have begun to control the spread of HBV, 
therapeutic intervention is the only option for those with established chronic HBV- 
associated liver disease. Acute HBV does not require specific treatment because more 
than 90% of adults will spontaneously clear their infection, although symptomatic 
treatment may be indicated (Gitlin, 1997). The primary objective of therapy for
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chronic HBV is eradication of the virus that will, in turn, lead to remission of necro- 
inflammatory liver disease and an improved long-term prognosis. Two therapeutic 
approaches have been used to prevent HBV replication: immune modulators, such as 
interferon (IFN) alpha, and antiviral agents in the form of nucleoside analogues (e.g., 
lamivudine).
1.4.2A Interferon
Interferons have immunomodulatory, but also antiproliferative and antiviral effects 
(Goodboum et al., 2000; reviewed by Karayiannis, 2003). The aim of therapy with 
IFN alpha is to stimulate the immune system to attack HBV-infected hepatocytes, 
thereby inhibiting viral protein synthesis. In about 30-40% of chronic HBV patients, 
IFN alpha therapy will induce a long term remission which is identified by the loss of 
HBeAg and HBV DNA, normalization of serum aminotransferase levels and 
improvement in liver lesions (Perrillo et al., 1993; Gitlin, 1997). Indeed, IFN alpha 
therapy improves the clinical outcome even in the presence of cirrhosis (Niederau et 
al., 1996). It is also recommended to use IFN alpha therapy in children who have 
chronic hepatitis after being well selected, on a similar basis to that used in adults, as 
it may reduce the chance for the development of major complications (Roberts, 2000). 
Factors that have been associated with a favorable outcome following IFN alpha 
treatment include high pre-treatment ALT and low serum HBV-DNA levels (Brook et 
al., 1989; Perrillo et al., 1990; Gitlin, 1997; Nair and Perrillo, 2001). In contrast, 
factors that have been associated with poor response include male sex, length of 
chronic state, Asian origin, precore mutations, homosexuality and HIV co-infection 
(Lai et al., 1987; Lok et al., 1988, 1995; Gitlin, 1997; reviewed by Karayiannis,
2003). Moreover, IFN alpha treatment is expensive, administered by injection and
34
Chapter 1 Introduction
poorly tolerated with side effects including flu-like symptoms, injection-site reactions, 
anorexia, rash, neutropenia and thyroid disorders (Vail et al., 1997, Gitlin, 1997). 
1.4.2B Nucleoside analogues
The development of nucleoside analogues greatly improved the outcome of HBV 
treatment. These agents block viral replication directly by being incorporated into 
newly synthesized HBV DNA, causing chain termination, but they also inhibit the 
HBV polymerase, and thus viral replication. To date, lamivudine and adefovir are the 
only nucleoside analogues to have been approved for the treatment of chronic 
hepatitis B. A number of other nucleoside analogues have been tested or being 
evaluated presently against HBV including: famciclovir, entecavir, emtricitabine, 
ganciclovir and FIAU. Early studies have shown that lamivudine reduces rapidly 
HBV replication and suppresses HBV DNA to undetectable levels after few weeks of 
treatment (Dienstag et al., 1995; Lai et al., 1997). Furthermore, long term trials in 
both Asian and Western patients have shown that lamivudine significantly reduced 
the progression of hepatic histopathological changes and normalized serum ALT 
levels (Lai et al., 1998; Dienstag et al., 1999; Suzuki et al., 1999; Liaw et al., 2000). 
Lamivudine has also many advantages over IFN alpha such as better tolerability, oral 
administration and most importantly, its effectiveness irrespective of the patient’s sex 
or onset of infection (Lai et al., 1998; Maddrey, 2000). However, as with all antiviral 
therapies, lamivudine is associated with the emergence of strains of HBV that are less 
sensitive to treatment. The YMDD (tyrosine-methionine-aspartate-aspartate) motif 
forms the catalytic side of the viral DNA polymerase (see section 1.3.4), and 
mutations in this and other regions of the gene result in reduced sensitivity to 
lamivudine (Allen et al., 1998; Lai et al., 1998). The main amino acid substitutions 
that confer drug resistance are either valine or isoleucine instead of methionine at
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position 552 within the YMDD motif (Tipples et al., 1996; Liaw et al., 1999; 
Chayama et al., 1998).
It has been suggested that combination therapy with two or three nucleoside 
analogues or combination with IFN alpha treatment might delay or prevent the 
emergence of viral resistance (Lee, 1997; Rosenberg et al., 1999). Data from one 
study have demonstrated that the use of combination of lamivudine and IFN alpha is 
more effective than either monotherapy (Schalm et al., 2000), however, more studies 
are still needed to confirm the superiority of this combination and to investigate 
different regimens of combination.
Adefovir, other than acting as a DNA chain terminator, is also thought to stimulate 
natural killer cell activity and to induce endogenous interferon production (reviewed 
by Karayiannis, 2003). It is a potent inhibitor of HBV replication (Heijtink et al., 
1993; Nicoll et al., 1998). This drug is also active against lamivudine-resistant 
mutants (Benhamou et al., 2001; Mutimer et al., 2001; Walsh et al., 2001). Adefovir 
appears to have potential as an effective drug against HBV, and may prove a strong 
condidate in combination therapies (reviewed by Karayiannis, 2003).
1.4.2C Other Approaches
Immunomodulatory agents such as thymosin a l  (T al) whether alone (Mutchnick et 
al., 1999) or in combination with IFN alpha (Rasi et al., 1996) have been tested in 
chronic HBV carriers with promising results. However, further trials are still needed 
to assess this combination.
Therapeutic vaccines are another interesting approach to stimulate the immune system 
against HBV. As the current HBV vaccines promote production of antibodies and a 
Th2 biased immune response, for effective therapeutic vaccination, both humoral and 
CTL responses may be necessary to eradicate infected cells. MF59 and CpG DNA, as
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alternative adjuvants showed promising results in human and animals, respectively 
(Heineman et al., 1999; Wright et al., 1999; Malanchere-Bres et al., 2001; Davis, 
2000). Other approaches employing a DNA-based vaccine, which induces both 
humoral and cellular immune responses, showed promising results in mice, 
woodchucks and ducks (Geissler et al., 1997; Lu et al., 1999; Rollier et al., 1999). 
These approaches deserve further studies and clinical trials.
Finally, molecular approaches such as antisense oligodeoxynucleotides (ODN) and 
ribozymes have been tested in vitro (Nakazono et al., 1996; Moriya et al., 1996; Von 
Weizsacker et al., 1995; Beck and Nassal, 1995; Welch et al., 1997; Kim et al., 1999); 
they were efficient in inhibiting viral protein expression and viral replication.
1.4.2D Liver transplantation
Liver transplantation is often the only therapeutic option for patients with acute 
(fulminant) or chronic liver failure caused by HBV infection (Perrillo and Mason,
1993). However, HBV reinfection of the liver graft is a major problem in these 
patients who receive immunosuppressive medication to prevent graft rejection. In 
theses cases, retransplantation may be required due to the rapidly progressive course 
of the disease which often leads to graft failure and high mortality rates (O’Grady et 
al., 1992; Samuel et al., 1993). Therefore, prevention of HBV reinfection after liver 
transplantation is quite important and mainly entails the use of anti-HBs, although 
escape mutants with frequent mutations within the S gene, especially in the MHR, are 
often observed in some of these patients (Carman et al., 1996; Protzer-Knolle et al.,
1998).
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1.5 HBV GENOTYPES
HBV genomes can be classified into at least eight genome groups (genotypes A to H) 
based on the degree of similarity in their nucleotide sequence. A genetic classification 
of HBV strains using the nucleotide sequence of the complete genome was performed 
on 18 HBV clones by Okamoto et al (1988). This classification, based on nucleotide 
divergence of 8% or more between the strains, enabled the identification of genotypes 
A to F (Okamoto et al., 1988; Norder et al., 1992a). Genotype G showed a nucleotide 
divergence of >11.8% from other HBV isolates (Stuyver et al., 2000). Finally, 
genotype H, which was recognised previously as a divergent clade within genotype F, 
showed 13.2-15.7% divergence from other HBV strains (Arauz-Ruiz et al., 2002). 
Variation within a sub-component of the S gene within the major hydrophilic region 
(MHR) of HBsAg, the “a determinant”, is strongly associated with subtype variation 
(Okamoto et al., 1987). The “a” determinant is common but there are two pairs of 
mutually exclusive determinants, d/y and w/r, found at residues 122 and 160, 
respectively. These characterise four HBsAg subtypes. Subdeterminants of w (wl to 
w4) have allowed the further characterisation of ayw and adw subtypes into a total of 
10 subtypes: aywl, ayw2, ayw3, ayw4, ayr, adw2, adw4, adw4q-, adrq+ and adrq-. 
The q determinants were found to be absent from adr strains in the Pacific region, 
thus, defining adr and adw as either q+ or q- (Courouce-Pauty et al., 1978). 
Collectively, these results indicated that, classifying HBV genomes on the basis of S 
gene alone is feasible and is consistent with the classification based on the complete 
genome. Genotypes and subtypes probably evolved in ethnic backgrounds over 
centuries (Esteban et al., 1999), and the relationship of these ten subtypes to genomic
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Table 1.2 Relationship between HBV genotypes and subtypes.
Genotype A B C D E F  G H
Associated adw2 adw2 adr ayw2 ayw4 adw4q- adw2 adw3
Subtype aywl aywl adrq- ayw3 adw2
ayr ayw4
groups A to H has been established. Some subtypes can be found in more than one 
genotype (Table 1.2); hence, confer additional heterogeneity within the genotypes . 
Strains specifying adw are found in types A, B, E, G, F and H and those specifying
ayw in types A, B, D, and E (Norder et al., 1992a; Arauz-Ruiz et al., 2002). Strains
specifying r have so far only been found in group C (Okamoto et al., 1988). Between 
strains, ayw and adw subtypes demonstrate considerable genetic heterogeneity 
(Norder et al., 1992a). Over the last decades however, subtype determination has 
gradually been replaced by genotyping.
1.5.1 HBV genotypes: distribution
HBV genotypes have a characteristic geographic distribution, largely in agreement 
with subtype distribution (Norder et al., 1993a). The HBV subtypes located to smaller 
and more distinct geographical areas than genotypes (see below). The genotypes of 
HBV correlated well with geography (Figure 1.11) (Norder et al., 1993b). Genotype 
A, which might represent a more ancient genomic group (Norder et al., 1993b), is 
widely distributed in Western Europe, USA, Sub-Saharan Africa as well as Asia and 
as far as east as the Philippines. Genotypes B and C belong to the indigenous 
population of South East Asia (Okamoto et al., 1988; Kidd-Ljunggren et al., 1995). In 
addition, genotype C is found in the populations of the Pacific Islands, and can be 
sub-differentiated geographically by subtype in this region. As compared to strains
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from South East Asia, four adrq- strains formed a distinct cluster within the Pacific 
area (Norder et al., 1993b). Genotype D has been found worldwide with its highest 
prevalence in the Mediterranean area, the Middle East, and South Asia (Norder et al., 
1993b). Moreover, genotype D has been reported as the only prevalent genotype 
infecting IV drug users in the Western World (Kidd-Ljungrren et al., 2002). Genotype 
E is found in West and South Africa. Genotype F demonstrated the highest degree of 
divergence from the other HBV genotypes (Norder et al., 1993) and is believed to be 
the original genotype of the New World (Kidd-Ljunggren et al., 2002); it is found in 
South and Central America. Genotype G has been found in France and the USA 
(Stuyver et al., 2000) but has not been widely studied. The distribution of genotype H 
seems to be restricted so far to the Northern part of Latin America including Central 
America and Mexico (Arauz- Ruiz et al., 2002). HBV strains within each genomic 
group show a characteristic geographic distribution, and it has been proposed that 
HBV diverged into genomic groups according to the distribution of humans among 
the different continents (Telenta et al., 1997).
It is believed that the prevalence of different HBV genotypes in many countries 
reflects the origin of the immigrants and other patterns of migration (Kidd-Ljunggren 
et al., 2002) (see sections 1.8.3 and 1.8.4). This is best exemplified by HBV-infected 
populations living in South Pacific Islands, where the prevalence rate of HBV is 
amongst the highest in the world. The common genotype is C. This correlates with 
immigration from South East Asia where genotype C is common (Diamond et al., 
1988; Hagelberg et al., 1993; Redd et al., 1995; Kayser et al., 2000) The presence of 
genotype D in Central America reflects the westward immigration of the Spanish in 
whom genotypes A and D are common (Arauz-Ruiz et al., 1997).
40
Chapter 1 Introduction
HBsAg Provalence
Geographic Distribution of Chronic HBV Infection
'8% • High
2-7% - In term ediate 
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Figure 1.11: HBV prevalence and HBV genotypes geographic distribution.
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Further, Yamashita et al. analysed the geographical interface of adr (genotype C) and 
adw (genotypes A and/or B) strains from Japan. They found an apparent south-to- 
north gradient of the r determinant and concluded that Japan may have been inhabited 
originally by people infected with adw (Philippines and Indonesia), and later, people 
from the Asian continent infected with adr (South East Asia) (Yamashita et al., 1975).
1.5.2 HBV genotypes: clinical relevance
Although the serologic and genotypic classification of HBV has been well 
documented, the significance of HBV genotypes in terms of the therapeutic response 
to antiviral therapy remains largely unknown, as does the impact of genotypes on 
clinical outcome. Some believe that the genotypes do not have any replication 
advantage over each other or different pathogenic potential. However, many authors 
have tried to explain the outcome of HBV infection by differences in HBV strains 
(Shiina et al., 1991; Rodriguez-Fraise et al., 1995; Kao et al., 2000a, b; Orito et al., 
2001). So far, these variations in different HBV genotypes have been studied on Far 
East Asian patients with respect to genotypes B and C as well as New World and 
Mediterranean patients with respect to genotypes A and D. One example is the 
prevalence of A1896 in genotypes B, C, and D and its absence in other genotypes, 
which might explain why this mutation is uncommon among carriers of Western 
Europe and North America (see section 1.7.3B).
A correlation has been observed between pre-S2 variation and HLA type in chronic 
patients with high levels of ALT. In a majority of adr- infected patients, the HLA 
class-I phenotype was A24; in adw and/or ayw it was A2. However, in patients with 
normal ALT, none of those phenotypes of HLA class-I have been found. Cupps et al. 
investigated the immune response to an HBV vaccine containing pre-S and S (adw 
subtype). The ayw peptides from pre-S2 (146-174), which were not present in the pre-
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S2+S vaccine, failed to stimulate a T cell proliferation response (Cupp et al., 1993). 
This is supported by the observation that the T- and B cell response is mostly subtype- 
specific. In mice immunized with peptides containing the pre-S2 region of the d and y 
subtypes, Milich and co-workers found that the responses were pre-S2-subtype- 
specific. They suggested that any new generation of HB vaccines should contain both 
the d and y subtype sequences of the pre-S region to increase the S-specific antibody 
response (Milich et al., 1990).
In several studies, a link between HBV genotype and risk of chronic outcome has 
been reported: an association of genotypes B and C with chronicity was reported in 
South East Asian studies (Ogawa et al., 2002). A large proportion of such HBeAg- 
positive patients were infected with subtype adr, which might to some extent be 
related to the fact that the pre-C stop codon mutation is more common in genotype B 
(Shiina et al., 1991; Lindh et al., 1999; Yuen et al., 2003). Genotype B may be 
associated with the development of HCC in young HBsAg carriers, suggesting 
possible pathogenic differences among HBV genotypes (Kao et al., 2000 a,b; 
Nakayoshi et al., 2003). On the other hand, core promoter mutants have been reported 
more commonly in patients with genotype C than with genotype B (Orito et al., 2001; 
Yoo et al., 2003; Yuen et al., 2003; Kao et al., 2003). Genotype C-infected patients 
often have more advanced liver disease with more acute exacerbations (including 
HCC) compared to genotype B (Kao et al., 2000a, 2001, 2003; Chan et al., 2003; 
Nakayoshi et al., 2003). Similarly, genotype A was suggested to lead more often to 
chronicity as it was found more often in chronic HB patients than genotype D, 
whereas, the opposite situation was found in patients with acute hepatitis (Mayerat et 
al., 1999). Sustained remission after seroconversion to anti-HBe was reported to be 
higher in genotype A than genotype D or F (Sanchez-Tapias et al., 2002). Genotype D
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is associated with more severe disease in post-transplant patients (in whom the pre- 
and post-transplant sequences were similar) (McMillan et al., 1996). Further, 
genotype D may be associated with fulminant hepatitis more commonly than 
predicted from its prevalence in chronic carriers. Similar to genotype B, most 
genotype D strains in anti-HBe positive patients have pre-C mutations (A1896 and/or 
A1899) (Sanchez-Tapias et al., 2002).
Recombination between genotypes has been reported mainly from South-East Asia. 
Recombination between genotype A and C from Vietnam (Hannoun et al., 2000b), 
between C and D from Tibet (Cui et al., 2002), and between B and C from South-East 
Asia (with the exception of Japan) (Sugauchi et al., 2002, 2003) have been reported. 
Using nucleotide sequences from databases, Morozov and colleagues analysed the 
evolution of complete HBV genome and three ORF sequences: S, C and X. They 
found hot spots for recombination in those ORFs. As there is a high recombination 
rate between genotype B/C, they suggested that such genomes could obscure the real 
genotype-related differences in the pathogenicity of HBV (Morozov et al., 2000). 
Genotypic changes have been reported in several studies after anti-HBe 
seroconversion: genotypic shift from D to A (Friedt et al., 1999) and A to D (Gemer 
et al., 1998). However, it seems unlikely that a new genotype could evolve under 
selection within such a short period a time. These observations may indicate that 
infection with different genotypes of HBV can occur simultaneously (although there 
is no direct evidence) (Gemer et al., 1998; Morozov et al., 2000).
There are hints that genotype C may be more resistant to IFN (Kao et al., 2000b; Wai 
et al., 2002). This is similar to hepatitis C, where genotypes 2 and 3 are more sensitive 
to IFN therapy than 1 or 4 (Hoofnagle et al., 1997). This finding might be related to 
the fact that both core promoter and pre-core stop codon mutations have been reported
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to influence response to IFN (Erhardt et al., 2000). In general, it has been described 
that Asian HBV carriers have a lower response rate to IFN than non-Asian carriers 
(because of infection at an early age) (Lai et al., 1987; Lok et al., 1988; Hoofftagle et 
al., 1990), in keeping with the different genotypes infecting Asian and non-Asian 
ethnic groups. It may also be that the adw subtype is associated with a higher risk of 
lamividine-resistance than ayw (Zollner et al., 2001, 2002). However, this observation 
was in contrast to the finding that genotype B has a better virologic response to 
lamivudine compared to genotype C and that both genotypes showed a similar risk of 
developing lamivudine-resistance after 1 year of therapy (Kao et al., 2002). Taken 
together, these data suggest pathogenic and therapeutic differences among HBV 
genotypes and indicate a potential role for HBV genotypes in the virus-host 
relationship.
1.5.3 HBV genotypes: HBcAg amino acid variability
The genetic differences between HBV genotypes are not limited to the S gene. 
Characterisation of HBV strains by subtyping and/or genotyping using other HBV 
proteins has been used for tracing a source of infection (Ogata et al., 1993; Hawkins 
et al., 1996; Kidd-Ljunggren et al., 1999)
Although the amino acid sequence of the core region is relatively conserved 
(compared to surface gene), amino acid substitutions have been observed in several 
reports (Ono et al., 1983; Okamoto et al., 1986; Ferrari et al., 1991; Ehata et al., 
1992,1993; Chuang et al., 1993; Akarca et al., 1995a; Hosono et al., 1995; Hur et al., 
1996; Alexopoulou et al., 1997; Carman et al., 1997b; Fujiwara et al., 1998; Gunther 
et al., 1998; Takahashi et al., 1998) (Table 1.3). This is largely linked to the clinical or 
serological picture (Chuang et al 1993; Ehata et al, 1992,1993; Akarca et al., 1995a; 
Carman et al., 1995b). Core variability has been shown to correlate with disease
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activity. Mutations within the core gene have been linked to persistence (Carman et 
al., 1995b; Ehata et al., 1992,1993; Akarca et al., 1995a; Hosono et al., 1995). 
Although core aa substitution was reported in many studies, some of these variants are 
actually the consensus sequence from other genotypes. Therefore, in view of the 
heterogeneity of HBV strains, it is difficult to determine whether substitutions 
recorded only once represent naturally occurring variants or merely an immune- 
selected mutation in those patients. For example, based on the results presented in 
chapter 3.1.2, aa residue 74 of the core gene contains 5 possible natural aa variations 
in both HBeAg and anti-HBe positive carriers, indicating that these are normal 
variations linked to different ethnic/HBV genomic groups; in some studies however, 
these variations were reported as true mutations after HBeAg seroconversion, IFN 
therapy etc. Perhaps this reflects the variable definition of a “standard” sequence in 
such studies, due to different genotypes, as well as differences in ethnic background. 
So far, no systematic study has been conducted to correlate HBeAg diversity with 
HBV genotypes and/or subtypes and ethnic background. This background 
information would not only be critical for the correct interpretation of sequences 
observed in clinical studies, but may aid in the design of immunotherapies specific for 
persons of a particular ethnic origin. Until now, no identical C gene consensus 
sequence has been identified due to its heterogeneity between different HB genomic 
groups and subgroups in different geographic regions. The published core aa 
sequences in the databases therefore do not represent the consensus aa/nucleotides 
occurring at critical positions, and conserved HB core protein sequences are rarely 
reported. There are a number of issues to be considered in developing a C gene 
database. First, the core region is highly divergent in anti-HBe carriers (Sanantonio et 
al., 1991 a, b; Carman et al., 1995b). Consequently, core sequences obtained during
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the HBeAg-positive phase should have less disease-related sequence deviation. 
Second, as the most conserved regions of the C gene are short stretches in 
approximately the first and the last 150 nucleotides (Kodama et al., 1985; reviewed by 
Lok, 1997), the middle section should be used for this purpose. Third, studies have 
shown that in certain populations where HBV is endemic, a higher variability of HBV 
might be expected (Carman et al., 1997b). Thus, T-cell epitopes could have various 
locations on account of the divergent distributions of HLA types in different countries 
and different aa sequences in the HBV subtypes (Chuang et al., 1993) (see section 
1.7.1). Consequently, it is important to sequence geographically divergent HBV 
genomes to define the extent of natural variation (Norder et al., 1994).
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Table 1.3: The most frequent amino acid changes in HBeAg sequence (hot spot positions). 
Amino Acid Position Amino Acid Change
5 T, H, Q, A, S,P
12 A, P, Y, S, T
13 A, L, T, E, M, G, V
21 A, D, H, F, N, V, P, S, T
27 A, L, G,N, S, T, I, V
35 A, S ,T
38 F, H, G, N, Y
40 A, D, E, K, Q
49 C, E, S, T, Y
50 A, H, N, P, S, T
55 I, L
59 G, I, V, S, T
60 E, I, L, V
63 A, E, D, G, N, P, R, V
64 D, E
67 G, S, N, T
74 A, F, S, I, R, G, V, T, N
77 D ,, E, Q, T
79 P, Q
80 A, G, I, S, T, V
84 A, D, L, Q, R, V
87 G, T, S, N
91 I, L
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92 H, T ,N
93 L, M, T, V
97 I, F ,L
100 I, F, L, T
105 I, L, T, V
113 D, E, L, Q, S, V
116 I, L ,V
130 A, L, N, P, Q, S, T
135 A, E, L, P, Q, S, T
147 A, C, S, T
151 C, E, G, P, R, Q
153 C, D, G, R, V
155 P, S, T, W
181 P,S
Note: amino acids numbered from the beginning of HBeAg. The normal variations are on the 
basis of different genotypes studied.
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1.6 HBeAg EPITOPES
The identification of immunodominant T cell epitopes within the core molecule could 
theoretically be useful for the design of more effective alternative vaccines against 
HBV infection and possibly to plan future strategies to manipulate the immune 
response to HBV in subjects who do not spontaneously clear the virus. The analysis 
of antigenic determinants has been successfully accomplished by monoclonal 
antibodies. Since high titres of anti-HBe antibodies are produced to a range of 
epitopes during the course of the infection, this has allowed more accurate location of 
the epitopes. However, epitope mapping of viral protein sequences with mAbs does 
not always identify epitopes identical to those recognized by human B cells, despite 
their ability to specifically compete with human antibodies. Also, different mAbs with 
identical specificity in cross-competitive experiments may give varying results when 
mapping epitopes (Sallberg et al., 1991). A summary of different HBeAg immune 
epitopes is shown in figure 1.12 and table 1.4.
1.6.1 B cell epitopes
1.6.1 A HBeAg B cell Epitopes
The region of HBeAg involved in binding to naive B cells has not been fully mapped 
(Lazdina et al., 2003). However, studies in humans and mice have shown that the 
binding of HBeAg to naive B cells occurs between linear motifs on the surface of 
immunoglobulin molecules (Lazdina et al., 2001) and the repetitive, highly ordered 
protein spikes on the core shell which might be optimal for cross-linking of B cell 
antigen receptors (Bottcher et al., 1997; Milich et al., 1997a). HBeAg is thought to 
form a highly conformational epitope, which is not recognized when denatured by 
detergents. On the other hand, the HBeAg epitopes are presumed to be linear, since 
HBeAg denaturation does not prevent the binding of anti-HBe to the detergent-treated
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HBc particles (Ferns and Tedder, 1984). Further, the capacity of anti-HBe mAh to 
inhibit the binding of human polyclonal anti-HBe indicated that the majority of anti- 
HBe bind to one area of the molecule and suggested the existence of either a unique 
or immunodominant epitope (Ferns and Tedder, 1986; Waters et al., 1986). In cross­
competition assays mAbs recognized a broadly similar antigenic determinant on 
HBeAg (even in the presence of human antisera). It was therefore proposed that 
HBeAg, unlike HBeAg, has a single reactivity (Ferns and Tedder, 1986; Waters et al.,
1986). However, Takahashi et al., (1983) obtained mAbs against two determinants 
that are expressed on the surface of the core particle. Using pre-S as a foreign epitope 
inserted at different regions of HBeAg, Schodel et al, (1992) found that insertion 
between residues 75 to 83 abrogated recognition of HBeAg by 5 of 6 anti-HBe 
monoclonals and diminished recognition by human polyclonal anti-HBc.
The exact location of the HBeAg dominant B cell epitope remains controversial after 
studies using synthetic peptides and monoclonal as well as polyclonal antibodies. 
However, it appears to be between aa residues 73 to 89 (GVNLEDPASRDLVVSYV) 
(Salfeld et al., 1989; Tordjeman et al., 1993; Pushko et al., 1994; Rodriguez-Frias et 
al., 1995). In an attempt to localise immunodominant epitopes with a different 
approach, Conway and colleagues (1998) used cryoelectronmicroscopy to pinpoint 
the binding site of a monoclonal antibody that recognizes residues 78 to 83. Residues 
73-83 seem to form a non-helical loop between two alpha-helical segments at the tip 
of the capsid spike (Bottcher et al., 1997; Conway et al., 1998b). The second B cell 
epitope, residues 128-135 of the HBc protein, contains a shared T cell (Milich et al.,
1989), and B cell determinant, and P I29 has been found to be essential for mAb 
binding to the B cell epitope. Thus, this is an example of a T cell-dependent B cell 
epitope (Sallberg et al., 1991). HBeAg, however, has been proposed to be a strictly T
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cell dependent Ag (Milich et al., 1988). Another immune epitope has been located 
between aa residues 107-118, though this is linear (Colucci et al., 1988; Sallberg et 
al., 1994). Finally, another group of antigenic and immunogenic sites have been 
identified within the C-terminus region of HBeAg (aa 148-160), called HBicAg 
(hepatitis B inner core Ag) (Machida et al., 1989; Sallberg et al., 1994). Only one of 
these epitopes (amino acid residues 107-118) has a relatively conserved sequence; the 
other two have a high rate of variation. Collectively, in these reports, anti-HBc 
recognized many epitopes located in the HBeAg. This indicated that the antigenicity 
of the core particle is due to many epitopes that are distributed over the entire primary 
structure of the HBc protein, although once they are assembled into the capsid, they 
are unable to bind more that one antibody molecule, because of steric hindrance 
(Tordjeman et al., 1993).
1.6.IB HBeAg B cell epitopes
Because HBeAg and HBeAg share an identical 149 aa sequence, there is a strong 
possibility that the two antigens may display cross-reactivity. Peptide residues 74-89 
are recognized by both anti-HBc (Tordjeman et al., 1993) and anti-HBe-specific 
antibodies (Sallberg et al., 1993).
There are two major HBeAg B cell epitopes. HBc/HBel, is a linear region spanning 
aa 76-89 (Ferns and Tedder, 1984; Salfeld et al., 1989). This is on the surface of the 
core particle and overlaps with the conformational HBc determinant. At the C- 
terminus of HBeAg, aa 130-138 form the HBe-2 epitope (Ferns and Tedder, 1984; 
Salfeld et al., 1989; Sallberg et al., 1993). Unlike the HBc epitope, HBe-1 was found 
to be linear (Waters et al., 1986; Salfeld et al., 1989). This would imply the 
concomitant presentation of HBc/HBe antigenic determinants in two major structural 
states: in a dimeric, HBeAg state, exposing two antigenic determinants (the HBe-2
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determinants and the HBc/HBe-1 determinants as HBe-1 only); or, in the core 
particle, HBe-2 is masked and additional conformational HBc epitopes are introduced 
into the exposed HBc/HBe-1 determinant (Salfeld et al., 1989). This would imply a 
shared antigenic region between two Ags encompassing different regions in several 
reports. That HBeAg and HBeAg share structural features is supported further by 
Salfeld’s finding that the aa sequence around position 80 is exposed and recognised as 
a major antigenic determinant in both HBeAg and HBeAg; a surface location of this 
sequence is also suggested by its preferential tolerance to naturally occurring 
mutational aa changes. Unlike the HBe-1 epitope, HBe-2 has little aa variation within 
HBV subtypes. One of the reasons might be that the two prolines at residues 129-130 
are essential for recognition by most mAbs, perhaps for steric reasons (the C-terminal 
part of HBeAg may be internal and thereby less accessible to antibodies) (Sallberg et 
al., 1991, 1993).
1.6.2 T Helper Epitopes
Ferrari and colleagues described a dominant T-helper cell epitope (positions 50-69 in 
HBeAg) which is recognised by CD4+ lymphocytes from 95% of patients with active 
or chronic HBV infection. They identified two additional less frequently recognised 
sequences in the majority of the patients: residues 1-20 (in 69%) and 117-131 (in 
73%) of patients regardless of their HLA backgrounds (Ferarri et al., 1991; Penna et 
al., 1992) (Figure 1.12; Table 1.4). Interestingly, when epitope 50-69 is not dominant, 
T cells are mainly focused on epitopes 1-20 and/or 117-131. From anti-HLA class-II 
blocking experiments these epitopes preferentially activated CD4+ T cells. These T 
cell responses occurred irrespective of the patients genetic background, in contrast to 
Milich’s observation that the fine specificity of the murine T cell response to HBeAg 
was more dependent on the MHC haplotype of the responder strain (Milich et al.,
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1987). These dominant T cell epitopes are located in the portion of the nucleoprotein 
molecule common to both HBeAg and HBeAg, which confirms, as described earlier 
in this chapter, that core and e Ags are cross-reactive.
1.6.3 CTL Epitopes
Using different synthetic peptides, at least two different HLA class-I-restricted CD8- 
positive CTL epitopes have been identified so far within the HBeAg, which are both 
shared by HBc and HBe Ags. First, aa residues 11-27, an HLA-A2-restricted epitope, 
has been shown to induce a specific CTL response during acute HBV infection 
(Bertoletti et al., 1991).
Table 1.4: Proposed antigenic epitopes within HbcAg.
Epitope/Amino Acid 
Positions
Type of Cell/Epitope Author
1-20 Th Penna-1992
18-27 CTL Bertoletti-1991
50-69 Th Ferrari- 1991
74-89 B Salfeld-1989
84-101 CTL Ehata-1992
107-118 B Colucci-1988
117-131 Th Ferrari-1991
128-135 B Salfeld-1989
141-151 CTL Missale-1993
148-160 B Machida-1989
Note: Numbers indicate amino acid residues within the core protein. B, Th and CTL represent B- 
cell, T helper and CTL epitopes, respectively.
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Second, aa residues 141-151 have been shown to induce a specific CTL response that 
was restricted by two independent HLA class-I alleles in vivo in human; HLA-31 and 
HLA-Aw68 (Missale et al., 1993). The latter responses have been shown to focus on 
precisely the same 11-residue sequence, recognized by patients with acute HBV.
From various clinically-based observations, a number of CTL epitopes have been 
proposed within the core gene encompassing aa residues 84-101 (Figure 1.12, table 
1.4) (Ehata et al., 1991, 1992, 1994); 141-151 (Khakoo et a l, 2000) and 147-155 
(Chuang et al., 1993). The basis for identification of such CTL epitopes was that 
chronically HB-infected patients with ineffective CTL responses showed a relatively 
high mutation rate in these regions. They therefore suggested that these putative CTL 
epitopes might be sites under immune pressure, leading to emergence of CTL- escape 
mutants. However, they did not present data to support the existence of such CTL 
epitopes.
1.7 HBV PATHOGENESIS
The diversity of clinical syndromes and disease manifestations associated with HBV 
strongly suggest that the outcome of this infection is determined by the quality and 
vigour of the antiviral immune response produced by each infected individual. Several 
factors must coexist for the immune response to clear the virus. First, the local 
immune response must be vigorous enough to mount a strong CTL response. Second, 
the infected cell must be able to produce the appropriate antiviral activity in response 
to the immune cell-mediator. Third, the virus life cycle must include functions that are 
susceptible to those antiviral factors, e.g., degradation of viral RNA post- 
transcriptionally by CTL and inflammatory cytokines (Tsui et al., 1995; Guidotti et 
al., 1997). The pathogenic mechanisms responsible for liver cell injury in HBV 
infection are not well understood, though it appears that the virus is not directly
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cytopathic for the infected hepatocytes. This finding is based on one of the 
observations that ASC (asymptomatic chronic) HBV carriers have normal liver 
morphology and function despite the presence of high levels of viral replication 
within their hepatocytes (Milich et al., 1995a). In contrast, a direct cytotoxic effect of 
large amounts of accumulating viral proteins could cause a sudden necrosis of the 
hepatocytes (Stemeck et al., 1997). Chisari et al (1987) has shown in a transgenic 
mouse model that intracellular accumulation of large surface protein is directly 
cytopathic to the hepatocytes (ground glass appearance). Similarly, introduction of a 
pre-S mutant (G133E) into ducklings resulted in hepatic destruction (Lenhoff et al., 
1998). High level accumulation of intracellular HBcAg can also be cytotoxic for 
hepatic cells (Roingeard et al., 1990a; Rosmorduc et al., 1994).
1.7.1 HLA Antigens and HBV pathogenesis
HLA associations with HBV infection have provided evidence for a genetic 
predisposition to development of the chronic carrier state. Antigen-specific T cell 
receptors recognise peptide bound to HLA molecules and the repertoire of peptides 
bound depends on the HLA type of the individual. Therefore, HLA type is likely to 
influence susceptibility to chronic HBV infection. Although each individual HLA 
allele has the potential to bind many different peptides, there is a degree of specificity 
that results in different HLA molecules having individual peptide-binding repertoires. 
This is widely thought to be the molecular basis for many of the well known 
associations between HLA type and chronic infections, such as malaria (Almarri et 
al., 1994). The relationship between HLA types and certain diseases has focused 
attention on HBV persistence and, in particular, DR alleles. The hypothesis that the 
outcome of HBV infection is influenced by the HLA-associated immune response has
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been evaluated in many studies. For example, the association of HLA-BW15, HLA- 
A1 and B8 with persistent HBs antigenemia was known in the 1970s (Hillis et al., 
1977). HLA-B7 in white carriers (Sampliner et al., 1981), but DQA1*0501, 
DQB1*301 and DRB1*1102 in African-American carriers (Thio et al., 1999) were 
found to confer resistance to chronicity. Also, an association between resistance to 
chronicity and HLA-DQB1*1101/1104 and HLA-DQA1*301 has been reported in 
Chinese patients (Jiang et al., 2003). Carbonava et al, (1983) demonstrated a linkage 
between HBV chronicity and HLA-B40 in males as well as AW30, CW5, B18, B14 
and DR1 in female patients. Moreover, they found a negative association with DR4 in 
females, in keeping with a hypothesis that even if HLA is not of major importance in 
the carrier state, a protective effect by DR4 may exist, similar to DR2 in type I 
diabetes. There is an association between a self-limited course of acute HB and 
presence of HLA-DR Bl-1302 in West Africa (Thursz et al., 1995), DR Bl-1301 and 
1302 among Caucasians (Hohler et al., 1997) and DR13A in Asians (Ahn et al., 
2000). This indicates a strong association between HLA-DR13 and more vigorous 
HBcAg-specific CD4+ T cell responses, which are associated with a self-limited 
course of HBV infection and protection from chronicity (Diepolder et al., 1998; Cao 
et al., 2002). DR Bl-1301 and 1302 are also believed to protect against non­
responsiveness to the recombinant HBV vaccine (Hohler et al., 1997, 2002). In 
keeping with these findings, alleles DRB1*01, DRB1*I1, DRB1*15, DQB 1*0501 
and DPBI*0401 were strongly associated with a higher response (reviewed by Milich, 
2003). Furthermore, immunodominant CTL epitopes restricted by HLA-A2404 have 
been identified in East Asia (Sobao et al., 2001). Collectively, these results suggest 
that the epitopes for CTL/Th recognition might be different on account of the diverse 
distributions of HLA antigens in different geographic regions. Analysis of patients
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with different HLA haplotypes revealed that several sequences within the HBV 
proteins, in particular core, could induce significant levels of T cell response. These 
issues will be discussed in more detail below.
The presence of HBcAg-specific-CD4+ and CD8+ T cells in the infected liver is well 
documented (Ferarri et al., 1987; Penna et al., 1992). The relation between HLA class 
I and II restricted T cell responses to nucleocapsid antigens in patients at different 
stages of HBV infection has been studied in several clinically-based studies. Various 
immunodominant epitopes for both T cell groups have been identified.
1.7.1 A HLA-class I Molecules
Previous results, mostly based on CTL studies, have shown that HLA class I antigens 
have been involved as target structures in viral clearance. Using anti-HLA 
monoclonal antibodies, Lakhdar et al and Wallace et al, blocked the lysis of an EBV- 
transformed cell line by EBV-specific CTLs reactivated in vitro (Wallace et al., 1981; 
Lakhdar et al., 1984). Similar observations have been noted for influenza virus 
(McMichael et al., 1977).
The presence of HLA class-I and class II on the hepatocyte membrane has been 
described by Montano et al (1982) and Lautenschlager et al (1984). They found that 
display of HLA class I in chronic HBV infection was closely related to both the 
HBeAg/anti-HBe status and histological activity; HLA class I Ag was undetectable on 
the hepatocyte membrane in the early immune tolerance phase of chronic HBV 
infection. These Ags became detectable in the immune clearance phase and persisted 
or even became more intense after seroconversion when replication ceased and 
inflammatory activity became minimal. They further suggested that the increase in 
expression of HLA class I in chronic HBV infection probably occurs during the 
period of seroconversion. Thus, expression of the viral determinants on the membrane
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of the hepatocytes seems closely related to active intrahepatic HBV replication (Ray 
et al., 1976; Chu et al., 1988). Similarly, extending their previous observations on 
mice, McMichael et al observed that CTL recognise viral Ags on hepatocytes only in 
the context of HLA class-I (McMichael et al., 1977).
HLA-A2-restricted epitopes have been mostly used for studies of HBV-specific CTL 
in patients with hepatitis B (Bertoletti et al., 1991; Penna et al., 1991; Chuang et al., 
1993; Hwang et al., 2002; Shimada et al., 2003), because it is a common haplotype. 
The most dominant HLA-A2-restricted CTL epitope within the core is from aa 18-27 
(Bertoletti et al., 1991). Missale et al, (1993) demonstrated that two independent class 
I molecules, HLA-A31 and HLA-AW68 bound to core aa 141-151 in acute HBV 
infection. In a small number of Southeast Asian patients, HLA-A24 was the most 
common HLA class I allele found in this region (Soboa et al., 2001).
In several studies in transgenic mice, CTL have also been shown to clear HBV RNAs, 
proteins, nucleocapsid particles, and DNA replicative intermediates from the liver and 
virions from the serum of these animals, mostly by non-cytopathic mechanisms 
(Guidotti et al., 1999, 2001, 2002; Kakimi et al., 2001; Baron et al., 2002; Thimme et 
al., 2003). The clearance occurs quite rapidly without massive destruction of the liver. 
Thus, it is possible that the immunopathological and antiviral effects of the CTL 
response could be due either to the direct cytopathic effect or to the action of antigen- 
nonspecific mediators, which post-transcriptionally degrade the viral RNA and 
possibly cccDNA without a cytopathic effect (Tsui et al., 1995; Guidotti et al., 1997, 
1999; Kimura et al., 2002; Thimme et al., 2003). This effect of non-cytolytic 
clearance of HBV from the hepatocytes by CTL-derived cytokines is several orders of 
magnitude more efficient than its destructive effect (Figure 1.13) (reviewed by Chisari 
et al., 1997), and it has been shown to decrease total HBV DNA by >50-fold
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(Thimme et al., 2003). The potential for a single CTL to kill many infected 
hepatocytes in vivo may be much less than the cytolytic capacity of the same CTL in 
vitro, because of differences in both target cell sensitivity and experimental conditions 
(Guidotti et al., 1996).
Like the case of HBV, other viruses, including adenoviruses (Zhang et al., 1998), 
coxsackievirus (Horwitz et al., 1999), and measles virus (Parra et al., 1999) are 
susceptible to the antiviral activity of cytokines produced by CTLs. Moreover, non- 
cytopathic inhibition of replication of these and other viruses including retroviruses, 
influenza viruses, vesicular stomatitis virus, HSV, vaccinia virus and reovirus by IFN- 
a/p has also been reported (Vilcek, 1996; Samuel et al., 2001).
1.7.IB HLA class-II Molecules
The humoral immune response during HBV infection is an important indicator of 
underlying T-cell function or dysfunction (Milich et al., 1995). The main function of 
HLA class II gene products is to bind antigenic peptides derived from exogenous and 
endogenous proteins and to present them, at the cell surface, to the T cell receptor on 
CD4+ T lymphocytes Penna et al., (1992) suggested that HLA class-II restricted CD4+ 
cells could also potentially participate in the clearance of infected hepatocytes. 
Expression of HLA class II determinants on the liver cell surface following HBV 
infection has only been reported by Van Den Oord et al., (1986) which therefore 
remains to be clarified. Whether CD4+ T cells directly cause liver injury or mediate it 
through the activation of HBc/eAg-specific CD8+ CTL is controversial. It is possible 
that CD4+ T cells mediate liver injury directly through a FAS-FASL mechanism, or 
alternatively, through the production of cytokines by a CD4+ Thi-like response (see 
below) (Milich et al., 1997b; Chen et al., 2001; Cao et al., 2001). The T cell 
independence of HBcAg was based on the observations that naive human B cells
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Figure 1.13: N oncytolytic clearance of HBV from the hepatocytes by CTL-derived cytokines.
As shown the curative effect o f the CTL response is several orders o f m agnitude more efficient 
than its destructive effect. Taken from Chisari et al., 1997.
were able to produce HBcAg-binding human IgM; however, HBsAg was unable to 
induce the production o f anti-HBs antibodies in the same manner (Milich et al., 1986; 
Cao et al., 2001). On the other hand, high levels o f antibody production in mice 
immunised with a mutant HBcAg indicated the ability o f the core particle to induce B 
cell immunogenicity through CD4+ T cell priming as well (Lazdina et al., 2003). The 
humoral response to HBsAg is T cell dependent and shows great variation with a 
significant fraction o f  humans responding poorly. The S gene product is also a 
relatively poor inducer o f the cell-mediated response (Ferarri et al., 1990; Milich et 
al., 1995a; Reignat et al., 2002).
There are distinct subsets o f regulatory CD4+ Th cells designated as Thi and Th2 
cells. Mouse experiments have demonstrated that HBcAg-induced cytokine responses
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are epitope-dependent. If the linkage of this skewing toward either a Thi- or Th2-like 
response in transgenic mice holds true for man, this would form the basis for linking 
the T cell subsets to the pathogenesis of chronic disease. In this regard, a number of 
investigators proposed an important role for cytokines as having both direct anti-HBV 
properties as well as determining the outcome of HBV infection. This is due to 
observations that Th-subsets are largely defined by a unique pattern of cytokine 
secretion.
Allelic differences in HLA molecules can modulate their ability to bind peptides, and 
thereby change the nature of T cell recognition by Th subsets that have different 
patterns of cytokine production (Abbas et al., 1996). The effects of 
immunomodulatory cytokines (IL-12, EFN-a, IFN-y) on HBV suppression has been 
studied in some detail (Porres et al., 1988; Fattovich et al., 1989; Kakumu et al., 1991; 
Guidotti et al., 1994; Brunetto et al., 1995; Aikawa et al., 1995; Rossol et al., 1997; 
Suri et al., 2001, Hyodo et al., 2003). Following stimulation, HBc/e antigen-specific T 
cells progress from nai've cells to Tho cells that further differentiate into Thi or Th2 
cells. HBcAg-induced Thi cells mainly produce interleukin IL-2, IL-12, TNF-P and 
IFN-y, thereby favouring cellular immune responses such as macrophage activation 
and delayed-type hypersensitivity (DTH) which can also lyse HBcAg-specific human 
B cells (Milich et al., 1995b, 1997b; Cao et al., 2001). Th2 cells mainly produce IL-4, 
IL-5, IL-6, IL-10 and IL-13, cytokines that not only stimulate humoral responses but 
can also suppress Thi cellular responses (Milich et al., 1997c, 1998; Penna et al.,
1997). Thi and Th2-type responses are thus antagonistic. Because both HBcAg and 
HBeAg are produced during wild-type HBV infection and because the Thi and Th2 
subsets are cross-regulatory, a dynamic balance between the HBcAg/HBeAg-specific 
Thi and Th2 subsets may exist. If so, alterations in the Thi -Th2 cell balance would be
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expected to influence the course of the infection in terms of both liver injury, 
persistence, and antiviral therapy (Millich et al., 1997c; Hultgren et al., 1998, Hyodo 
et al., 2003).
1.7.2 ACUTE HBV
The consequence of acute HBV infection in adults depends strongly on their 
immunological status (Koibuchi et al., 2001). During the early stages of acute HBV 
infection, before the immune system is fully mobilised, the first line of defense 
appears to be the production of interferon. It may exert an antiviral effect and enhance 
natural killer cell cytotoxicity.
1.7.2A NKT and NK cells
HBV virions and subviral particles contain glycolipids and phospholipids derived 
from the cellular membrane (Ganem et al., 1996), that can be processed by CD1+ cells 
(professional APCs and hepatocytes) and presented to intrahepatic natural killer T 
(NKT) cells (direct mechanism) (Kakimi et al., 2000). NKT cells are particularly 
abundant in liver and they are thought to play a role in HBV-immunity by producing 
anti-viral cytokines. NK cells are promptly activated by NKT cells and enhance 
induction of IFN-y production. Since the induction of IFN-y and IFN-a/p as well as 
the inhibition of HBV replication occurs before a significant number of inflammatory 
cells are recruited into the organ, it is likely that these cytokines are produced by cells 
that reside in the liver.
1.7.2B CTL/Th Response
Enhanced T cell responses directed to HBcAg in patients with acute HBV temporarily 
coincide with viral clearance. A few class-I and class II-restricted T cell epitopes have 
been defined in HBV proteins. The envelope and polymerase antigens are more often 
targeted by the class I-restricted CD8-positive CTL response in such patients
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(Nayersina et al., 1993; Chisari and Ferarri 1995; Rehermann et al., 1995). In acute 
infection an efficient CTL attack against hepatocytes expressing HBcAg-derived 
peptides plays a major role in the selective lysis of infected cells. This response 
extends to multiple viral epitopes (Missale et al., 1993); it is polyclonal and multi­
specific (reviewed by Chisari and Ferarri, 1995; Nayersina et al., 1993). In an 
important study, Bertoletti et al (1993) demonstrated that 90% of HLA-A2-positive 
patients with acute HBV infection produce an HLA-A2-restricted, CD8-positive CTL 
response to a 10-residue epitope that maps between aa 18 and 27 of HBcAg. 
Interestingly, this response was not detectable in HLA-A2-positive patients with 
chronic infection (Penna et al., 1991). Several HLA class I-restricted epitopes, 
specially core aa 18-27; envelope aa 183-191, aa 250-258 and aa 335-343; and 
polymerase 455-463 are recognized by the majority of patients during acute HBV 
(Nayersina et al., 1993; reviewed by Chisari and Ferarri, 1995). Thus, polyclonality 
and multispecificity of the CTL response mitigate against the emergence of viral 
escape mutants during acute viral hepatitis (Chisari and Ferarri, reviewed 1995). 
HBcAg is a major immune target (Mondelli et al., 1982; Chu et al., 1987; Ferrari et 
al., 1987; Milich et al., 1989) and serves as an inducer of the Th cells (Marinos et al.,
1994). Also, the class II-restricted, CD4-positive helper T cell is focused principally 
on the nucleocapsid Ag (Ferarri et al., 1990; Marinos et al., 1994; Chisari and Ferarri, 
reviewed 1995; Cao et al., 2001) and appears to be much more efficient than HBV 
envelope antigen with respect to activation of virus-specific T cells during acute HBV 
infection (Ferarri et al., 1990, Reignat et al., 2002, Hyodo et al., 2003). This is partly 
related to the fact that the humoral responses to the envelope Ags can show great 
variation from patient to patient during infection and after vaccination, ranging from 
high to non-responder phenotype (Milich et al., 1995a). Also, it is thought that T cell
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responses to HBcAg could contribute in vivo to HBV clearance by amplifying and 
accelerating the development of neutralising anti-envelope antibodies (Ferarri et al.,
1990). However, anti-HBc/HBe do not neutralize viral infectivity (Chisari and Ferarri, 
reviewed 1995).
1.7.3 CHRONIC HBV
For a non-cytopathic virus to persist, it must be able to evade immune surveillance; 
there must be either an ineffective antiviral immune response, or the virus must 
escape an otherwise efficient response. All of these might be involved in HBV 
persistency.
As tolerance against HBcAg/HBeAg eventually diminishes, there ensues a battle 
between virus and host, with different outcomes depending on immune status and 
HLA phenotype. Some progress has been made recently in teasing out the relationship 
between host and viral factors in this process. Viral persistence is generally thought to 
be due to an inadequate antiviral T lymphocyte response. This concept has derived 
from animal models of viral infection and from the study of patients who 
spontaneously clear the virus (in whom there is a strong virus-specific CD4 and CD8 
response). This view is supported by several observations that patients with 
concurrent HIV infection or patients receiving immunosuppressive therapy are more 
likely to develop viral persistence (Heathcote et al., 1994).
1.7.3A HBeAg Seroconversion
Seroconversion from HBeAg to anti-HBe usually signifies a reduction in viral 
replication or clearance of the virus (Cariani et al., 1992; Carman et al., 1995a) and 
resolution of an acute case or the appearance of a milder, chronic infection with low 
or undetectable virus levels. The term HBeAg/anti-HBe seroconversion has become 
complicated by recent information that anti-HBe production can coexist with serum
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HBeAg for long periods (years) in a very small proportions before the actual loss of 
HBeAg from the serum. It may be more accurate to view seroconversion as a long­
term process in which HBeAg and anti-HBe coexist within immune complexes first in 
HBeAg excess and then, over time, in anti-HBe excess (Maruyama et al., 1998). In 
patients with chronic hepatitis during HBeAg/anti-HBe seroconversion there is 
evidence of a vigorous immune response characterised by CD4+ T-helper-cell 
proliferation to HBcAg and emergence of anti-HBe (reviewed by Chisari and Ferrari,
1995). When HBeAg/anti-HBe seroconversion is followed by biochemical and 
histological remission, the subsequent low level of viral replication (detected only by 
PCR) implies that the dominant virus has been recognised and suppressed (or perhaps 
eliminated) by the immune response. The lack of serum HBV DNA in HBeAg 
positive patients can predict seroconversion to anti-HBe. However, when active 
disease persists with high level viremia, it is common that a virus (sometimes a pre-C 
mutant) has emerged that has evaded a critical element of the immune response 
(Carman et al., 1995a; Rodriguez-Frias et al., 1995; Maruyama et al., 1998).
1.7.3B HBV Variants
In populations worldwide, variants of HBV are selected after seroconversion to anti- 
HBe (Carman et al., 1989; Naoumov et al., 1992; Boner et al., 1995; Gemer et al.,
1998). In some cases, years of anti-HBe positivity were necessary before selection of 
the pre-C stop codon variant (Carman et al., 1994). However, there is dispute 
regarding their degree of pathogenic potential. In some patients who showed 
persistence of serum HBV DNA despite seroconversion to anti-HBe, a translational 
stop codon at the 3’ end of pre-C, predicting prevention of HBeAg synthesis, was 
reported in several studies on chronic HBV-infected patients (Carman et al., 1989; 
Naoumov et al., 1992; Maruyama et al., 1998). This variant has been found in
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asymptomatic carriers (Akarca et al., 1994; Gandhe et al., 2003), in fulminant 
hepatitis (Hasegawa et al., 1994; Friedt et al., 1999), in patients with hepatocellular 
carcinoma (Takahashi et al., 1998; Zhong et al., 2000), after interferon (IFN) therapy 
(Gunther et al., 1992; Zhang et al., 1996) and after immunization (Lee et al., 1996). 
A 1896 appears to be associated with severe liver disease in HBeAg negative patients 
with enhanced HBV replication (reviewed by Lok et al., 1997). However such a 
relationship between HBe-negative variants and severity of disease has not been 
confirmed by French and American researchers, who proposed epidemiological 
reasons for this correlation (Feray et al., 1993; Friedt et al., 1999). It is now 
recognised that the occurrence of Ai896 is restricted to HBV genotypes with a T at 
nucleotide 1858 (reviewed by Lok et al., 1997), and this may account for its high 
prevalence in Asia and the Mediterranean basin, where the predominant HBV 
genotypes (B, C, and D) frequently have Tisss (Chan et al., 1999; Yoo et al., 2003). It 
has a low prevalence in the West, South and central America (Feray et al., 1993; 
Laskus et al., 1993), where the predominant HBV genotype A, F and H, almost 
always have Cisss (Inoue et al., 1998; Chan et al., 1999; Norder et al., 2003), which 
prohibits development of Ai896 (Li et al., 1993; Inoue et al 1998; Sanchez-Tapias et 
al., 2002). An additional mutation A 1899 accompanies Ai896 occasionally (Carman et 
al., 1989; Laras et al., 1998). A1899 was also observed in isolates from several patients, 
but the functional implication of this mutation is still undefined (Cariani et al., 1992). 
A1899 is reported to be usually found with A] 896 (Carman et al., 1989). Similarly, Ai898 
is linked with Ai856 (reviewed by Carman, 1998). However, not all HBeAg negative 
carriers harbour the Ai896 variant (Naoumov et al., 1992). It is proposed that the most 
common pre-C mutants (Ai896, A1899 and Ai89s) enhance the stability of the lower 
stem of the encapsidation signal (e) by replacing less stable T-G pairs between
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nucleotides 1858-1896, 1855-1899 and 1856-1898, respectively, with more stable T- 
A pairs ( Fig 1.2) (reviewed by Lok et al., 1997; reviewed by Papatheodoridis, 2001). 
Collectively, these authors suggested that failure to produce a target antigen may be a 
way to evade the clearance of infected hepatocytes, which in turn will explain viral 
persistence of the HBe minus mutants after seroconversion to anti-HBe (Carman et 
al., 1993). It seems likely that secretion of HBeAg represents a viral strategy to 
maintain a long-term infection without eliciting an overly destructive immune 
response, which would eliminate the virus and/or kill the infected host (Milich et al., 
1997b). However, this is in contrast to the view that the severe liver damage is not due 
to the pre-C mutation per se, but to the high virus load despite the absence of the 
general marker for active infection, HBeAg, in serum (Hannoun et al., 2000a).
The serologic status after seroconversion of many chronic HBV patients is consistent 
with low level transcription of HBeAg-producing HBV DNA. Decreased levels of 
viral replication after seroconversion in these patients is marked by the inability to 
detect serum HBV DNA, decreased infectivity, and the decreased production of free 
HBeAg. It should be noted that the production of free HBeAg in chronic HBV 
patients can and does coexist with anti-HBe production. Therefore, it appears that 
HBeAg to anti-HBe seroconversion results from immune responses directed against 
HBeAg-expressing wild type virus, but this process does not necessarily involve the 
selection of e-minus HBV DNA variants. In fact, the low level of HBV infection that 
persists in many of these seroconverted-chronic patients is caused by pre-C wild type 
virus. This implies that small amounts of HBeAg co-exist with anti-HBe, possibly 
still modulating the immune response (Uy et al., 1986). This level of HBV replication 
may be below the threshold necessary to evoke an immune-mediated lytic response, 
and low level viral replication may be maintained by an ongoing antiviral immune
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response (Maruyama et al., 1998). Alternatively, it may be sufficient to stimulate an 
immune response and consequently eliminate the wild type, prolonging virus 
persistence (Lee et al., 1996).
During chronic HBV infection, HBcAg is the only antigen that elicits a prominent 
immune response (Milich et al., 1997c), and in many reports, aa variability of HBcAg 
has been linked to the severity of liver disease, both in the HBeAg and anti-HBe 
phase, which leads to the hypothesis that patients who cannot clear the virus via a 
CTL response are susceptible to anti-HBc-mediated lysis of hepatocytes with the 
consequent selection of escape mutants (Carman et al., 1994, 1997b; Naoumov et al., 
1997; Kratz et al., 1999). During the HBeAg-positive phase of chronic hepatitis, C- 
gene sequences have been reported to be relatively conserved, irrespective of disease 
activity (Carman et al., 1995a; reviewed by Lok, 1997). Selection of large numbers of 
aa substitutions within the core region seems to require not only seroconversion to 
anti-HBe, but also the previous selection of a pre-C stop codon.
Mid-core deletions have been found in patients with various types of chronic 
infection: in active liver disease (Wakita et al., 1991); in children with persistent 
viremia (Ni et al., 2000); in symptomatic carriers (Tsubota et al., 1998); and even in 
the HBeAg positive phase (Akarca et al., 1995b; Marinos et al., 1996). They have also 
been reported in HB-infected immunosuppressed patients (Gunther et al., 1996; 
Preikschat et al., 2002; Bock et al., 2003). Sequential analysis of core gene aa 
variability from the quiescent to the active phase of chronic infection showed that the 
mid core gene mutations may offer some advantage over viral replication and 
synthesis in persistent infection (Wakita et al., 1991; Tsubota et al., 1998; Bock et al., 
2003). However, in some other studies these deletion mutants were reported not only 
to be replication defective, but also to suppress the replication of wild type (Marinos
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et al., 1996; Ni et al., 2000). Core gene deletions were located within aa 81-113 
(Ackrill et al., 1993); 79-112 (Akarca and Lok, 1995); 63-132 (Wakita et al., 1991); 
20-132 (Ni et al., 2000), and 64-128 (Tsubota et al., 1998). These residues cover 
different epitopes: one CTL, two T helper, and three B cell (see section 1.6, table 1.4), 
and may change the immunological properties of HBcAg giving rise to immune 
escape.
Apart from pre-C and core variants, common changes during seroconversion include 
variants o f the basal core promoter (BCP), which is embedded in the X gene. 
Deletions, insertions and point mutations (Chan et al., 1999) have all been described. 
Among them, T1762/A1764 is common (Okamoto et al., 1994; Takahashi et al., 1998). 
Such mutations occur by substitution of A to T at nucleotide 1762, and G to A at 
nucleotide 1764, which may interfere with transcription of the HBeAg precursor 
(Okamoto et al., 1994; Laras et al., 2002). Although the effect o f such mutations on 
the synthesis and secretion o f HBeAg is not complete (Okamoto et al., 1997), Laras 
and colleagues found the absence or low levels of pre-C mRNA transcripts in patients 
who harboured these double mutations (Laras et al., 2002). Those mutations were 
significantly more common in patients infected with HBV who had C l858 (Chan et 
al., 1999). There is a striking presence of both BCP and pre-C mutants in anti-HBe 
positive infants with fulminant hepatitis (Friedt et al., 1999), however, the role o f such 
an association is controversial because they have also been found in some HBeAg- 
positive patients without fulminant hepatitis (Carman et al., 1995a; Hou et al., 1999; 
Chu et al., 2003a). In Chinese symptomatic and asymptomatic chronic HB infection, 
it was suggested that T1762/A1764 mutations were present or developed first to down 
regulate HBeAg expression, followed by introduction o f a pre-C stop codon mutation, 
which then completely eliminated HBeAg synthesis (Hou et al., 1999). There is some
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controversy in the literature concerning whether these mutations really enhance 
replication of HBV. As the pre-C gene and its products have also been reported to 
inhibit HBV progeny DNA synthesis (Laras et al., 1998), some hypothesised it is 
possible that one or several of the many substitutions interfered with the effects of the 
pre-C stop codon and the mutations on viral replication (Stemeck et al.,
1997, 1998).
Also, a number of X-region deletions and mutations have been described by a number 
of groups in chronic carriers (reviewed by Carman et al., 1998; Baumert et al., 1998; 
Baptista et al., 1999; Blackberg et al., 2003; Hwang et al., 2002, 2003). Finally, 
numerous missense and silent mutations in the preSl/S2 region were identified after 
anti-HBe seroconversion (Sanantonio et al., 1992; Gemer et al., 1998; Ding et al., 
2003; Sugauchi et al., 2003), but their significance is unclear.
1.7.3C Chronic HBV and T-cell Response
In chronic carriers, the HBcAg specific Th response is significantly weaker, and in 
many patients, undetectable. This difference in the HBcAg-specific Th activity 
between acute and chronic HBV infection supports the concept that the Th cell 
response to HBcAg may influence the outcome of HBV infection (Hyodo et al., 
2003). HBcAg-specific Th cell non-responsiveness (or tolerance) is reversible, 
enhancing both the humoral and cellular effector immune response to HBV in chronic 
patients. The induction of this response may play a role in the transition from the 
immunotolerant phase of chronic HBV to the active phase, and eventually 
seroconversion (Marinos et al., 1994).
Milich and co-workers (1986) observed that the two forms of the HBV nucleoprotein 
preferentially elicited different Th cell subsets and may have profound implications in 
terms of the mechanisms of viral persistence and immunopathogenesis. Many
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chronically infected patients maintain IgM anti-HBe, although usually at low titres. 
The switch from predominantly IgM to high titres of IgG anti-HBe requires T-cell 
help function, which may be variably present from patient to patient and defective in 
patients who progress to chronicity, as the T cell response to HBc/HBe antigens is 
strong during acute hepatitis and weak in chronically infected patients. Thus, a strong 
antibody response in chronically infected patients may be due to the known T cell 
independence of HBcAg. This would explain the slow decline in IgM anti-HBe titres 
during the first 1 to 2 years of chronic infection. Since T cell recognition of HBcAg 
and HBeAg is highly cross reactive, T-cell help for IgG anti-HBe production would 
presumably also stimulate anti-HBe production. One would then predict that the 
decline of IgM in favour of IgG anti-HBe should correlate with anti-HBe 
seroconversion (Milich et al., 1986). HBcAg elicited primarily IgG2a and IgG2b anti- 
HBe antibodies, whereas the anti-HBe antibody response was dominated by the IgGl 
isotype (Milich et al., 1997c). These results indicated that HBcAg preferentially, but 
not exclusively, elicits Thi-like cells and that HBeAg preferentially, but not 
exclusively, elicits Tho-or Th2-like cells. These results may have relevance in chronic 
HBV infection since circulating HBeAg may downregulate antiviral clearance 
mechanisms by virtue of eliciting anti-inflammatory Th2-like cytokine production 
(Milich et al., 1997a).
Other groups have shown that host genetic background determines Thi v TI12 
switching. Some alleles, such as DR3, DR13 and DR14 preferentially induce a Thi 
(cellular) response, which would inhibit the TI12 (humoral) response and limit the 
production of anti-HBs antibodies (Caillat-Zucman et al., 1998; Cao et al., 2001). 
Conversely, the response would be skewed towards TI12 responsiveness in subjects 
with DR1 and DR2 alleles (Caillat-Zucman et al., 1998).
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CTL exhaustion (or anergy) has been proposed as being involved in HB persistence. 
Chisari and Ferarri, (1995) have shown that the number of potentially infected 
hepatocytes in the human liver (-1X1011), compared to the number of CD8  (-25% of 
total body CTL population of -1X1012) would require an extraordinary high 
proportion of the total body CTL to be in the liver. This exhaustion of antiviral CTL 
stimulated by high dose antigen is supposed to occur in HB infection acquired in 
adulthood, whereas clonal deletion of HBV-specific T cells as a consequence of 
transplacental HBV infection is believed to be involved in vertically infected patients. 
Both of these factors reduce the number of HBV-specific T cells in chronically 
infected patients. However, in a recent study using MHC/peptide tetramers and ICCS 
(intracellular cytokine staining) methods, Reignat et al demonstrated that a population 
of envelope-specific CD8  cells escaped exhaustion mediated by high concentration of 
antigen. In addition, they showed that core (aa 18-27) and envelope (aa 183-191)- 
specific CD8  cells were able to expand, displaying the same proliferation potential, 
activation threshold and IFN-gamma production ability as memory CD8  cells present 
in immune individuals. These cells were characterized by altered HLA/peptide 
tetramer reactivity and could be reversed with repetitive stimulation. They suggested 
therefore that these cells were not “anergic”, but, “ignorant” instead (Reignat et al., 
2002).
T cell exhaustion and mutational escape have been shown to be involved in other 
persistent virus infections such as HCV, HIV and LCMV. Escape through “speed” has 
been demonstrated as a strategy of RNA viruses leading to high level antigen 
persistence in the presence of low levels of CD8  and CD4 T cells in human and 
animal models (Gallimore et al., 1998; Lenchner et al., 2000; Ou et al., 2001, 
reviewed by Lucas, 2001). CTL-escape mutations have also been described
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extensively in these viruses (Lechner et al., 2000; reviewed by Sewell, 2000; 
reviewed by Lucas, 2001; reviewed by Klenerman, 2002) although with some 
differences; e.g., only infection with high doses of LCMV results in the generation of 
CTL escape variants (Pircher et al., 1990).
1.7.3D Chronic HBV and HBcAg Localisation
For liver cells to become a “target cell” at least theoretically there should be viral 
antigens in the cell membranes before the process of necrosis. The significance of the 
membranous expression of viral antigens in the pathogenesis of hepatic injury has 
been studied extensively and some authors suggested a strong correlation between 
membranous expression of HBsAg with overall activity of liver disease (Ray et al., 
1976; Gowan et al., 1983; Chu et al., 1988; Chu et al., 1995 a and b; Sharma et al.,
2002). The same finding has been proposed for membranous expression of HBcAg 
during chronic HB infection (Wu et al., 1993), as the blocking effect of anti-HBe was 
attributed to the binding of the antibody to the corresponding antigen on the surface of 
the infected hepatocytes (Mondelli et al., 1982). Variable patterns of HBcAg 
expression in different forms of liver damage have led investigators to postulate that 
this expression may be a prerequisite for immune mediated liver cell damage (Ray et 
al., 1976; Chu et al., 1987; Wu et al., 1996). Differential expression of the HBcAg and 
HBsAg at the cellular level and the ultimate development of different histological 
types of hepatitis reported so far (Ray et al., 1976; Huang et al., 1979; Gowan et al., 
1983; Chu et al., 1994; ter Borg et al., 2000; Sharma et al., 2002), has led to the 
hypothesis of a combination of humoral and cellular immune response in the 
pathogenesis of liver cell injury.
The localisation of HBcAg has significant prognostic implications, as follows: first, 
core Ag possesses unique immunological features (Milich et al., 1997a), and C-gene
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products are major targets of the host immune response, particularly in chronic 
infection (Mondelli et al., 1982; Chu et ah, 1987; Ferarri et al., 1987, 1992; Milich et 
al., 1989). Second, the pattern of the intracellular distribution of C-gene as detected 
by immunostaining, has been associated with different levels of virus replication, liver 
disease activity, and liver cell regeneration (Ray et al., 1976; Akiba et a l, 1987; Wu et 
al., 1993; Ballare et al., 1989; Tong et al., 1990; Chu et al., 1994, 1997; Bock et al., 
2003). Third, the intracellular accumulation of non-enveloped core particles can be 
cytopathic (Roingeard et al., 1990a). Fourth, the presence of mutant core protein in 
liver cells can interfere with the efficiency of virus production (Scaglioni et al., 1994; 
Bock et al., 2003), and possibly with response to IFN therapy (Naoumov et al., 1995). 
The localization of HBcAg in hepatocytes varies even in the same tissue (Akiba et al., 
1987). Many reports in the literature suggested that HBcAg may be expressed in the 
cytoplasm, nucleus or both in infected or transfected cells (Yamada et al., 1977; 
Brechot et al., 1980; Gowan et al., 1983; Uy et al., 1986; Wu et al., 1987; Akiba et al 
1987; Hsu et al., 1987; Fang et al., 1994; Bock et al. 1996; Chu et al., 1997; Naoumov 
et al., 1997; Park et al., 1999; ter Borg et al., 2000; Sharma et al., 2002; Bock et al.,
2003). In fact, although early reports had shown that HBcAg was located in the 
nucleus (Ray et al., 1976; Huang et al., 1979), later reports have made clear that 
HBcAg can be seen in the nucleus or cytoplasm, or both.
Various markers have been postulated to identify patients with a higher general level 
of HBV replication during chronic HB: the presence of detectable HBV DNA (or 
HBV virion) in serum, and expression of HBcAg within the cytoplasm of infected 
hepatocytes (Brechot et al., 1980, 1981; Gowan et al., 1983; Chu et al., 1987; Hsu et 
al., 1987; Ballare et al., 1989; Ou et al., 1990; Chu et al., 1995). In different patients, 
the above markers of virus replication tend to co-exist, and such patients also tend to
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be those with histological evidence of active disease. For example, topographic 
distribution of HBcAg was closely related to HBeAg/anti-HBe status (Ballare et al., 
1989; Ou et al., 1990). Liver cell HBcAg expression can be correlated with the three 
phases of chronic HBV infection: first, HBeAg positivity, immune tolerant phase, 
characterised by nuclear HBcAg, mild disease and high viral replication; second, 
HBeAg seroconversion, immune clearance phase, with virus replication/elimination, 
cytoplasmic and/or membranous HBcAg, and third, inactive virus replication phase 
with negative HBcAg (integrated HBV DNA into host cell), and a bipolar disease 
spectrum (either normal histology, or, cirrhosis and HCC) (Hsu et al., 1987; Wu et al., 
1993; Chu et al., 1997; Serinoz et al., 2003). However, in some patients with 
circulating anti-HBe, no detectable circulating HBV DNA and less active forms of 
liver disease have been reported: intracellular HBV DNA tends to be in a high 
molecular weight form reflecting integration into host cell DNA (Brechot et al., 1981; 
Bonino et al., 1981; Hadziyannis et al., 1983; Gowan et al., 1983; Wu et al., 1987,
1996). The state of HBV DNA in the hepatocytes (free or integrated into the host 
genomes) (Brechot et al., 1981), and the presence of the HBcAg in liver tissue 
represent active replication of HBV. This concept was based on the observations that 
a high concentration of serum HBV DNA has been found in patients with positive 
HBcAg-staining hepatocytes (Chu et al., 1994; Wu et al., 1996). Further, Gowan et al. 
found a huge amount of HBV DNA, much of it in a single-stranded form, in the 
cytoplasm of infected hepatocytes in active cirrhosis. They suggested that the large 
pool of non-encapsidated cytoplasmic HBV DNA indicated cells undergoing 
replication with or without mature virion formation. Then they found a relation 
between HBcAg expression and this form of DNA; cytoplasmic HBcAg was highly 
predictive of the presence of large amounts of cytoplasmic DNA in the same cells,
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whereas, nuclear HBcAg was seen in cells with and without such levels of DNA, 
presumably undergoing latent or abortive infection (Gowan et al., 1983).
Although some authors believed that expression of HBcAg in the hepatocyte nucleus 
is helpful for estimating viral replication in chronic HBV infection (Wu et al., 1996; 
Chu et al., 1997; Lindh et al., 1999; Serinoz et al., 2003), many others suggested that 
cytoplasmic HBcAg was more appropriate as a marker of disease activity (Hsu et al., 
1987; Kakumu et al., 1989; ter Borg et al., 2000). Therefore, the pattern of 
preferential cytoplasmic core staining in different studies has led investigators to 
several speculations. The cytoplasmic expression of cAg was suggested to be due to 
the presence of a particular virus population characterised by multiple mutations in 
the C-gene, which possibly inactivated the function of the nuclear localisation signals 
of the core protein (see below). Mutations may also modulate envelope protein 
interaction with the core protein (Yeh et al., 1994). Point mutations of the pre-C 
region is suggested to prevent nuclear transport of HBcAg. This pattern has been 
shown by a study by Park and colleagues on chronic HB patients who had the A1896 
mutation; they found cytoplasmic expression without a single example of nuclear 
expression (Park et al., 1999).
Another mechanism for cytoplasmic localisation of HBcAg might be related to cell 
cycle regulation. In the G0/G1 phase, HBcAg is predominantly localised in the 
nucleus, whereas, in the S phase, the amount of HBcAg in the nucleus is greatly 
reduced and HBcAg found almost entirely in the cytoplasm (Yeh et al., 1993). This 
hypothesis suggests that the differential subcellular localisation of HBcAg in chronic 
HBV infection is related to the activity of hepatocyte regeneration. Chu and co­
workers demonstrated that almost all of the hepatocytes with nuclear expression of 
HBcAg were quiescent and resting, whilst most of the hepatocytes with cytoplasmic
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expression of HBcAg were regenerating and proliferating (Akiba et al., 1987; Wu et 
al., 1987, 1993; Ballare et al., 1989; Tong et al., 1990; Chu et al., 1995, 1997; Serinoz 
et al., 2003). On the contrary, Naoumov et al (1997) speculated that the influence of 
the cell cycle observed in cultured cells appeared to play only a minor role in vivo. 
Even in patients with cirrhosis and severe chronic hepatitis, with hepatocytes in 
different stages of the cell cycle because of liver cell regeneration, core gene products 
predominantly had nuclear localisation, similar to the finding in patients with minimal 
inflammatory reaction in the liver.
Taken together, the correlation between the degree of expression of HBcAg in the 
nucleus and/or cytoplasm and the level of liver disease activity is relative, not 
absolute. This conclusion is based on some observations on patients who showed a 
high degree of liver disease activity in the presence of nuclear HBcAg expression, and 
on the other hand, mild hepatitis in the presence of cytoplasmic HBcAg expression 
(Hadziyannis et al., 1983; Akiba et al., 1987; Chu et al., 1997).
There is still controversy about the correlation between HBcAg localisation and 
immune hepatocytolysis, as some investigators speculate that a shift of HBcAg from 
nuclear to cytoplasmic is secondary to immune-mediated liver cell injury rather than 
triggering the immune system by itself (Akiba et al., 1987; Chu et al., 1995). 
However, because cytoplasmic/membranous expression of HBcAg correlates rather 
well with the high degree of liver inflammatory activity (Akiba et al., 1987; Wu et al., 
1987, 1993, 1996; Ballare et al., 1989; Tong et al., 1990; Chu et al., 1995), it is 
therefore suggested that hepatocytes with cytoplasmic/membranous expression of 
HBcAg represent target cells for immune hepatocytolysis, which would be followed 
by both subsequent seroconversion from HBeAg to anti-HBe and disappearance of
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HBcAg and regeneration of hepatocytes (Ray et al., 1976; Chu et al., 1987; Wu et al, 
1993; Park etal., 1999).
1.8 HBV EVOLUTION
The origin(s) of viruses cannot be known with certainty. PCR and other sensitive 
molecular techniques will reveal some viral genome sequences from the relatively 
recent past, but very ancient viral genomes will remain a matter for speculation. 
Comparative sequence analysis suggests that both RNA and DNA viruses have deep, 
archaic evolutionary roots both for genome structural organisation and as regards 
certain genomic and protein domains. Both DNA and RNA viruses can emerge and 
evolve by a variety of mechanisms including mutation, recombination and 
reassortment (Holland et al., 1998). Nucleotide substitutions in viral genomes can 
have several effects, including evasion of vaccine-induced or natural immunity, drug 
resistance, and changes in pathogenicity, alteration in tissue or species tropism, and 
viral persistence.
Escape mutation is the process by which aa substitution at one or more positions alters 
the epitope to the extent that the virus can persist in the presence of an adequate 
immune response to the initial epitope. As recognition of the first epitope leads to the 
destruction of infected cells or neutralization of free virus, viruses that encode for the 
expression of a mutated epitope (or cells that present it on their surface) will survive. 
Viruses that are replicating more rapidly are more likely to develop mutations and for 
them to be selected (reviewed by Carman et al., 1995c). A comparison of the rates of 
synonymous and nonsynonymous substitution in viral genomes can elucidate, to some 
extent, whether there has been selection at the aa level. One would expect the rate of 
synonymous to be less than the rate of nonsynonymous substitution if there is 
selective pressure exerted on this viral gene (Mizokami and Orito, 1999).
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1.8.1 HBV Mutation Rate
Although the reverse transcriptase activity of HBV may be responsible for the high 
rate of nucleotide substitution of the virus compared to that of other DNA viruses, 
replication of the HBV genome may not always depend upon reverse transcription 
and thus, the frequency of mutation of the HBV genome during replication may not 
be as high as that of a retroviral genome (Kidd-Ljunggren et al., 1999). This is due to 
the fact that the mutation rate of HBV is influenced by some related factors. Firstly, 
the genome is very compact with overlapping ORFs, which limits the number of 
viable mutations (Morozov et al., 2000). In a virus with overlapping open reading 
frames, many mutations will generate non-viable virions though some mutations may 
give the virus a replication advantage (reviewed by Torresi, 2002). The second 
constraint is imposed by the need to conserve the direct repeats, promoters and other 
cis acting elements, which are involved in replication of the genome. Thirdly, HBV 
replication takes place inside the nucleocapsid and, unlike retroviruses, this process 
involves only one copy of the RNA pregenome, limiting the chance of homologous 
recombination (Morozov et al., 2000, Sugauchi et al., 2002). Despite these 
constraints, up to 12% of nucleotides may vary between isolates of HBV (reviewed by 
Carman et al., 1997c). The net result will be a higher mutation rate in unconstrained 
parts of the genome. One such region is the pre-S, especially pre-S2 (Kidd-Ljunggren 
et al., 1999). Considering the rate of synonymous substitution is higher than 
nonsynonymous substitution for all HBV-ORFs (Yang et al., 1995), it has been 
suggested that HBV genome variation is constrained by aa changes (Orito et al., 
1989). This led to the hypothesis that each protein or each domain of an ORF has its 
own functional and structural constraints which conserve the aa sequence over 
evolution time. The assumption is that the selective force on each ORF works
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independently of the region of gene overlap and that base exchanges in the 
overlapping regions are therefore the result of dual selection by the two overlapping 
ORFs (Kodama et al., 1985). The appearance of mutations in overlapping but 
unrelated viral genes (for example S and P genes) may produce HBV mutants with 
altered antigenicity and/or replication and a natural history that may be distinctly 
different to wild type HBV (reviewed by Carman et al., 1997; reviewed by Torresi, 
2002).
The rate of replication and mutation is an important factor in the genetic evolution of 
a virus. Some DNA viruses, such as hepadnaviruses, which include a reverse 
transcription step in their replication cycle, show rates of evolution in the range of 1 0 ” 
4 to 1 0 “5 substitution per nucleotide per year, which is approaching the values of some 
RNA viruses. HBV exhibits a mutation rate more than 10-fold higher than other DNA 
viruses. The estimated rate of evolution for HBV is <2x10^ base 
substitutions/site/year, which reflects a highly dynamic process with a large 
production of virus (reviewed by Domingo et al., 2001). This value is intermediate 
between DNA and RNA viruses (Morozov et al., 2000). Although the rate of 
synonymous substitutions for HBV is 104 times higher than that of a host genome, it 
is 10”2 less than that of retroviral genes (Orito etal., 1989). Nevertheless, this rate 
provides support for the hypothesis that HBV evolved from a retrovirus or retrovirus­
like progenitor through a process of deletion (Miller and Robinson, 1986; Okamato et 
al., 1987).
The HBV genome is extremely stable unless exposed to host immune responses, as 
exemplified by the completely conserved nucleotide sequence over a 20-35 year 
period in HBeAg-positive asymptomatic carriers with very high levels of virus 
replication. In contrast, mutations are seen in most, if not all, HBeAg-negative carriers
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and are distributed over all regions of the viral genome (Hannoun et al., 2000a). 
Some of these aa substitutions can be found as minor species at earlier time points 
suggesting that the selection process is slow and that multiple strains can co-exist 
(Carman et al., 1996). Some observations have also shown that if conditions do favour 
the emergence of a variant (for example in the case of a poor match vaccine between 
immunity and the virus), then the time-scale of emergence is likely to be in the order 
of decades. As HBV persists in individuals infected for long periods spreading the 
infection relatively slowly, a variant will only emerge slowly (Wilson et al., 1999).
1.8.2 Selection of the fittest strain
The term “fixation” refers to random mutations not being lost but becoming 
incorporated into sequences that undergo further rounds of replication and become 
progeny virions (Carman et al., 1993). There are two ways by which fixation occurs: 
one is the occurrence of mutations that do not affect fitness, which has been shown in 
cell culture in which viral populations gradually shift their consensus sequence while 
exposed to a constant in vitro environment. Lenhoff et al (1998) generated a 
cytopathic mutant of DHBV (G133E) in the pre-S protein of DHBV. Inclusion of this 
mutant into susceptible ducklings resulted in enhanced viral replication, increased the 
pool of viral cccDNA, and caused hepatocyte destruction. The liver damage caused by 
G133E DHBV subsided over time resulting in mild chronic hepatitis similar to that 
observed in wild type virus-infected birds and coincided with a reduction of viral 
replication to wild type virus levels in the liver. Further, they identified at least one 
noncytopathic revertant from the serum of G133E-infected birds after recovery, 
suggesting that acute liver injury could result from infection with a cytopathic 
hepadnavirus, but such viruses may be rapidly replaced by noncytopathic variants 
during persistent infection. In other words, these cytopathic viruses are not as
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replication fit as the wild type in the context of persistent infection (Bartholomeusz 
and Locamini, 2001).
The alternative mode of mutant fixation is positive selection of fitter virus as driven 
by antibodies, antiviral agents, or differences in cell biology. In the natural course of 
HBV infection, cellular and humoral immune pressure against virus-specific proteins 
may select the fittest viral strains (Liu et al., 2002). The type and number of mutations 
that accumulate in an individual genome are either a marker of the duration and/or 
severity of the liver disease, or the type and the intensity of immune response 
(Gunther et al., 1999). Selection by the host is a major force for evolutionary change 
within a virus population (reviewed by Carman et al., 1998). Changes in host 
selection pressure may greatly affect substitution rates in HBV, with lower rates of 
changes in those individuals who continue to produce the viral HBeAg compared to 
those who have cleared it (Carman et al., 1995a; Okamuru et al., 1996; Bozkaya et al., 
1996, 1997). In numerous studies, investigators have shown that during the HBeAg- 
positive active replication phase of chronic infection, despite the virus being capable 
of mutating because of the poor proof-reading ability of reverse transcriptase, 
sequences able to translate HBeAg remain dominant. Possibly, HBeAg-producing 
sequences have an intracellular advantage over HBeAg-nonproducers. Because of the 
dominant replication efficiency of HBeAg-producing strains and thus tolerance, few 
cells appeared to be destroyed before the elimination phase, therefore, there appears to 
be no selection pressure and thus e-minus mutants are lost or remain as minor 
populations. However, during the elimination phase of chronic disease, there is the 
added factor of positive selection pressure, and hepatocytes with HBeAg- 
nonproducing strains become dominant. At the molecular level, this is explained by 
the presence of pre-C mutants (Carman et al., 1996b). Moreover, it has been shown
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that once the resistant virus became predominant in the viral quasispecies obtained 
after treatment with lamivudine, drug removal led to the rapid replacement of the 
resistant virus by the wildtype (Abdolhamed et al., 2002). Other studies showed that 
the pre-C and core promoter mutations were replaced by wild type during long term 
therapy, but with continuing therapy, mutations reappeared independent of viral 
breakthrough (Cho et al., 2000; Suzuki et al., 2002). Selection is likely to occur if the 
immune response is incomplete (by using vaccines or monoclonal antibody 
immunotherapy) (reviewed by Domingo et al., 2001).
1.8.3 HBV Origin
Attempts have been made to relate these observations to HBV evolution. Much of our 
knowledge about human hepatitis has relied heavily upon information derived from 
infection (natural and experimental) of non-human primates during the last 50 years. 
However, there seem to be some difficulties due to the relationship between the 
human genotypes A-E and G (and even more divergent genotype F) to each other and 
to other primate-associated genotypes. The origin of HBV in humans is as confusing 
as that of the hepadnaviruses from other primates. Different theories have been 
proposed by investigators on HBV origins based on the hypothesis that the numbers 
of nucleotide and aa substitutions over time, the molecular clocks, are indicators of 
viral evolution (Mizokami et al., 1999). A primate origin for HBV infection was 
proposed by MacDonald et al., 2000. This theory based on the finding of variants in 
chimpanzees (McDonald et al., 2000), woolly monkeys (Lanford et al., 1998), and 
orangutans (Warren et al., 1999), suggested that these viruses co-evolved with their 
primate hosts over periods of 10-35 million years. This hypothesis has been supported 
by the observations that areas of high HBV prevalence in humans are those in which 
contact with, and cross-species transmission from primates are most likely (South
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America, Sub Saharan Africa and Southeast Asia). Indeed, certain HBV genotypes are 
specific to these three areas (F, E, B/C, respectively). Moreover, the mixture of HBV 
genotypes found outside these areas, such as Europe and North America, may result 
from much more recent epidemic spread (Simmonds et al., 2001a). In contrast, a 
recent emergence hypothesis for HBV infection indicated that the current wide 
distribution of HBV in apes must have arisen through several cross-species or 
subspecies transmission in the relatively recent past (Starkman et al., 2003)
Based on Norder and her co-worker's observation that most of the dendrograms 
obtained from gibbon and chimpanzee strains represented early lineages, assumptions 
were made that these viruses were indigenous to their respective hosts and not recent 
acquisitions from man (genotype F). Therefore, they suggested that either genotype F 
represents an early cross-species transfer from a non-ape primate to man, or that an 
hepadnavirus of a common ancestor to man and apes gave rise to two viral lineages 
(Norder et al., 1996). Thus, they proposed that the evolutionary history of HBV 
corresponds to the spread of anatomically modem humans as they migrated from 
Africa 100,000 years ago (Norder et al., 1994; Magnius and Norder, 1995), and 
different genotypes infecting humans evolved since this dispersal. However, this 
hypothesis does not explain the origin of the various non-human primate vimses 
which are interspersed among the human genotypes in the phylogenetic tree. The 
phylogenetic tree of the various primate HBV variants in no way reflects the 
phylogeny of the host species, as would be expected for co-speciation (Simmonds et 
al., 2001b). For example the presence of genotype F in native American populations is 
inconsistent with the presence of genotype B and C in their genetically nearest 
relatives, the Mongoloid Northeast Asian. Indeed, there is little relationship between 
HBV genotype distribution with any of the other human population groups (Southeast
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Asian, Caucasians, and African population) (Simmonds et al., 2001b). Alternatively, 
the HBV genotypes may have evolved later than, and independent of, human 
migration (Gunther et al., 1999).
According to the finding that HBV showed a substitution rate of 2.1xl0-5  
substitutions per site per year over a mean observation period of 22 years, Orito and 
co-workers proposed that the human genotypes of HBV would have originated from a 
common ancestor approximately 3000 years ago (Orito et al., 1989). In this study, 
they showed that three major clusters of HBV (birds, mammals and humans) diverged 
from their common origin in the same order as that of host evolution. They concluded 
that the evolution of the hepadnavirus family was independent of host-species 
divergence and for HBV in humans this has taken place much more recently than has 
divergence of humans.
Alternatively, a New World origin for HBV was proposed by Bollyky and colleagues 
who suggested that HBV originated from the Americas and spread into the Old World 
over the last 400 years after contact from Europeans during colonisation; a genotype F 
origin. Further, they considered the possibility that if the virus originally entered the 
Americas from Asia, this may have required a higher rate of nucleotide substitution as 
it adapted to this naive human population (Bollyky et al., 1999). However, the main 
problem for this hypothesis is the observation of the widespread distribution of HBV 
in Old World primate species. A remarkable example is a shared genotype of HBV 
infecting West African chimpanzees (McDonald et al., 2000; Takahashi et al 2000), 
which showed approximately 11% divergence from the human genotypes A-E. This 
finding was based on analysis of mutations in the C-terminus region of the core 
protein (which is well conserved among hepadnaviruses) between human genotypes 
E/F and the chimpanzee one. Interestingly, HBV-E/F and the non-human primate
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hepadnavirus had a common motif within 2 0  nucleotides upstream from the stop 
codon for the core gene, whereas, HBV-A/B/C/D genotypes contained a different 
motif at this site (Takahashi et al., 2000). It has been revealed that sequences in wild- 
born Old World primates from Africa and Southeast Asia were unrelated to five 
human HBV strains (A to E) ; the conclusion is that the virus was not acquired from 
humans, and all the Old World non-human primate HBVs were on a common 
ancestral branch (Robertson et al., 2001). This finding together with the observation 
that the closest relative of the woolly monkey HBV is genotype F (Lanford et al., 
1998), led to the speculation that chimpanzees have their own hepadnavirus, which 
resembles the human hepadnavirus (genotype F) (Takahashi et al., 2000; Robertson et 
al., 2 0 0 1 ).
At present, the problems associated with each of these hypotheses for the origin of 
HBV prevent a definitive conclusion. Resolution of these issues requires more 
extensive sequence analysis of HBV in poorly sampled areas as well as combined 
human and primate studies together with utilizing models of DNA substitution which 
better describe the process of viral evolution (Bollyky et al., 1999).
1.8.4 HBV-genotypes evolution
The genetic variability of HBV is observed both as the evolution of genotypes (and 
thus subtypes), i.e. a divergence of the viral genome in the carrier population, and as 
the emergence of mutations in each infected subject (Lindh et al., 1999). Subtypes of 
HBV have largely evolved separately with their hosts over time and random mixing 
of different subtypes within individuals has been rare (Kodama et al., 1985). Okamoto 
et al (1987) observed that a 54-year old patient was chronically infected with three
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different clones of HBV. They suggested that the clones would have evolved from a 
common ancestor virus during 54 years after the primary infection rather than 
infection by three different strains of HBV (triple infection). Further, they suggested 
that following a small-dose infection, only one genotype of virus, predominant in the 
donor, would most likely infect the recipient. In another study the predominant HBV 
genotype was shown to be quite stable over a period of some 30 years (Blackberg et 
al., 2 0 0 0 ).
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Chapter 2 Materials and Methods 
2.1 Materials
2.1.1) DNA Extraction from serum by High Pure Viral Nucleic Acid Kit (Roche 
Diagnostics, Lewes, East Sussex, UK)
Binding Buffer 6 M guanidine HC1, lOmM Urea, lOmMTris-
HC1, 20% Triton® X-100 (v/v), pH 4.4 
Poly (A) carrier RNA 0.2mg/40ul (after reconstitution)
Proteinase K 20mg/ml (after reconstitution)
Wash buffer 20mM NaCl, 2mMTris-HCl (pH 7.5)
Elution buffer Nuclease-free redistilled H2O
High Pure filter tubes Polypropylene tubes have two layers of glass
fiber fleece and can hold up to 700ul of sample 
volume
Collection tubes 2ml Polypropylene tubes
2.1.2) Synthetic oligonucleotides
Oligonucleotides used during this work are listed in tables 2.1. Specific primers were used for 
amplifying C and S genes (conventional PCR) (table 2.1 A). For mutagenesis study, 
oligonucleotides designed in length between 24 to 39 bases with 5’ end phosphorylated (table 
2. IB). The mismatch portion was at or near the 5’ end of each primer with more than 20 
correct bases on the 3’ end (purchased from MWG, Biotech, Milton keynes).
2.1.3) Enzymes
Taq DNA polymerase, restriction enzymes and T4 DNA ligase were obtained from Roche 
Diagnostics. RNase was purchased from Sigma. EcoRl and Hind III from Life Technologies.
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Table 2.1 (A) Primers used in this study.
Primer Gene Sequence 5'— ► 3* of Oligonucleotides Base Type
Position
Cl Core CGG GAT CCG AGG AGT TGG GGG AGG 1726-1754 Sense
AGATT
C3A Core G(R)T CTR TGT A(W)T AGG AGG CTG 1763-1783 Sense
(R=A/G) (W=A/T)
C4 Core CCT TAT GAG TCC AAG G(R)A TA (R=A/G) 2478-2459 Anti-sense
SI Surface CCT GCT GGT GGC TCC AGT TC 56-75 Sense
S2Na Surface CCA CAA TTC (K)TT GAC ATA CTT TCC A 1003-979 Anti-sense
(K=G/T)
S6 C Surface GCA CAC GGA ATT CCG AGG ACT GGG 113-146 Sense
GAC CCT G
S7D Surface GAC ACC AAG CTT GGT TAG GGT TTA 857-823 Anti-sense
AAT GTA TAC C
Oligonucleotide primers used for PCR and sequencing. Base positions numbered from the EcoRI site.
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Chapter2 Materials and Methods
2.1.4) Reagents and buffers for PCR
lOx PCR buffer 200mM Tris-HCl (pH 8.4), 500 rnM KC1
1 Ox dNTPs 1 OOmM of each dATP, dCTP, dGTP, dTTP
TaqStart Antibody 1.1 ug/ul in storage buffer: 50mM KC1, 10
mM Tris-HCl (pH 7.0), 50% glycerol 
TaqStart dilution buffer 50mM KC1, lOmM Tris-HCl (pH 7.0)
lOx TBE 89mM Tris HC1 (pH 8.0), 89mM boric acid,
ImM EDTA (Ethylenediaminetetra- acetic acid 
(disodium salt)
lOx agarose gel loading buffer lx TBE, 1% SDS (Sodium dodecyl sulfate), 50%
sucrose, 1 mg/ml 
bromophenol blue
X-gal (10%) 5-Bromo-4-chloro-3-indoyl-p-D-
galactopyranoside
IPTG 100 mM Isopropyl-1-thio-p-D- galactopyranoside
2.1.5) Materials provided in ExSite™ PCR-Based Site-Directed Mutagenesis Kit
ExSite™ DNA polymearse blend (5 U/ul)
Cloned pfu DNA polymearse (2.5 U/ul)
Dpn I restriction enzyme (10 U/ul)
T4 DNA ligase (4U/ul)
1 0  x mutagenesis buffer 
lOmMrATP
25 mM dNTP mix (6.25 mM each dNTP)
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pWhitescript™ 4.5-kb control template (1.5 ug/ul)
Oligonucleotide control primer #l[phosphorylated 24-mer (75 ng/ul)]
Oligonucleotide control primer #2 [30-mer (75 ng/ul)]
Epicurian Coli® XL-Blue supercompetent cells
pUC 18 transformation control plasmid (0.1 ng/ul in TE buffer)
2.1.6) Bacterial strain and growth media 
Escherichia coli. Genotype:®8OdlacZAM
DH5a 15, rec A l, endAl, gyrA96, thi-1, hsdR17 fo ’, mf),
supE44, rel A1, deoR, (lacZYA-argF) U 169
L-broth Luria-Bertani liquid medium (10 g NaCl, 10 g
Bacto Tryptone, 5 gm Bacto-yeast extract in 
one litre distilled water.
L-broth in agar As above plus 10 g Bacto-agar
2.1.7) Plasmid
pRK5 was used to express full-length core gene in COS-7 mammalian cells. PRK5 
contains: a cytomegalovirus (CMV) promoter which allows very high expression of 
proteins in a variety of mammalian cells, a multiple cloning site (MCS) downstream of 
the promoter, a SV40 origin of replication for single stranded DNA, and an ampicillin 
resistant gene (AMPR) for prokaryotic selection (a kind gift from professor H. Will, 
Hamburg, Germany).
2.1.8) COS7 culture system
These monkey kidney cells were originally derived from an African -monkey kidney cell 
line transformed by an origin defective mutant of SV-40. Cells were grown in Dulbecco’s
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modified Eagle medium (DMEM) supplemented with 10% bovine calf serum, 100 IU/ml 
penicillin/ lOOug/ml streptomycin and 2mM glutamine. Trypsin (0.25% trypsin dissolved 
in Tris-saline) and Versene (600mM EDTA in PBS A, 0.0015% (w/v) phenol red) were 
used for splitting of the confluent cells.
2.1.9) Reagents and solutions for small scale plasmid preparation
Miniprep Solution I 25mM tris HC1 (pH 8.0), 50 mM glucose,
lOmM EDTA (pH 8.0)
Miniprep Solution II 0.2M NaOH, 1% SDS
Miniprep Solution III 3M K. acetate, 5M acetic acid
Ethanol 100% and 70% (diluted with distilled water)
2.1.10) Reagents and solutions for large scale plasmid preparation using Midiprep 
QIAGEN Kit (Crawley, West Sussex, UK).
Buffer PI
Buffer P2 
Buffer P3 
Buffer QBT
Buffer QC
Buffer QF
50mM Tris HC1 (pH 8.0), lOmM EDTA,
lOOng/ml Rnase A
0.2 M NaOH, l%(w/v) SDS
3M potassium acetate (pH 5.5)
750mM NaCl, 50mM MOPS (pH 7.0), 15% 
isopropanol, 0.15% triton X-100 
1M NaCl, 50mM MOPS (3-(N-Morpholino) 
propanesulfonic acid (pH 7.0), 15% 
isopropanol
1.25 M NaCl, 50mM Tris HC1 (pH 8.5), 15% 
isopropanol
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2.1.11) Reagents and solutions for transfection
2.1.11A) LIPOFECTAMINE Plus Transfection Reagent (Invitrogen, Paisley)
Lipofectamine Plus Transfection Reagent package consists of LIPOFECTAMINE ™ 
Reagent and the proprietary Plus Reagent prepared for pre-complexing DNA.
2.1.11B) FuGENE™ 6 Transfection Reagent (Roche, Lewes)
FuGENE Reagent is a proprietary blend of lipids (non-liposomal formulation) and other 
compounds in 80% ethanol, filter sterilised.
2.1.12) Antibodies for immunofluorescence
Rabbit anti HBeAg polyclonal IgG Zymed, San Francisco, CA
FITC conjugated goat anti rabbit IgG Sigma and used as secondary detection Ab
at a working dilution of 1:64
2.1.13) Commom Reagents
Manufacturer Chemicals
Beecham Ampicillin
Sigma Aphidicolin
Melford X-gal
Gibco BRL IPTG (isopropyl-p-D) thiogalactopyranoside
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2.2 METHODS
2.2.1 HBV DNA Extraction, PCR, Sequencing and Phylogenetic analysis 
2.2.1A) High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Lewes, UK).
For the Roche kit, 200 ul of working solution (binding buffer supplemented with poly (A) 
carrier RNA) and subsequently 40 ul of 20 mg/ml proteinase K were added to 200 ul of 
serum in a sterile Eppendorf tube, mixed and incubated for 10 min at 70° C. After the 
incubation, 100 ul of isopropanol was added. The filters and collection tubes were 
combined and the samples pipetted into the upper reservoir followed by centrifugation for 
1 min at 8,000 x g and flowthrough discarded. The filter was washed twice with the wash 
buffer and the flowthrough discarded after each wash. Finally, centrifugation for 10 
seconds at full speed removed the entire residual wash buffer. Collection tubes were 
discarded and clean nuclease-free 1.5 ml tubes were used to collect the eluted DNA in 50 
ul of elution buffer. The eluted DNA was stored at -20°.
2.2.1B) PCR amplification of the extracted DNA
Hot start PCR was performed using a hemi-nested protocol and antibody to Taq 
polymerase to amplify the core gene of HBV. Five ul of extracted DNA was amplified in 
50 ul solution containing: 1.25 U Taq polymearse (Gibco, Paisley, UK), 2.5 ul TaqStart 
antibody (Clontech Laboraties Inc., Palo Alto, Ca, USA), 0.25 mM dNTPs (Pharmacia, 
St. Albans, UK), 10X PCR buffer (supplied with Taq polymerase), and 25 pmol of each 
primer (Cl: sense and C4: antisense) (Table 2.1 A); cycled for 5 cycles of 95° C for 1 
min, 55 ° C for 1 min, and 72° C for 90 seconds followed by 35 cycles. One microliter of 
first round PCR product was then re-amplified in the same solution as above except for 
heminested primers, (C3a: sense and C4: antisense, table 1). For 5 cycles of 95° C for 1
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min, 55 ° C for 75 seconds, and 72° C for 90 seconds followed by 25 cycles with the 
denaturation temperature reduced to 90° C. A nested protocol was used for the 
amplification of the surface region. Primers SI and S2 followed by S6 c and S7D were 
used to amplify the surface gene (Table 2.1 A). The reaction mixture and program cycles 
of Biometra TRIO Thermoblock, were similar to those used in C gene amplification. 
Amplification of S gene was employed to confirm the PCR or sequencing results of C 
gene.
2.2.1C) Agarose gel electrophoresis
Agarose gel electrophoresis was used to confirm the right size of our amplified PCR 
products by visualising the gel on an ultraviolet transilluminator. Also, it was used to 
check linearised plasmids (after enzyme digestion and before ligation) and restriction 
digests of miniprep DNA. Gels were prepared by adding 1 g agarose to 100ml IX TBE 
buffer. The solution was boiled until dissolved and left to cool. Then, 50ul ethidium 
bromide (lmg/ ml) was added before pouring the gel. One ul of agarose gel loading 
buffer was used to each sample before loading, followed by running the gel at 80 V in IX 
TBE buffer for 25 min.
2.2.1D) Purification of the PCR products by High Pure PCR Product purification 
kit (Roche Diagnostics, Lewes, UK)
250ul of binding buffer was added to 50ul of PCR reaction product and mixed well. The 
mixture was poured onto the High Pure filter tube and centrifuged at 13,000rpm for 30 
seconds. The filter tube was washed twice. Finally, the filter was inserted in RNase free
1.5 ml tube and CIH2O was applied to elute the DNA (higher volumes of dH20 for elution 
are preferred as it increases the elution efficiency).
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2.2.1E) DNA sequencing 
2.2.1E I) DNA purification and sequencing
DNA was firstly purified by using the previously mentioned kit. Sequencing of the C 
gene was performed either directly from the purified PCR products or after C gene 
cloning (by mutagenesis, see section 2.2A) using an automated sequencer (ABI Prism, 
377 DNA sequencer, Applied Biosystem, Perkin Elmer) according to the manufacturer’s 
instruction. The HBsAg genotype of the sequences was defined by substitutions between 
codons 122 and including 160. The reaction mixture was prepared by adding 2-4 pmol of 
lpmol/lul of each primers (core: C3a and C4; surface: S6 C and S7D) (Table 1.2A) to 1-2 
ul of PCR products or 400-800 ng of cloned DNA up to 6  ul of reaction mixture by 
adding dH^O. Because of unavailability of DNA materials, we did not sequence the S 
gene of Indian samples.
2.2.1 E II) Sequence data analysis
The sequence Navigator software program (Applied Biosystem, Cheshire, UK) was used 
to analyse our sequence data. The sequences were aligned and the consensus sequence 
was determined for sequences that have the same subtype/ genotype.
After allocating a sequence to an HBV genotype by analysis of the S gene, the core gene 
amino acid/nucleotide variations that were found uniquely in that subtype or genotype 
were recorded. Variants found in a majority of HBeAg sequences (> 50%) from a 
particular geographical area were confirmed with HBeAg sequences from the same area 
obtained from EMBL, GenBank and NCBI (Table 3.1.2). Sequences were only selected 
from databases if the subtype, country of origin and serological picture were provided. 
Finally, geography-specific nucleotide and amino acid variations in each genotype were
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identified. To qualify, they had to be both unique to a geographical region and found in a 
majority of sequences from that region. Sequences studies from chapter 3.1 have been 
submitted to Genbank, numbered from AF323463 to AF323470 and from AF324066 to 
AF324148. Those sequences obtained from the Pacific (chapter 3.2) study are numbered 
from AY269035 to AY269047, from AY269050 to AY269061 and from AY269064 to 
AY269086.
2.2.1F) Phylogenetic Analysis
Sequences of core and surface genes were aligned using the BioEdit Package version 
5.0.9, and a neighbor joining phylogenetic tree constructed using the Treecon Package 
employing a Kimura distance matrix. Associations were tested by bootstrap re-sampling 
analysis using 100 replicates. Associations with a bootstrap value of greater than 70% 
were deemed significant.
2.2.2 Molecular cloning and transfection methods
2.2.2 A) ExSite™ PCR-Based Site-directed mutagenesis
Site-directed mutagenesis was performed by a PCR method using oligonucleotides 
(Table 2.IB) to revert mutated sequences back to the original sequence, according to 
manufacturer’s instructions (Figure 2.1) (Stratagene, La Jolla, CA). PCR reactions were 
set up for two separate reactions: control and sample reactions. Oligonucleotides (primers 
1 and 2) and plasmid template control (an ampicillin-resistant pWhitescript™ 4.5 kb 
control reaction) were included in this kit.
2.2.2A I) Reaction Setting Up
The control reaction contained the following:
PWhitescript 1 ul (0.5 pmol, -1.5 ug)
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lOx mutagenesis buffer 
dNTPs mix
Primer# 1 (phosphorylated)
Primer#2
ddH2o
The sample reaction contained the followings: 
DNA
lOx mutagenesis buffer 
dNTPs mix
Primers (side-directed mutagenesis) 
ddH2o
Then 1 ul of ExSite DNA polymerase blend 
overlaid with 2 0  ul of mineral oil.
2.5 ul
lul of 25 mM 
2  ul (15 pmol, -150 ng)
2 ul (15 pmol, -150 ng)
15.5 ul (to a final volume of 24 ul)
0.5 pmol of template
2.5 ul
lul of 25 mM
15 pmol of each primer
to a final volume of 24 ul
(5 U/ul) added to each reaction tube,
2.2.2A II) Cycling Parameters
As shown in table 2.2, the following cycling parameters were used for PCR reaction in 
the site-directed mutagenesis procedure. Because of PCR negativity of some samples, 
different annealing temperatures between 50° to 56° were applied.
2.2.2A III) Digestion and polishing the product
Following the PCR, the reactions were cooled on ice for 2 min. Nonmutated plasmids 
were subsequently digested by Dpn I. The addition of 1 ul (lOU/ul) of Dpn I, 0.5 ul (2.5 
U/ul) of P /u  DNA polymerase (to remove extended
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Template DNA
P C R
Template DNA PCP product p
Dpn I restriction enzyme
zPfu DNA polymerase
T4 DNA ligase
Transform E. coli
Figure 2.1 A diagram  on the basis o f E xS ite1'1 PCR-Based Site-directed m utagenesis. (Taken from: 
http://w w w .stratagene.com /displavproduct.asp).
The ExSite method uses increased tem plate concentration. The resulting m ixture of tem plate DNA, 
newly synthesized DNA and hybrid parental/newly synthesized DNA is treated with Dpn I and Pfu 
DNA polymerase. Dpn I digests the in vivo m ethylated parental tem plate and hybrid DNA, and Pfu 
DNA polym erase polishes the ends to create a blunt-ended PCR product. The end-polished PCR  
product is then intram olecularly ligated together and transformed into E. coli.
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Table 2.2: PCR cycling parameters
Step Cycle Temperature Time
1 1
o'"'tOs 4min
oO
2 min
72° 2 min
2 8 94° lmin
50° 2 min
72° lmin
3 1 72° 5 min
3’ extension at the end of PCR products) below the mineral oil. Digestion was carried out 
by incubation at 37° for 30 min. The reaction was then incubated for 30 min at 72°. The 
Dpn I- cloned P /u  DNA polymerase-treated DNA was then ligated at 37° for 1 h with 1 
ul (4U/ul) of T4 DNA ligase.
2.2.2 AIV) Transformation
The Epicurian Coli XLl-Blue supercompetent cells (kept at -70°) were thawed gently on 
ice for a few min. 80 ul of cells aliquoted to a Falcon® 2059 polypropylene tube, 2 ul of 
ligase-treated DNA added to cells, swirled, and incubated on ice for 30 min. For control 
transformation, 0.1 ng of pUC18 transformation control plasmid added to cells, swirled 
and incubated for 30 min on ice. Then, the tubes were heat pulsed for 45 s at 42° and then 
placed on ice for 2 min. Then the entire volume of transformed cells plated on LB- 
ampicillin agar plates that have been spread with 20 ul of 10% (w/v) X-gal prepared in 
dimethylformamide (DMF) and 20 ul of 100 mM IPTG prepared in filter-sterilized dF^O, 
incubated overnight (>16 h).
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2.2.2B) Small Scale Plasmid Preparation (Mini-prep)
After checking the control plasmid (which should appear as blue on agar plates 
containing EPTG and X-gal), white colonies of transformed bacteria were inoculated into
2-3 ml of LB broth containing ampicillin at lOOug/ml and incubated in a shaker at 37° C 
overnight. One ml of the overnight culture was transferred to a 1.5 ml eppendorf tube and 
centrifuged at 13,000 rpm for 30 seconds. The pellet, after decanting the supernatant, was 
resuspended in lOOul of ice cold solution (I) and left at RT for 5 min. 200ul of freshly 
prepared solution (II) was added, mixed gently and left on ice for 2-3 min. 150ul of 
solution (III) was added, mixed by few inversions, left on ice for 2-3 min. 150ul of 
phenol/chloroform was added to the mixture, vortexed and centrifuged at 13,000rpm for
3-5 min. The aqueous phase was transferred to a fresh tube, 800ul of 100% ice cold 
ethanol was added to precipitate the plasmid DNA and centrifuged for lOmin. The pellet 
was then washed with 70% chilled ethanol, air dried and finally resuspended in 50ul 
dtLO containing RNase at 20ug/ml to remove any contaminating RNA.
2.2.2C) Restriction enzyme digestion
Restriction digestion of plasmid DNA was carried out to confirm successful cloning. The 
standard mixture consisted of 1.5ul 10X restriction buffer (B), 0.2ul (2 U) of each 
restriction enzyme (EcoRl and Hind-III), 2.5-5ul plasmid DNA and dLLO to a final 
volume of 15ul. The digest mixture was then incubated at 37° C for 2-3 hr.
2.2.2D) Large Scale Plasmid DNA Preparation
Large scale plasmid preparations were performed to purify plasmid DNA, using the 
QLAGEN midi kit. 0.5 ml of the overnight culture, of confirmed clones, was added to 
50ml L-broth containing lOOug/ml ampicillin and incubated overnight at 37° C. The
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culture volume was divided into two equal parts which were spun at 3,000rpm for 15 min 
at 4° C. One of the cell pellets was stored at -20 ° C, while the second was resuspended 
by vigorous vortexing in 4ml of buffer PL 4ml of buffer P2 was added and mixed gently 
by several inversions. After 5 min incubation at RT, 4ml of chilled buffer P3 was added 
and mixed gently. The lysate was poured into the QIAfilter cartridge with screw cap on 
and incubated at RT for 10 min. At the meantime, QIAGEN-tip 100 was equilibrated 
with 4ml of buffer QBT. The lysate filtrate was then transferred from QIAfilter to the 
equilibrated QIAGEN-tip and left to drip by gravity flow. After all the lysate filtrate had 
dripped through the QIAGEN-tip, the resin tip was washed twice with wash buffer QC. 
Elution of the plasmid DNA from the resin tip was finally achieved by addition of 5ml 
elution buffer QF. The plasmid DNA was precipitated by the addition of 3.5ml 
isopropanol followed by centrifugation at 11,000 rpm (Sorvall SM24 rotor) for 30 min at 
4° C. The pellet was then washed with 70% ethanol, air dried and resuspended in lOOul 
dH20. Finally, the plasmid DNA concentration was determined by measuring the 
absorbance at 260 nm.
2.2.2E) Cell culture
It is known that the distribution of expressed HBcAg antigen is cell cycle dependent. 
Sequential thymidine and aphidicolin blocking steps produced monolayers of 
synchronised Cos-7 cells. Cos-7 cells were seeded at a density of 3X104 cells per well in 
a 24-well plate in growth media 12 hours before treatment with cell cycle blocking agents 
(Fig 2.2). Then, media containing 2mM thymidine was substituted, and 12 hours later 
cells were washed twice by PBS and refed with normal media. Transfections were carried 
out after cell release, using FuGENE- 6  and/or Lipofectamine Plus Transfection Reagent
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A
COS-7
Overnight
+Thvmidine
x3 wash
1 2  h
Cells platting
Thymidine withdrawal
x3 wash 1 2  h
Transfection
1 2  h
+ Aphidicolin
Fig 2.2. A diagram  showing sequential thym idine and aphidicolin blocking stepsfor 
cell cycle synchronisation.
107
Chapter2 Materials and Methods
methods according to the manufacturer’s instructions (see bellow). A further 13 hours 
later, cells were washed by PBS twice and media containing 2.5 pg/ml aphidicolin was 
added, then incubated for further 36 hours. Aphidicolin blocks cells in the Gl/S phase of 
the cell cycle, in which HBcAg expression is predominantly nuclear (Yeh et al., 1993). 
2.2.2F) Transfection
2.2.2F I) FuGENE ™ 6 Transfection Reagent
In this method, The DNA was transfected into subconfluent monolyers of COS-7 cells on 
13 mm coverslips. 1.5 ul of FuGENE was added to 25 ul of Optimum 1 reduced-serum 
medium (Life Technologies, Paisley, UK), followed by 300-500 ng of DNA, incubated 
for at least 15 min at RT. Then, this mixture was added to the adherent subconfluent 
COS-7 cells in 24 wells plate each well contained 1 ml DMEM, incubated at 37° C at 
various timescales according to cell cycle blocking protocol.
2.2.2F II) LIPOFECTAMINE™ PLUS Reagent
25 ul of Optimum reduced-serum medium (Life Technologies, Paisley, UK), inserted into 
a clean sterile 1.5 ml eppendorf tube followed by 200-300 ng of plasmid DNA, mixed 
and then 4 ul of PLUS Reagent added, mixed again and incubated at RT for 15 min. In a 
separate 1.5 tube lul of LIPOFECTAMINE™ Reagent added to 25ul of Optimum, 
mixed. The contents of pre-complex DNA combined to the diluted LIPOFECTAMINE™ 
Reagent tube, mixed and incubated at RT for 15 min. This mixture added to each well 
containing fresh medium (0.2 ml) incubated at 37° for 3 h.
After 3 h, the medium volume increased to normal volume and incubated at 37° in 
different timescale according to cell cycle protocol. Different reagents and volumes used 
in this protocol summarized below.
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DNA (ug) 0.2-0.3
PLUS Reagent (ul) 4
Optimum (ul) 25
LIPOFECTAMINE Reagent (ul) 1
Transfection Medium (ml) 0.2
Transfection Volume (ml) 0.256
2.2.2G) FACS Analysis
Cell cycle status of cultured cells was determined by flowcytometry of permeabilised 
cells that were stained with propidium iodide (PI). Cos-7 cells were dissociated with 
EDTA at the appropriate time post-transfection and resuspended in PBS. Samples were 
centrifuged at 1500 g for two minutes, then cells were fixed with 70% ethanol. After 
fixation on ice for 20 minutes, cells were centrifuged, washed once with PBS and 
centrifuged again. Pelleted cells were resuspended in 1 ml of a solution contained 100X 
Triton, PI, and RNase. After 30 minutes incubation at room temperature, the total DNA 
contents was analysed by Becton Dickinson FACScan instrument with CellQuest 
software (Becton Dickinson, San Jose, CA).
2.2.2H) Immunofluorescence
Transfected cell monolayers on coverslips were washed twice with PBS. The cells were 
then fixed with ice cold methanol (at RT for 10 min), washed three times with PBS and
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permeabilised with 0.5% triton-XlOO in PBS. The permeabilised cells were rinsed twice 
with 0.05% Tween in PBS and incubated with rabbit anti-core polyclonal IgG antibody at 
RT in a moist dark box. After washing, the cells were further incubated with FITC 
conjugated goat anti-rabbit IgG as secondary antibody at 1:64 dilution, incubated for 45 
min. After three washes, the coverslips were dried carefully and mounted on glass slides 
with a drop of Citifluor, a glycerol/PBS solution.
2.2.2F) Confocal Microscopy
Localisation of core protein was studied using confocal microscopy. Then cell samples 
were examined in a Zeiss LSM510 confocal microscope with laser excitation line at 
488nm. The microscope was a Zeiss Axiplan with either a 40X or 63X oil immersion 
objective lens. Data sets were processed with the Laser Scanning Microscope (LSM 510) 
software.
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CHAPTER 3 - Core Gene Variability, Geography and Ethnicity
3.1 Aims of study
Although "core aa substitution" was reported in many studies, some of these variants are 
actually the consensus sequence from other genotypes. However, in view of the heterogeneity 
of HBV strains, it is difficult to determine whether core gene substitutions, recorded in the 
literature (in addition to those characteristic of genotype), only once represent naturally 
occurring variants or an immune-selected mutation in individuals. The aims of this study 
were: to characterise the core gene variability in diverse geographic regions and ethnic 
groups; to determine subtype/genotype-specific variants; and to specify country/ethnic- 
specific variant. The current work can be divided into two parts. In the first, Sera from 91 
HBsAg positive patients from 9 countries, including 49 samples from California (39 from 
Asian origin persons living in California and 10 from Caucasians), 12 from Italy, and 10 each 
from Scotland, India, and the Pacific (Table3.1.1) were analyzed by sequencing the core 
gene. All were positive for HBsAg with a variety of clinical features and HBeAg/anti-HBe 
serological status. The Asian-origin samples from California were previously sequenced for a 
pre-core variability study (results not shown). These findings then were compared to 
sequences of known geographic origin in the database to confirm the associations.
Unique sequences were obtained from the Pacific group at both aa and nucleotide level, (first 
part of this chapter), leding us to more investigation on core gene variability in this area. We 
selected randomly 58 samples from HBV-infected patients from 4 different islands. HBV 
isolates from C and D genotypes were identified. Genotype C is predominant in Vanuatu, Fiji 
and Tonga, while D is the dominant genotype in Kiribati. HBs Ag positive samples were 
collected from four Pacific islands (Table 3.2.1): Kiribati (14), Vanuatu (14), Fiji (15) and 
Tonga (15). Geographically, these islands are located as follows: Kiribati in Micronesia; Fiji 
and Vanuatu in Melanesia; and Tonga in Polynesia (Fig 3.2.1). They were chosen from a
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previous study of surface variability and correlation with the history of human populations 
and immigration patterns of the Pacific region (Basuni 2001).
PCR was employed to amplify the C and S genes, followed by direct sequencing using a 
variety of forward and backward primers to eliminate sequence variation caused by possible 
errors of Taq polymerase. The nucleotide sequences were then edited and assembled using 
Sequence Navigator software. We already knew the genotype as this had previously been 
characterised by surface gene sequencing. Comparative sequence analysis to detect important 
nucleotide changes and motifs was performed using the BioEdit Package version 5.0.9. 
Tables showing alignments of amino acid and nucleotide sequences are shown in the 
appendices at the back of this thesis.
3.2 Results
3.2-a) Phylogenetic Analysis
Figures 3.1.1, A and B show that sequences grouped into 6  major clusters. Four of these were 
occupied by genotypes A to D. Pacific sequences composed 2 additional clusters (in both C 
and S trees), one in genotype C and one in D. Compared to the rest, the most homogeneity 
was observed in Pacific sequences. In genotype D strains, most of the Indian sequences 
comprised a sub-cluster in the C tree. Similarly, a majority of the strains found in Scotland 
and the USA (genotype A), were homogenous in both C and S trees. The phylogenetic trees 
constructed based on S and C genes revealed that the topological features of all strains except 
of A4, A 5 ,154 and I I 13 in the phylogenetic trees were identical. The C gene of A5 belonged 
to genotype B, whereas, the S gene belonged to genotype C (the Pacific adrq-). Similarly, 
strains 154 and 1113, based on core sequencing had genotype D, whereas, the S genes were 
genotype A. In one genotype D cluster, there were 2 Western-derived samples amongst 
Indian sequences. These samples showed homology at the amino acid level; however, there 
was a substantial amount of synonymous nucleotide variation (Tables A.I.l and A.I.2).
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3.2-b) Genotype/Subtype-specific Nucleotide Substitution
At the nucleotide level, it was possible to identify unique variants for subtypes adw2 
(belonging to genotypes A and B), aywl, ayw2, adr and adrq- (there was no ayr subtype in 
the sequences studied). Overall, 37 genotype specific nucleotide substitutions in 26 positions 
were found (Tables 3.1.3 and A.I.2), of which 16 were silent (synonymous) and 21 were 
missense (non-synonymous). Of 37 variations, it was possible to define 9 unique nucleotide 
variants for specific subtypes: C221 and G342 for ayw2 ; C342 for ayw3 strains; T66, G75 and G175 
for adrq-; and C289 for adrq+. A454 was characteristic for adw2 and A404 was characteristic for 
aywl, both belonging to genotype B. Our results concurred with those of sequences in 
databases.
3.2-c) Amino acid Substitutions and Genotype/Subtype
The amino acid residue at 9 codons (27, 59, 67, 74, 83, 87, 91, 97 and 116), and an insertion 
at amino acid position 152, allowed allocation of a specific subtype (Table 3.1.4). Of these 9 
residues, the following were characteristic for genotypes and their corresponding subtypes: 
N74 and N87 in adw2 genotype A (adw2); F97 and 1116 in genotype D (ayw2 and ayw3 
strains); V59 and 191 in genotype C strains (for adrq-). All sequences which encoded adw2 
(genotype A) had a 2-codon insertion corresponding to amino acid 153 and 154 in the core 
gene, independent of origin. The most divergent residues were amino acids 74 and 91 with 5 
and 3 possible variant amino acids respectively. Tables A.I.l and A.I.2 show amino acid and 
nucleotide alignment of all HBcAg sequences in the countries studied, respectively. Most 
amino acid substitutions involved the HLA-restricted CTL, T helper and B cell epitopes, 
irrespective of HBV subtypes (Table 3.1.4; see chapter one table 1.3).Genotypes A (adw2 
subtype) and D sequences had 5 amino acid substitutions in common at residues 12, 27, 67, 
83 and 91, which were not present in other strains. Distinguishing adw2 (genotype A) and 
ayw2 was possible by examination of residues 74, 87, 97, and 116 (Table 3.1.4), confirming
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that substitutions in these positions alone explain d/y variation in the C gene. The most 
heterogeneity was seen in ayw2 strains derived from Indian, Italian, Pacific island and 
Scottish patients (Table A.I.l). Residue 74 showed the most discrepancy between countries in 
which ayw2 is common: T in Pacific, V in Scottish and Italian, and G in Indian. At the amino 
acid level, the core gene sequences belonging to adw2, aywl (both belonging to genotype B) 
and adrq+ did not show any unique amino acid substitution (however, see nucleotide results). 
Interestingly, with the exception of two samples, all strains with 97L (instead of I) were 
HBeAg negative or had a pre core stop codon, Aig96 (results not shown).
3.2-d) Country-Specific Changes
A specific motif, consisting of S I2,127, N67, S74, E83 and V91, was observed in a majority 
of samples from South-east Asia and the Pacific irrespective of HBV genotype, but not in 
core sequences from other regions studied (Table 3.1.5A). Similarly, Western-derived 
sequences (USA-Caucasian, Scotland and Italy) shared a specific motif at the same residues, 
but with different amino acids: T12, V27, T67, N/V74, D83 and T91 (Table 3.1.5A). This 
pattern seemed slightly different at amino acid position 74 in which all variation depended on 
genotype: N74 in genotype A and V74 in genotype D. This finding was strengthened by 
analysis of the nucleotide sequence (Table A.I.l). In both populations, 19 unique nucleotide 
changes were found, of which 8 were missense changes for 6 amino acid residues (Table 
3.1.5-B). There were nine Indian and nine Italian strains of genotype D, subtype ayw2. One 
sequence (represented by six examples) dominated in each country; the remaining three 
sequences were represented by one example each (Table A.I.1). Further, the five Scottish 
strains of genotype D, subtype ayw2 or ayw3, were identical to the majority strains in India 
or Italy, while all the Pacific-derived strains of genotype D were unique and identical.
Seven amino acid positions allowed definition of a particular country’s genotype D sequence. 
In the Pacific all sequences belonging to ayw2 contained A35, D40, and T74; V59 and 191
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was observed in a majority o f adrq-strains from that region. 180 was seen in Indian sequences 
and G87 in Korea (Table 3.1.6). The most heterogeneity was seen in ayw2 strains derived 
from Indian, Italian, Pacific island and Scottish patients. Residue 74 showed the most 
discrepancy between countries in which ayw2 is common: T in Pacific, V in Scottish and 
Italian, and G in Indian (Table A.I.l).
However, there were additional synonymous nucleotide substitutions that were characteristic 
for specific countries in our study (Table 3.1.6). For example, in a majority o f samples from 
India, we observed T12, C55, T57, Am, G132, A238, G255 and T291. In all strains belonging to 
ayw2  from the Pacific region, we observed T66, G75, G103, G105, T120, Ai89, C221 and T255. A342 
and C289 were characteristic for Italian and Korean sequences respectively.
Finally, subtype-related specific nucleotide variations were observed in a majority of samples 
from specific countries. In keeping with the amino acid sequence, the ayw2 subtype 
contained the most nucleotide divergence (Table 3.1.7): 16 nucleotide substitutions were 
unique in ayw2 sequences from India, 10 from Pacific, and 2 from Italy. The same 
heterogeneity was observed in adrq+ and adrq- strains (Table 3.1.8): all Pacific strains with 
adrq- subtype showed 5 specific changes. A258 and C289 were unique in adr strains from 
Chinese and Korean sequences respectively.
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Fig. 3.1.1- Neighbour joining phylogenetic trees of core (A) and surface (B) genes sequences from 91 
HBcAg samples. Note: C and S gene trees rooted with sample 198 and U8, respectively. The figue shows 
bootstrap values of £70% and scale denotes percent diversity. Coding numbers indicate samples hat have 
been analysed in the figure. Because of unavailability of DNA materials, we did not sequence the ! gene of 
Indian samples. Scotl=Scotland; Pacif=Pacific and Vietn=Vietnam.
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Table 3.1.1: Origin of 91 HBsAg positive sera that were used as the source for HBcAg sequencing.
Country Number of Samples
South-East Asia
China 20
Californian samples Korea 8
<
Japan 5
Vietnam 6
Pacific 10
Caucasian
USA 10
Scotland 10
Italy 12
India 10
Total 91
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Table 3.1.2: Identification of core sequences obtained from databases for comparison.
Accession Identification Origin Subtype Genotype
Number
M57663 pFDW294 Philippines adw2 A
X02763 PHBV3200 USA adw2 A
X51970 HBV991 Germany adw2 A
X70185 HBV-A938 Germany adw2 A
AF297624 Isolate 656 Africa adw2 A
V00866 PHBV933 USA adw2 A
Z35717 pHB614 Poland adw2 A
X97850 Patient-4 China adw2 B
X97851 Pateint-6 China adw2 B
AB033554 RTB299 Indonesia adw2 B
AB033555 PAD744 Indonesia adw2 B
AF121249 AF121249 Vietnam adw2 B
AF282917 HBV-Bj China adw2 B
AF282918 h b v -b 2 China adw2 B
AB031261 HBV Vie A-2 Vietnam adw2 B
AB031263 HBV Vie A-5 Vietnam adw2 B
AB031264 HBV Vie F-l Vietnam adw2 B
AB031262 HBV Vie A-3 Vietnam adr C
AB031265 HBV Vie F-2 Vietnam adr C
AB033553 SK619 Indonesia adw C
D50489 HPBA11A Japan adr C
L08805 HPBETNC Japan adr C
D16666 HPBE88A Japan adr C
S75184 S75184 Japan adr C
AF241411 8290 Vietnam adr C
AB031260 HBV VieA-1 Vietnam adr C
X52939 HBV prex China adr C
M3 8454 pADR-1 China adr C
M38594 M38594 Korea adr C
M38636 pHBV107 Korea adr C
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X04615 pYRB259 Japan adr C
X14193 pADRm Korea adr C
D12980 SRADR Japan adr c
D00630 pHBV330 Japan adr c
X01587 pHBVadr4 Japan adr c
D00331 pAK66 Japan adr c
X75656 HHVCCHA Polynesia adrq- c
X75665 HHVBC New Caledonia adrq- c
AB033557 pIWK146 Indonesia adw c
AF121240 HBV/94-11066 Vietnam ayw D
AF121242 HBV/98-1218 Vietnam ayw D
AB033558 JYW796 Japan ayw D
AB033559 JYW310 Papua New Guinea ayw D
X65258 HBVAYWCI Italy ayw D
X59795 HBVAYWMCG Italy ayw D
X02496 pHBV320 Latvia ayw D
AJ131956 AJ131956 Germany ayw D
L27106 HPBMUT Israel ayw D
X72702 HBVORFS Germany ayw D
X85254 HBVPRESS12 Italy ayw D
Note: Each sequence is listed under accession number.
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Table 3.1.3: Unique C-gene nucleotide differences which perm it subtype classification.
Nucleotide Subtype (genotype)
Position adw2(A) adw2(B) ayw l(B) adr(C) adrq-(C) ayw2(D) ayw3(E
66 C C C C T C C
75 T T T T G T T
8 i C T T T T A A
159 T G G A A T T
174 C T T T T A A
175 A A A A G A A
180 C G G G G T T
204 A A A G G A A
221 A G G G G T/G/C T
249 T A A A A C C
260 A G G G G G G
289 A A A A /C A T T
324 T T T T T C C
342 T T T T T G/A C/A
346 C C C C C A A
390 A T T C C A A
393 C A A T T T T
396 T T T C C T T
404 C C A C C C C
454 C A C C c C C
454-459
insertion
CGG
GAC
- - - - - -
Note: Underlined numbers indicate the locations of the missense nucleotides. Nucleotides are represented  
by single letters and num bered from  the beginning of HBcAg.
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Table 3.1.4: The most frequent differences in HBc Ag amino acid sequences between subtypes.
Subtype/
Genotype CD8 CD4 CD8
27 59 67 74 83 87 91 97 116
adw2/A V I T N D N T I L
adw2/B I I N S E S V I L
aywl/B I I N S E S V I L
adr/C I I N s E s V I L
adrq-/C I V N s E s V/I I L
ayw2/D V I T G/T/V D s T F L/I
ayw3/D V I T V D s T F I
Note: CD4 = CD4 recognized epitope. CD8 = CD8 recognized epitope. Each variation was found in a 
majority of strains from each subtype and the combination was unique for that subtype. Numbering of 
amino acid in bold is from the beginning of HBcAg.
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Table 3.1.6- Unique HBcAg amino acid and nucleotide changes in specific countries.
Country Amino Acid Position Nucleotide Position
India 180 T 12-C55-T57-A 111-G 132-A238-G255-T291
Pacific A35-D40-V59-T74-I91 T66-G75-G 103-G 105-T 120-A 189-C221-T255
Italy - A342
Korea G87 C289
Note: Amino acids and nucleotides are numbered from the beginning of  the HBcAg. using the single 
letters code.
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Table 3.1.7- Correlation of nucleotide sequences of  C genes of ayw2 strains between different 
geographic regions.
Subtype Region 12 55 57 75 78 103 105 111 120 132
ayw2 India T C T A A T A A A G
ayw 2 Pacific C T G T C G G G T T
ayw 2 Italy C T G T A T A G A T
Subtype Region 138 189 207 221 228 238 239 243 246 255
ayw 2 India A G C G A A T C G G
ayw2 Pacific G A T C G G C T G A
ayw2 Italy G G T T A G C T A A
Subtype Region 267 288 291 298 342 346 501
ayw2 India T A T C G A G
ayw2 Pacific C G C T G C A
ayw 2 Italy C G C C A A G
Note:Nucleotides are numbered from the beginning of the HBcAg.
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Table 3.1.8- Correlation of  nucleotide sequence of C-gene of adrq+ and adrq- strains between  
different genotype C-regions.
Nucleotide Position China
(adrq+)
~~66 C~
75 T
105 T
255 A
258 A
271 G
289 A
Japan
(adrq+)
Korea
(adrq+)
Pacific
(adrq-)
C C T
T T G
T T A
A A T
C C C
G G A
A C A
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Chapter 3.2
3.2.1 Aims of Study
As mentioned earlier, a pilot study (Chapter 3.1) revealed that specific motifs (aa and 
nucleotide) were defined for the Pacific regions (both genotypes C and D), but we now 
intended to study this in greater depth. Unique sequences obtained from the Pacific group at 
both aa and nucleotide levels (first part of this chapter), led us to more investigation on core 
gene variability in this area. We selected randomly 58 samples from HBV-infected patients 
from 4 different islands. HBV isolates from C and D genotypes were identified. Genotype C 
is predominant in Vanuatu, Fiji and Tonga, while D is the dominant genotype in Kiribati. 
HBs Ag positive samples were collected from four Pacific islands (Table 3.2.1): Kiribati (14), 
Vanuatu (14), Fiji (15) and Tonga (15). Geographically, these islands are located as follows: 
Kiribati in Micronesia; Fiji and Vanuatu in Melanesia; and Tonga in Polynesia (Fig 3.2.1). 
They were chosen from a previous study of surface variability and correlation with the 
history of human populations and immigration patterns of the Pacific region (Basuni 2001). 
Amplifying of C and S genes carried out by PCR, followed by direct sequencing. After 
construction of simple Neighbour-joining Trees based on core and surface proteins further 
phylogenetic trees were constructed using sequences from the database. Genotypes C and D 
strains from the database and from chapter 3.1 (C gene variability and ethnicity) were also 
included for comparison. Tables showing alignments of amino acid and nucleotide sequences 
are shown in the appendices at the back of this thesis.
3.2.2 Results
3.2.2A Genotype and subtype prevalence in Pacific islands
Table 3.2.1 shows the distribution of genotypes and subtypes of strains studied from 
individual islands. The following preparations were genotype D: in Kiribati, 13 out of 14; in 
Fiji, 5 out of 15; in Vanuatu, 1 out of 14; and in Tonga, 2 out of 15. The remaining sequences
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were genotype C. Subtype adrq- was the main subtype in genotype C-occupied islands while 
ayw2 was the prevalent one in Kiribati.
3.2.2B Genotype/subtype-specific substitutions common to Pacific region
Tables A.I.3 to A.I. 14 show the complete aa and nucleotide sequences of all four Pacific 
island strains (see Index, BioEdit tables). Comparing genotypes C and D, there were 11 aa 
variations at 10 positions (Table 3.2.2): S/T12, I/V27, A/S35, D/E40, I/V59, N/T67, S/T74, 
D/E83,1/V/T91 and F/I97. These variants were not island-specific with the exception of V91 
found only in Vanuatu.
It was also possible to identify nucleotide variants for genotypes C and D, subtypes adrq- and 
ayw2 (Tables A.I. 12 and A.I. 14). Overall, 90 genotype/subtype-specific nucleotide 
substitutions in 45 positions were found (Table 3.2.3), of which 67 were silent. 23 were 
missense (genotype specific) in the 10 positions detailed above. Interestingly, a majority of 
adrq- strains derived from Vanuatu (but not other islands) contained nucleotide variants 
identical to ayw (genotype D) in 4 positions: 78, 138, 234 and 255.
3.2.2C Substitutions that distinguish specific islands
Island-specific nucleotide variants were identified which increased or decreased in frequency 
from West to East (from Vanuatu to Fiji and on to Tonga) (Figure 3.2.1, table 3.2.4). 
Nucleotide changes at positions C36, T109, Cm, G255 and T267 were found in a majority of 
strains from Tonga. On the other hand, changes including C78.T234 A246, A255, G271, C354, C366, 
A454 and G510 were predominant in Vanuatu. However, no island-specific nucleotide variants 
were detected in Fiji and Kiribati. All nucleotide changes that were specific to an island 
group, except G271 (which corresponded to residue V91 in Vanuatu), were silent mutations. 
There were six strains from Tonga (3309, 3415, 3417, 3419, 3428 and 3629) and four from 
Vanuatu (5017, 5022, 5230 and 5072) of genotype C, adrq- subtype, which showed high 
variability at the nucleotide level compared to other Pacific strains (Tables A.I.8 and A.I. 10.
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However, in genotype D-studied strains, the only major heterogeneity was seen in isolate 
2143 from Kiribati (Table A.I.6). All these strains originated from different cities in each 
island with various HBeAg/anti-HBe status.
3.2.2D Comparison with international database
Choosing the correct reference sequence is mandatory, especially in cross-sectional studies, 
otherwise over- and/or under-estimations can occur. The adrq- subtype is rarely found in 
Genbank; of eight available, six were submitted as part of our previous study (Jazayeri et al, 
in press) and two isolates (HMA and Cha), published by Norder et al., (7), constituted our 
reference sequences. No ayw sequence from Pacific (excluding this study) has been reported 
in Genbank. We chose one genotype C from a Chinese (A35) and one Indian genotype D 
(0123), both from our pilot study for comparison between corresponding Pacific strains. For 
genotype C, there were 2 amino acid and 12 nucleotide variations between our predominant 
Pacific genotype C sequence and A35 (Chinese reference) (Table A .I.ll and A.I.12). 
However, in genotype D, we found 5 amino acids and 30 nucleotides different between our 
Pacific D and 0123 (Table A.I.13 and A.I.14).
3.2.2E Phylogenetic Analysis 
3.2.2E-I Genotype C Tree
Figure 3.2.2 shows that all the genotype C sequences, from the pilot study (green codes), 
database (blue codes) and adrq- strains (from this study, red codes), grouped into two major 
clusters. The first is completely occupied by Pacific adrq-, including one of the database 
sequences, X75656 (7); a majority of strains belonging to Vanuatu composed a major sub­
cluster. The second cluster contains adrq+ sequences (including from the database) derived 
mainly from S.E Asian populations, which are heterogeneous.
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3.2.2.E-II Genotype D Tree
Figure 3.2.3 shows alignment of all genotype D sequences. They grouped into 2 major 
clusters. The first, similar to the genotype C tree, was entirely made up of Pacific strains (red 
codes). The second cluster contained two sub-clusters: the first had those from Western 
populations (a majority from Europe); the second had a combination of Asian and a few 
European sequences. Inside the Euro-Asian cluster, there was an Indian sub-cluster. Unlike 
genotype C, the Pacific genotype D shows relative homogeneity with only a few nucleotide 
mutations, indicating that genotype D arrived recently in the Pacific as a relatively 
homogenous population. We have been unable to identify a likely source of this migration in 
this study.
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Fig 3.2.1- Pacific map showing boundaries of the Pacific islands and surrounding countries. Fiji and  
Vanuatu located in Melanesia, Tonga and Kiribati located in Polynesia and Micronesia, respectively.
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Table 3.2.1- Origin and Distribution of HBsAg positive sera that were used in this study as well as
genomic/subgenomic identification of Pacific islands strains.
Island Sample
Code
Genotype Subtype Island Sample
Code
Genotype Subtype
Fiji Vanuatu
0142 C adrq- 5022 C adrq-
0143 C adrq- 5072 C adrq-
0314 c adrq- 5073 C adrq-
0349 c adrq- 5075 C adrq-
0480 c adrq- 5081 C adrq-
0550 c adrq- 5093 C adrq-
0800 c adrq- 5114 C adrq-
0880 c adrq- 5311 C adrq-
0026 c adrq- 5186 C adrq-
0075 c adrq- 5230 c adrq-
0078 D ayw2 5264 C adrq-
0079 D ayw2 5265 C adrq-
0092 D ayw2 5017 C adrq-
0456 D ayw2 5029 D ayw2
0470 D ayw2
Tonga Kiribati
3415 C adrq- 2080 C adrq-
3417 C adrq- 2006 D ayw2
3097 C adrq- 2007 D ayw2
3419 C adrq- 2019 D ayw2
3428 C adrq- 2119 D ayw2
3629 C adrq- 2127 D ayw2
3099 C adrq- 2317 D ayw2
3221 C adrq- 2483 D ayw2
3365 C adrq- 2109 D ayw2
3369 C adrq- 2110 D ayw2
3519 C adrq- 2117 D ayw2
3309 C adrq- 2143 D ayw2
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3509 C adrq- 2039 D
3414 D ayw2 2084 D
3343 D ayw2
Note: 10 of the above samples had been used in the pilot study (see tables A.I.1 andA.1.2).
ayw2
ayw2
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Table 3.2.2. The most frequent differences in core gene amino acid sequences between 
genotypes/subtypes of the Pacific region.
Amino acid Genotype D Genotype C
Position Subtype ayw Subtype adrq-
12 T S
27 V I
35 A S
40 D E
59 I V
67 T N
74 T S
83 D E
91 T I/V*
97 F I
Note: Each specific amino acid was found in a majority of strains from each genotype/subtype and the 
combination was unique for that genotype/subtype. Amino acids are represented by single letters and are 
numbered from the beginning of the core gene.
V* was only seen in adrq- strains from Vanuatu.
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Table 3.2.3. Unique C-gene nucleotide differences which permit genotypes C and D classification.
Nucleotide
Position
Genotype D 
Subtype ayw
Genotype C 
Subtype adrq-
Nucleotide
Position
Genotype D 
Subtype ayw
Genotype C 
Subtype adrq-
34 A T 200 C A
51 G T 204 A G
66 C T 219 T A
75 T G 221 C G
78* C T 228 A G
79 G A 234* T C
81 A - 243 T C
90 T C 249 C A
93 A C 250 c T
96 T c 255* A G/T
103 G T 272 C T
105 G A 288 G A
120 T G 289 T A
135 T G 308 T C
138° G A 324 C T
159 T A 342 G T
174 A T 348 A T
175 A G 387 C T
180 T G 390 A C
183 C T 396 T C
189 A T 418 C T
192
193
A
C
G
T
435 G A
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Note: Nucleotides are represented by single letters and numbered from the beginning of the core gene. 
Dash lines represent no variant specified for that position. Bold numbers and letters indicate amino acid 
altered positions (missense mutations).
*: A majority of adrq- strains from Vanuatu had C78.
A majority of adrq- strains from Vanuatu had Ci38. 
adrq- strains from Vanuatu contained T2 3 4 . 
f: A2ss seen in a majority of samples from Vanuatu despite belonging to adrq- subtype.
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Table 3.2.4. Nucleotide differences between prevalent strains in Fiji, Tonga and Vanuatu.
Nucleotide Vanuatu Fiji Tonga
Position/changes
C36T 2 2 9
C78T 10 1 1
T109C 1 2 9
C114T 0 4 15
G138A 11 1 1
T234C 11 0 1
A246G 11 1 1
G255T 0 2 7
A255T 9 1 0
T267C 0 2 9
G271A 12 1 0
C354T 11 2 0
C366T 11 1 0
A454C 7 2 0
A501G 11 5 0
G510A 11 2 0
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Fig 3.2.2. Neighbour joining phylogenetic tree of core gene sequences of genotype C from Pacific 
adrq- strains (red colour), adr subtypes from the chapter 3.1 (green colour) and database (blue 
colour) strains rooted with samples 198. Figure shows bootstrap value of 70% and scale denotes 
percent diversity.
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Fig 3.2.3. Neighbour joining phylogenetic tree of core gene sequences of genotype D from the Pacific 
(red colour) and chapter 3.1 (green colour) and database (blue colour) ayw strains, rooted with 
samples 198. A majority of Indian sequences which form a separate sub-cluster in the Euro-Asian 
set, are indicated. Figure shows bootstrap value of 70% and scale denotes percent diversity.
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3.3 Discussion
The prevalence of hepatitis B in South East Asia and western Pacific (except in Australia, 
New Zealand and Japan, where the mean carrier rate is less than 2%, see chapter 1.4) is 
amongst the highest in the world; more than 75% of the world’s chronic carriers are 
living in such densely populated regions (Maynard et a l, 1989). Since the world-wide 
distribution of HBV follows a geographic pattern (Norder et al., 1993b), there may be a 
strong influence of ethnic background, perhaps driven by T-cell selection, on this 
distribution, reflected by divergence of amino acid substitutions within certain regions of 
the core gene (Bertoletti et al., 1991; Zampino et al., 2002).
HBV antigenic subtypes generally reflect the country or regions of origin (Courouce- 
Pauty et al., 1983). However, there are a number of confounding factors. First, some 
subtypes are not geographically localized but are worldwide. Second, there are 
differences in HBV strains between native and foreign carriers in each geographic area 
(Courouce-Pauty et al., 1983); this means that genetically homogenous HBV strains 
cannot simply be presumed to be linked epidemiologically. Third, some subtypes are 
genetically heterogeneous and belong to more than one genotype (see chapter 1.5, table 
1.2) (Norder et al., 1992). Knowing the degree of HBV variation to be expected in a 
certain community could be useful in epidemiological investigations (Blackberg et al., 
2000).
Our comparison of 139 new complete core genes and those in databases verified that 
amino acid/nucleotide specific substitutions correlate with both ethnicity and HBV 
genotypes/subtypes. Motifs and specific individual mutations were observed that 
correlated with broad ethnic background, country, genotype and subtype. Our finding that 
HBcAg variability was distributed geographically was entirely consistent with Norder’s 
study of S genes (Norder et al., 1993b). Moreover, construction of phylogenetic trees 
(Figure 3.1.1), of C and S genes showed an almost identical pattern of HBV genotype
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distribution. Some samples had discrepant genotype allocation based on analysis of the C 
and S genes. These discrepancies were not surprising, as recombination events between 
different genotypes have been described previously (Mizokami et al., 1997); between A 
and C from Vietnam (Hannoun et al., 2000b), between C and D from Tibet (Cui et al., 
2002) and between B and C from different countries of South-East Asia (with exception 
of Japan) (Suguachi et al., 2002). Of interest is that sample A-5 came from Korea, where 
recombination between genotypes B and C has been reported, designed as genotype Ba (a 
for Asia). This is in keeping with Suguachi’s study (Suguachi et al., 2002). In our study, 
recombination between A and D was found in two Italian sequences (Figure 3.1.1). 
Below, we briefly discuss some aspects of our findings.
Comparisons of our data with HBcAg sequences in databases (except aywl strains, of 
which there were no examples) were almost entirely consistent. In other's work, codon 97 
showed the highest variation (Yuan et al., 1999, 2000); however, here, codon 74 
contained the most discrepancy between sequences. Of 9 variable residues observed 
throughout the C gene, 7 were characteristic for genotypes A and D, and 2 residues were 
characteristic for the adrq- subtype. As some subtypes belong to more than one 
genotype, these variants may also be found in more than one genotype. Further variants 
were identical in specific subtypes allowing proper categorization.
The findings at the amino acid level were mirrored at the nucleotide level. At the 
nucleotide level (Table 3.1.4), the best correlation between our data and those obtained 
from databases was found in genotypes A (adw2 subtype) and D strains. Because 6 of 8 
adw2 (genotype B) sequences in our study were derived from Chinese patients, we 
compared these to other Chinese adw sequences in the database (Chuang et al., 1993). 
These were almost identical. Adrq+ strains in the databases were also very similar to 
ours, but adrq- strains did not contain T 7 5 . Tables 3.1.3 and 3.1.4 propose amino acid and
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nucleotide substitutions that are critical sites for defining genotypes and their 
corresponding subtypes.
It is particularly interesting that peoples of a broad ethnic background share amino acid 
substitutions in the core gene despite having different subtypes (Table 3.1.5A). This was 
particularly true of samples from the South-east Asian (including Pacific) regions. It 
would appear that there are shared host-factors, most likely immunological, which act on 
these sequences despite their background subtype. Of interest is that Asian immigrants to 
the USA shared identical sequences to those from the home country. In keeping, in a 
large -scale study on HBV genotype distribution in the USA between different ethnic 
groups, Chu et al, (2003b) found that among the patients bom outside the United States, 
the distribution of HBV genotypes was related to the prevalent HBV genotype in the 
place of birth, and between all epidemiologic factors, only ethnicity and place of birth 
were independently related to HBV genotypes. It thus appears that there are no signature 
sequences in the USA, probably because of long-term, widespread importation of 
sequences. One of our hypotheses was that specific ethnic groups would maintain the 
virus that originated in their home country. Immigration to the USA had no effect on 
Asian sequences, in keeping with circulation of HBV amongst ethnic minorities or the 
likelihood that in an intra-ethnic sexual partnership, it is the Asian partner who is more 
likely to be the primary infecting source (because of high prevalence rate of infection, see 
chapter 1.5). Nevertheless, genotype/subtype-specific variants were identical whatever 
the geographic origin.
The pattern in Western-derived sequences (including from US-Caucasians, Scotland and 
Italy) was slightly different, as there were no specific substitution that correlated with 
individual countries (Table A.I.2). Nevertheless, a clear motif was identified that was 
common to Western populations. We did not study genotype F, which is native to the 
Americas.
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The Pacific region comprises a unique region of admixing of two HBV genotypes, C and 
D, with specific identities which have not been identified in other regions. Adrq+ is the 
prevalent subtype in South-East Asia, while adrq- is only found in Oceania. Geographical 
transition from Asian adrq+ to South American adw4q- has been suggested to be via the 
adrq- subtype in Oceania (Courouce-Pauty et al., 1983). The gradient of nucleotide and 
aa variations from west to east in our study (shared sequences between Tonga and Fiji 
and, on the other hand, variations between Tonga and Vanuatu), are most consistent with 
the hypothesis of migration of Polynesian people from Southern China through 
Melanesia and Fiji and their radiation across the Pacific to fill the Polynesian triangle in 
different times (Diamond et al., 1988; Hagelberg and Clegg, 1993; Redd et al., 1995; 
Kayser et al., 2000). In contrast, back migration from Polynesia to Melanesia could also 
be responsible for this variation gradient (see below). Of interest is that 10 strains from 
Vanuatu, all genotype C isolates, constitute a subcluster in genotype C tree (Figure 3.2.2, 
cluster B). However, two isolates from Vanuatu were extremely divergent and found 
within subcluster A. Within the subcluster A, 6 strains from Tonga constitute a separate 
branch (see Figure 3.2.2). The presence of different strains from all islands (in particular 
Fiji and Tonga) in cluster A may indicate admixture of isolates in Fiji due to its 
geographical location between other 3 islands (Figure 3.2.1). The gradient of nucleotide 
substitutions between 3 islands in table 3.2.4 showed commonality between Fiji and 
Tonga, rather than Vanuatu. This is in keeping with the history of an isolated Vanuatu.
In contrast, genotype D strains including those from databases showed that the Pacific 
islands contain a unique homogenous cluster separated from other genotype D groups. 
The few D sequences on other islands show a similar homogeneity, indicating recent 
contact between Kiribati (which is almost an isolated island in Micronesia with limited 
transfer of virus-see figure 3.2.1) and the genotype C-dominated islands. This suggests
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that genotype D arrived in the Pacific as a relatively homogenous population and has 
been distributed by admixing with stable human populations (Basuni, unpublished data). 
As Indian immigrants usually have genotype D, one might expect Indians to be the origin 
of genotype D strains in this region. However, our results did not show such an 
acquisition of these new strains by migration, there was substantial variability between 
these two ethnic groups. This is best seen as the two separate clusters in figure 3.2.3. The 
study on S genes by Basuni et al, also revealed no strong evidence for Indian admixture 
in Pacific genotype D populations. In fact, results from our previous pilot study showed 
that at the nucleotide level the Pacific genotype D sequences were closer to Caucasian 
strains rather than Indian (Tables A.I.l and A.I.2). Thus, a Pacific origin for genotype D 
cannot be ruled out.
In the Pacific, the contrast between the silent mutations that predominate within Pacific 
genotype C sequences and non-synonymous changes that separate Pacific from the S.E 
Asian sequences is suggestive of an interaction with human genetic variants, especially 
HLA, in the evolution of geographically separated HBV lineages. Once in the Pacific, no 
further immune mediated amino acid selection seems to have occurred, probably because 
there are only a few Pacific HLA types. On the other hand, the significant nucleotide 
variability is in keeping with random mutation in isolated island population.
Overall, the high diversity for genotype C (including silent mutations) and the island- 
specific sequences, suggest a long history of evolution and isolation for genotype C- 
islands. In contrast, the low diversity of genotype D indicates a recent, limited, spread 
over the rest of the Pacific with a single lineage.
HBcAg contains helper T cell (Jung et al., 1995) and cytotoxic T lymphocyte (CTL) 
epitopes (Ehata et al., 1992; Chuang et al., 1993; Wakita et al., 1991). Different HLA 
restricted CTL/T helper epitopes have been identified within the core gene which are
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capable of inducing significant T-cell responses in HBV infected patients. (Ferrari et al., 
1991; Ehata et al., 1992,1993). Previous results have suggested that epitopes for CTL/T h 
recognition might be different on account of the diverse distribution of HLA antigens in 
different geographic regions (Thursz et al., 1995; Thio et al., 1999). Core variation was 
most likely to occur at positions within known epitopes which can tolerate naturally 
occurring variants (Bertoletti et al., 1991; Ehata et al., 1994; Akarca et al., 1995; Hosono 
et al., 1995; Ferrari et al., 1996; Yuan et al., 1999, 2000) i.e. residues 12, 27, 67, 74, 83, 
87, 91, 97 and 116 (Table A.I.l). In keeping, a majority of nucleotide variants, either 
country-specific or subtype/genotype-specific, were distributed in known dominant 
epitopes including regardless whether silent or missense mutations, residues 27, CTL 
(Bertoletti et al., 1991); 50-69, Th (Ferarri et al., 1991); 74-89 and 107-118, B cell 
epitopes (Colucci et al., 1988; Salfeld et al., 1989). Most changes were synonymous. This 
might be due to a lack of a positive selection advantage or a strong bias towards 
maintaining that amino acid. The similarity in amino acid/nucleotide distribution in adw2 
(genotype A) and ayw2 (genotype D) strains found in Western countries (USA- 
Caucasian, Italy, and Scotland), showed that considerable constraints must exist against 
HBV variability in a particular genotype infecting a person of a particular background. 
In addition, the "South-East Asian" and "Western" motifs suggests either that there is 
positive selection on specific variants or that genetic drift in HBV is relatively slow 
(Wilson et al., 1999). According to the almost unique amino acid variation in residues 35, 
40, 59, 74, 80, 87 and 91 in particular countries (Table 3.1.6), we hypothesize that 
differences in distribution of HLA antigens, or other immune genes between diverse 
geographic areas (Ehata et al., 1994) (see chapter 1.7.1), probably contributed to the 
selection of amino acid variation. However, primary data need to be accumulated to 
investigate this issue.
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Subjects and study design
The third section of this thesis deals with in vitro biological effects of HBV C gene
variability. It has been shown that, after seroconversion to anti-HBe, multiple amino
acid substitutions appear in different regions of the hepatitis B core protein. It is not
known if these have any biological significance and little is known about the cellular
localisation of HBcAg variants. If sequence could be shown to correlate with
distribution of HBcAg, especially if the distribution changes with selection of
mutations in individual patients, this may give important clues to potential
mechanisms of liver damage. To address this issue, confocal microscopy was used to
visualise HBcAg cellular expression in 40 clones (including mutagenised samples)
from various stages of HB disease from patients with different HBeAg/anti-HBe
status in the presence of cell cycle blocking agents. This was correlated with sequence
variation within B cell epitopes and the C-terminus. Then, using mutagenesis, we
directly investigated the influence of these mutations on intracellular trafficking.
14 Greek patients were selected after previous characterisation of their sequential
HBV pre-core/core sequences with known serological markers of HBV infection
(Carman et al., 1996). 26 clones were studied. They fell into three groups: six
patients, had a sample taken from the time when HBeAg was positive (Table 4.1.1
1 ^
group 1-A, including 2 initial samples taken from the first patient, 1A and 1A ), plus 
a second sample after anti-HBe seroconversion (Table 4.1.1 group 1-B); five patients, 
were from continuously anti-HBe positive with active disease, in whom one sample 
was chosen from an early period when few HBcAg mutations were apparent (Table
4.1.1 group 2-A), and a second after selection of either a pre-core stop codon and/or at
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least one HBcAg mutation (Table 4.1.1 group 2-B). Three HBeAg-positive chronic 
patients provided single time-point samples (Table 4.1.1 group 3-A).
PCR was employed to detect and amplify the core gene, followed by direct 
sequencing of the amplicon. Cleaned PCR products were digested with restriction 
enzymes, then ligated into a eukaryotic expression vector (pRK5), transformed with 
competent E.coli DH5a, and a large scale DNA preparation was obtained and then 
sequenced. After transfection of the cloned samples with a liposome-based method in 
the presence of cell cycle blocking agents (confirmed by flow cytometry), localisation 
of core protein was studied using immunofluorescence and confocal microscopy. 
Correlation between HBcAg localisation and core gene sequences was then analysed. 
Next, certain samples were selected for a PCR-based site-directed mutagenesis. This 
was carried out using oligonucleotides to revert mutated sequences back to the 
original sequence. This was followed by studies of the resultant intracellular 
distribution.
4.1 Results
4.1.1 Synchronisation of Cos-7 cells by Thymidine-Aphidicolin
To study the influence of cell cycle on the subcellular distribution of HBcAg, Cos-7 
cells were synchronised by two blocking agents (see chapter 2, figure 2.2). In initial 
experiments (data not shown) aphidicolin used alone soon after transfection yielded 
low transfection efficiencies. Consequently, a two step cell cycle synchronisation was 
employed. As a first step, cells were incubated in the presence of thymidine for 12 
hours to enter G0/G1 phase of the cell cycle (Figure 4.1.1, panel B). Afterwards, cells 
were withdrawn from thymidine and permitted to progress out of G0/G1 and into the 
S, G2, and then M phases of the cell cycle for 12 hours (Figure 4.1.1, panel C). After 
cell cycle release, they were washed twice with PBS and transfection was carried out
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Table 4.1.1- Identification, serologic data and clinical status of HBsAg positive sera that were used as
the source for HBcAg cellular expression with different serological and clinical status.
Sample
Code
Genotype HBeAg/
anti-HBe
Clinical
Outcome
HBcAg
Localisation
B-cell Epitope 
Mutation
C-terminus
Mutation
Pre-core^ 
Stop Codoi 
Mutation
Group 1 
1A1 A +/- N _ _
1A2
IB
+/-
-/+ Remission
C
C
+
+
+
+
-
2A D +/- N - - -
2B -/+ Remission C - + +
3A D +/- N - - +
3B -/+ Remission C + + +
4A D +/- N - - -
4B -/+ Active C + + +
5A D +/- N + - -
5B -/+ Active C + + +
6A D +/- N + + +
6B -/+ Active C + + +
Group 2 
7A D -/+ NC + + .
7B -/+ Remission NC + + +
8A D -/+ N - + +
8B -/+ Active C + + +
9A D -/+ N + - -
9B -/+ Active NC + + +
10A D -/+ C + - +
10B -/+ Active N - - -
11A D -/+ N + + +
1 IB -/+ Active C + + +
Group 3 
12A D +/- Chronic disease N -
13A A +/- Chronic disease N - - -
14A D +/- Chronic disease N - - -
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Note: These are three groups of patients: HBeAg to anti-HBe seroconverters, group 1; 
continuously anti-HBe positive, group 2, and single samples from HBeAg positive patients, group 
3. There are two early samples taken from patient 1 (1A1 and 1A2). Pre-core stop codon mutation 
is A]896. Distribution of HBcAg is as follow: N, nuclear; C, cytoplasmic; NC, nuclear and 
cytoplasmic. +, presence of mutation; -, absence of mutation. Note that the pre-C region was not 
within the cloned product so did not directly affect localisation.
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using FuGENE-6 and/or Lipofectamin Plus Transfection Reagent methods. At the 
second step, after 12 hours post-transfection, cells were treated with 2.5 pg/ml 
aphidicolin for 30 hours. Synchronisation by aphidicolin resulted in 94 % of cells 
remaining in Gl/S phase (Figure 4.1.1, panels D and E).
4.1.2 Distribution of mutations in the core gene B cell epitopes and C-terminus 
region
Overall, 34 mutations were distributed in different known B cell epitope regions 
within the core gene (see table 4.1.2). 22 (64%) occurred in residues 74-89; 3 (9%) in 
107-118; and 9 (26%) in 128-135 (Table 4.1.2). 8 out of 22 mutations in the first B 
cell epitope, aa residues 74-89, occurred at aa position 80. 13 (59%) out of 22 C- 
terminus mutations occurred within aa residues 148-160 (Table 4.1.2).
4.1.3 Cellular distribution of core protein
The expression of HBcAg was predominantly nuclear in 13 cases, both nuclear and 
cytoplasmic in 3 samples, and predominantly cytoplasmic in 10 cases. Of 13 patients 
who showed predominantly nuclear, 9 were HBeAg and 4 anti-HBe positive (note 
that 3 of them were initial samples: 8A, 9A, 11A and 10B) (see below). Only one 
patient with predominantly cytoplasmic distribution was HBeAg positive (1 A2), i.e., 9 
were anti-HBe positive. In keeping, none with both nuclear and cytoplasmic 
distribution were HBeAg positive, i.e., all were anti-HBe positive. Also, we observed 
a form of nuclear expression associated with the membrane using standard 
microscopy (Figure 4.1.2, 7A and 9B; Figure 4.1.3 3B, 4B, with double mutagenesis, 
and 11B). Figures 4.1.2 and 4.1.3 and tables 4.1.1 and 4.1.2 detail the patterns of core 
localisation from all patient-derived HBV core genes cloned into pRK5 and 
transfected into G0/1-arrested Cos-7 cells. Consequently, our first finding is that 
cytoplasmic distribution is related closely to HBeAg negativity/anti-HBe positivity.
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Fig 4.1.1- FACS anlysis of Cos-7 cells determined by flow cytometry.
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Note: The peak to the left corresponds to cells in the G1 phase of the cell cycle; the peak to the 
right corresponds to cells in the G2 phase. The shoulder between the two peaks corresponds to 
the S phase. Differential cell cycles shown variable features according to the treatment described 
in the materials and methods. Asynchronously growing cells were given a characteristic trimodel 
profile, as negative control (A); the thymidine-treated cells (B) with 84% of cells were in GO/1. 
The release period in which cells were thymidine-free (C); the aphidicolin-treated cells after 12 
hours (D); and after 30 hours (E) post-aphidicolin. 88% and 94% of Cos-7 cells arrested in Gl-S 
phase of the cell cycle after 12 and 30 hours incubations with aphidicolin, respectively.
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4.1.4 Core gene sequences from the initial samples showed nuclear distribution
Tables 4.1.1 and 4.1.2 show the results of core gene substitutions in 11 initial samples 
(either HBeAg or anti-HBe positive) and 3 single time-point HBeAg positive 
samples. 12 of these 15 samples were predominantly nuclear (only one of the later 
samples, 10B, had nuclear localisation; in total 13 were predominantly nuclear). 8 out 
of 13 (all but one were HBeAg positive) did not have any mutation. The remaining 5 
(3 of 5 were anti-HBe positive) had mutations in either C-terminal region and/or B 
cell epitopes. Two of these were mutated only in B cell epitopes: A74V/G (two 
possible variants for genotype D-see chapter 3.1C, table 3.1.4) and T80A in samples 
9A and 5A, respectively. Another two contained mutations in both regions: T80A, 
Q130P, C153G and T155S in 6A; S135P, Q151R and T155S in 11 A. Only one 
sample with a C-terminus mutation alone was observed: C153G in 8A.
As noted below, later samples from all these five developed further mutations and 
shifted to the cytoplasm. Finally, the HBcAg from the remaining 2 initial samples, 
10A and 7A, showed either predominantly cytoplasmic or both nuclear and 
cytoplasmic distribution, respectively (Figure 4.1.2). Thus, all initial samples, but 
two, showed predominantly nuclear expression. It was unusual to observe C-terminus 
and/or B cell epitope mutations and nuclear localisation of samples with HBeAg 
positivity.
4.1.5 Accumulation of B cell epitope/C-terminus mutations and HBcAg 
localisation
In the five patients with initial samples which contained B cell epitope and/or C- 
terminus mutations and predominantly nuclear localisation (Table 4.1.1: 5A, 6A, 8A, 
9A, 11 A), there was a shift over time both in cellular distribution and sequence. Later 
samples (table 4.1.1: 5B, 6B, 8B, 9B, and 11B) had predominantly cytoplasmic
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distribution (see below): all sequences in the latter group contained additional 
mutations in the same and/or other regions (Table 4.1.2). Thus, it appears that there is 
a relationship between accumulation of further mutations and shift to the cytoplasm.
4.1.6 A shift in cellular distribution to the cytoplasm is linked to substitutions in 
the carboxy terminal and/or B-cell epitopes
In the later samples, of ten with predominantly cytoplasmic distribution, 8 contained 
both C-terminus and B-cell epitope mutations (Tables 4.1.2 and 4.1.3). 2B only 
contained a C-terminus mutation, A160T, while 10A only had mutations in two B cell 
epitopes: A74V/G and P131A. 10B although taken in the anti-HBe positive phase, 
shifted back to the nucleus: in keeping, all the mutations in the first sample (10A), 
reverted back to the wild type (no mutations) in sample 10B (Figure 4.1.2; Table 
4.1.2). 8A from the initial phase, which had a C-terminus mutation, C153G (see 
above), reverted back and L156P arose in the anti-HBe positive phase (Table 4.1.2 
sample 8B). In this patient, an additional amino acid variation occurred in the later 
sample, 8B: G74V. Both of these variants in amino acid position 74 are specific for 
genotype D (see section 3.1.C; Table 3.1.4). Of two samples which showed both 
nuclear and cytoplasmic distribution (7B and 9B), both contained mutations in both 
C-terminus and B cell epitope regions (Table 4.1.2). In sequences with mutations, 
there were no differences in the distribution of those mutations between the two 
clinical groups i.e., HBeAg to anti-HBe seroconverters and the continuously anti-HBe 
positive. Thus, all later samples showed predominantly cytoplasmic (including both 
nuclear and cytoplasmic distribution) and contained B cell epitope and/or C-terminus 
mutations. All but one were anti-HBe positive. As a result, cytoplasmic distribution 
of HBcAg was strongly correlated with the presence of mutations in B cell epitopes 
and/or the C-terminus region of the C gene and anti-HBe positivity.
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4.1.7 Correlation of HBcAg localisation with clinical outcome
Of the 11 later samples, 4 were in clinical remission and seven had active disease. 3 of 
patients in clinical remission showed a shift in distribution of HBcAg from nucleus to 
cytoplasm after seroconversion to anti-HBe. Of the seven patients with active disease 
all but one (10B) showed a shift from nuclear to cytoplasmic expression between the 
earlier and later sample (Table 4.1.1). Interestingly, with exception of 10B, all active 
and all remission phase samples contained B cell epitope and/or C-terminus mutations 
(Table 4.1.2). Consequently, 9 out of 11 later samples either in remission or in active 
disease shifted from predominantly nuclear to predominantly cytoplasmic indicating 
that there was no clear difference between different clinical outcomes and HBcAg 
localisation.
4.1.8 The cellular distribution of the core protein is dependent on the sequence
Some of the shifter samples (Table 4.1.1) were chosen for site-directed mutagenesis 
(Table 4.1.3). Samples 3B, 4B and 5B had double mutagenesis at the same time on 
both C-terminus and B cell epitopes. As sample 10A did not contain a C-terminus 
mutation, but had mutations in two different B cell epitopes (Table 4.1.2), it was 
selected for double mutagenesis on these epitopes. All experiments were designed to 
revert the mutated amino acid to the expected aa variant for each genotype which was 
also that observed in the first sample of the pair (or the second in the case of patient 
10). All clones were sequenced to confirm reversion (Figure 4.1.4). After reverting 
the sequence in the C-terminal and/or B-cell epitopes of the later sample back to the 
original, a shift back to the original nuclear and/or both nuclear and cytoplasmic 
distribution was observed as follows. After mutating single amino acids in B cell 
epitopes, 4 out of 5 samples shifted back partially i.e., they localised to both nucleus 
and cytoplasm (Figure 4.1.3, 3B, 4B, 10B and 11B). In contrast, mutagenesis of C-
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terminus mutations resulted in predominantly nuclear localisation in all cases (Figure
4.1.3, 2B. 4B and 5B; Table 4.1.3). In keeping, all double mutated samples shifted 
back to either nucleus (Figure 4.1.3, 5B and 10A) or nucleus and cytoplasm (Figure
4.1.3, 3B and 4B). Consequently, reversion of C-terminus mutations leads to HBcAg 
shifting back to the nucleus. Reversion of B cell epitope mutations leads to a mixed 
nuclear and cytoplasmic distribution. The effect of dual mutations is the same as for 
C-terminus mutations.
4.1.9 Pre-core variants
8 out of 13 samples with predominantly cytoplasmic localisation contained the 
precore stop codon mutation at aa 28 of the pre-core region; in predominantly nuclear 
cases it was found in 4 out of 13 (Table 4.1.1). Consequently, the pre core region did 
not appear to influence the effect of C gene localisation.
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Fig 4.1.2- Intracellular localisation of HBcAg using confocal m icroscopy. Im m unoflourescence 
staining o f HBcAg in Cos-7 cells transfected with constructs containing clones o f : A) initial and 
B) later sam ples of patients with chronic HBV infection, C) individual HBeAg positive samples as 
described in the text.
Negative Control
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14C
13C
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Table 4.1.3 In vitro mutation of cytoplasmically distributed sequences.
Mutated Mutagenesis Position HBcAg Localisation
B-cell Epitopes C-terrminus
Virus N N&C C
HBc-1 HBc-2
2B T160A +++ +
3B A80T +++ +
3B S181P ++ ++
3B A80T S181P + +++
4B E77Q, P79Q, A80P + +++
4B S181P +++ +
4B E77Q, P79Q, A80P S181P +++ +
5B Q177K +++ +
5B A81T Q177K +++ +
10A V74A ++ ++
10A A131P ++
10A N74A A131P + +++
1 IB P135Q + +++
The mutations generated are listed according to their amino acid position within an epitope. 
HBc-1, residues between aa position 74-89; HBc-2 residues between aa position 128-135. +, 
represented 25% of stained-cells. Letters before each number indicates the mutated sequence to 
wild type and letters after numbers indicates the original sequence before mutagenesis.
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Fig 4.1.3 Localisation patterns o f HBcAg in Cos-7 cells transfected with constructs containing  
m utagenised clones in the B-cell epitopes, C-term inus, and both C-term inus and B-cell epitope 
regions.
2B. C-terminus mutagenesis, T160A 3B. B cell epitope mutagenesis, N74A.
3B. C-terminus mutagenesis, S181P. 3B. Double mutagenesis, N74A and S181P.
Chapter 4  In Vitro H B cA g Localisation
4B. C-terminus mutagenesis, S181P
4B. B cell epitope mutagenesis, E77D, 
A79Q, S80P
5B. Double mutagenesis, A81T, Q177
4B. Double mutagenesis, E77D, A79Q, 
S80P and S181P
5B. C-terminus mutagenesis, Q177K
10A. B cell epitope mutagenesis, V74A
173.
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10A. Double mutagenesis (both B cell 10A.B cell epitope mutagenesis, A 13IP
epitopes), V74A and A131P
1 IB. B cell epitope mutagenesis, P135Q
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4.2 Discussion
The entire HBV genome is extremely stable in the early high-replicative HBeAg positive 
phase, when the immune response is considered to be weak (Hannoun et al., 2000a). 
However, after HBeAg seroconversion to anti-HBe, multiple clusters of mutations appear 
in different regions of HBcAg, in particular immunodominant epitopes (see chapter 1.4.4, 
figure 1.7 and table 1.1). Several studies have shown that amino acid variability of 
HBcAg is related to the severity of liver disease, both in the HBeAg and anti-HBe phases 
(Wakita et al., 1991; Ehata et al., 1992; Chaung et al., 1993; Carman et al., 1994, 1995b, 
1997b). There are reports describing HBcAg distribution in the cytoplasm, nucleus, or 
both, in infected or transfected cells (Yamada et al., 1977; Brechot et al., 1980; Gowans 
et al,. 1983; Uy et al., 1986; Akiba et al., 1987; Hsu et al., 1987; Wu et al., 1987; 
Nakopoulou et al., 1992; Fang et al., 1994; Bock et al., 1996; Aiba et al., 1997; Naoumov 
et al., 1997; Chu et al., 1997; Park et al., 1999; Serinoz et al., 2003). Recently, Kawai and 
colleagues found that hepatocytes exhibiting cytoplasmic HBcAg expression contained 
more core promoter double mutations (T1762 and A1764) than hepatocytes exhibiting 
nuclear expression (Kawai et al., 2003). Studies on liver biopsies have suggested that the 
intracellular distribution of HBcAg correlates with disease activity, cytoplasmic 
expression being associated with more severe disease (Wu et al., 1987; Akiba et al., 
1987; Ballare et al., 1989; Tong et al., 1990; Kawai et al., 2003). The cell membrane of 
HBV-infected hepatocytes may also express HBcAg during chronic infection (Ferrari et 
al., 1987; Naoumov et al., 1993). However, whether HBcAg intracellular distribution is 
associated with liver damage is unclear.
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Previous studies have been carried out on biopsy material in which the additional 
influence of host factors makes it difficult to delineate the mechanisms responsible for the 
intracellular distribution of HBcAg. The present study has confirmed previous 
observations that there is a close relationship between the topographic distribution of 
HBcAg in vitro and the inflammatory status of the liver in vivo. The staining pattern is 
unlikely to be caused by different transfection efficiencies, because the amount of 
plasmid DNA used was standardized and the experiments in some instances repeated 
more than two times. For the first time, it has been shown that the distribution of 
expressed HBcAg is strongly linked to the viral sequence. The presence of cytoplasmic 
expression of HBcAg correlated with the existence of mutations in the B-cell epitopes 
and/or carboxy-terminus of the protein. These experiments were carried out in the 
presence of aphidicolin to block cells in Gl/S; consequently, any shift to cytoplasmic 
expression was not a result of nuclear membrane dissolution. However, to prove that 
sequence was critical in HBcAg localisation, reversion of C-terminus and/or B-cell 
epitopes mutations back to the wild type was performed: in most cases, this shifted 
HBcAg localisation back to the nucleus. Some possible explanations for this shifting 
follow.
First, only phosphorylated core protein specially targets the nucleus via signal sequences 
in the C-terminus (Eckhardt et al., 1991; Liao et al., 1995), which interact with kinase or 
other cellular factors (Hui et al., 1999). Removal of the last 36 C-terminal aa completely 
abolished phosphorylation of the core without interfering with particle formation 
(Schlicht et al., 1989). Consequently, altered amino acid residues in close proximity to 
SPRRR motifs may influence the behaviour of HBcAg in that they may induce a
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conformational change, suppressing phosphorylation by ap34crfc2 kinase. HBcAg would 
then remain in the cytoplasm. Although this work was carried out on DHBV core 
particle, for which size and position of the phosphorylation sites differ from human HBV, 
the concept that phosphorylation alters the localisation of core protein still remains valid. 
Second, Machida and co-workers reported an antigenic site within the C-terminus region 
called HBicAg (hepatitis B inner cAg, aa residues 148-160) as a potential B cell antigenic 
determinant (Machida et al., 1989, 1991; Sallberg et al., 1994). Here, 13 out of 22 C- 
terminus mutations occurred within aa residues 148-160 (Table 4.1.3). If the arg-rich C- 
terminus can stimulate a B-cell response in humans. As this region is also known to affect 
nuclear localisation, mutations would explain the shift of HBcag to the cytoplasm. This is 
in line with observations that escape mutations appeared in the B cell epitopes in patients 
with ongoing disease (Carman et al., 1997b), as double mutagenesis of both a B-cell 
epitope and C-terminus residue: all samples shifted back to both nuclear and cytoplasmic 
and/or predominantly nuclear.
Although B-cell epitope mutations tended to shift HBeAg to the cytoplasm, this was not 
as effective as C-terminus mutations, which probably direct HBeAg intracellular 
trafficking by a different mechanism(s). A majority of B cell mutagenised samples 
localised into the both nucleus and cytoplasm, while all C-terminus mutagenised samples 
showed predominantly nuclear distribution. This was also observed in 2 of 3 double 
mutagenised samples. The reason underlying this phenomenon is unclear and deserves 
more investigations.
We clearly showed, in samples with both nuclear and cytoplasmic localisation, that 
HBeAg could be associated with the nuclear membrane. This unusual pattern has been
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reported before (Yamada et al., 1977; Bock et al., 1996; Wu et al., 1996). As there is no 
sharp boundary between G1 and S phases, transport of HBeAg to the nuclear membrane 
may occur during the transition. It may be that nuclear/cytoplasmic localisation may be a 
transition step between the two compartments (Akiba at al., 1987). Alternatively, there 
may have been high levels of nuclear HBV DNA with inefficient transportation from the 
nucleus. However, there is no strict division between predominantly nuclear and 
predominantly cytoplasmic core protein localisations in vivo, because core particles are 
usually present in both compartments (Yamada et al., 1977; Naoumov et al., 1997).
In a majority of cases, a predominantly cytoplasmic distribution in vitro was found in 
both samples from patients in remission and with active disease. These samples (1A1, 
1A , 2B and 3B) selected more mutations in Th epitopes than in C-terminus region and/or 
B cell epitopes (Table 4.1.2). Of the seven patients with active disease six showed a shift 
from nuclear to cytoplasmic expression between the earlier and later sample of which, 
four had a higher proportion of mutations in B cell epitopes than other regions (Table 
4.1.2, 4B, 9A, 10B and 11 A). All samples with active disease were anti-HBe positive, of 
which 4 showed predominantly nuclear staining (see above). In keeping, in 4 samples 
from continuously anti-HBe positive patients with predominantly nuclear staining, all 
were taken from patients with active disease. The only apparent correlation in HBeAg 
sequences between this group (samples 8A, 9A, 10B and 11 A) and other anti-HBe 
positive with predominantly cytoplasmic staining was that fewer mutations in these 
samples have been found compared to later ones with predominantly cytoplasmic 
distribution (Table 4.1.2). Although this unusual expression has been reported before 
(Wu et al., 1996; Borg et al., 2000; Kawai et al., 2003), it is likely that after HBeAg
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seroconversion to anti-HBe there is co-existence of both antigen and antibody for some 
time (Maruyama et al., 1998), with concurrent persistence of low concentration of 
integrated HBV DNA in the liver after the disappearance of HBeAg (Wu et ah, 1996). 
Nevertheless, various studies reported continued liver disease activity after conversion to 
anti-HBe status in certain patients that might be related to continued viral replication and 
secretion with the presence of HBcAg in the nuclei. Even in some patients with cirrhosis 
and severe chronic hepatitis, HBcAg has been reported to be predominantly nuclear (see 
chapter 1.4.IF). The reason underlying this pattern is not clear, but might be related to the 
specific patient population studied (Hadziyannis et ah, 1983).
We believe that the differential subcellular distribution of HBcAg in chronic HBV 
infection in different reports might be related to genotype-specific sequence variability 
between different ethnic groups indeed. This is currently under investigation but would 
be in keeping with recent data on different clinical outcomes in some East Asian patients 
infected with either genotype B or C (Lindh et ah, 1999; Kao et ah, 2000a and b, 2001; 
Orito et ah, 2001; Yoo et ah, 2003).
In summary, we have shown that subcellular expression of HBcAg is related to serology 
and depends on HBcAg sequence even in sequential samples from individual patients. C- 
terminus and/or B cell epitope mutations are involved in the shifting of HBcAg between 
nucleus and cytoplasm. These results were generated using an artificial system. As there 
is no susceptible cell line that can be truly infected by HBV, the biological importance of 
such variants on the viral life cycle and cell behaviour are still unclear.
If expression of HBcAg is predominantly cytoplasmic, it is conceivable that at least some 
of these processed peptides would express on the cell membrane (Saito et ah, 1992) (see
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chapter 1.4.3F), which renders this target viral antigen susceptible to immune attack and 
severe liver injury. Conversely, if HBcAg is localised to the nucleus, then little or no 
HBcAg should be expressed on the cell surface with a concomitant decrease in liver cell 
injury.
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5.1 Aims of study
Because of the unavailability of a relatively susceptible cell line that can be infected by 
hepadnaviruses, there is no readily available system for studying the early events of the HBV 
life cycle. Thus, most studies are carried out by transfection. FTO 9.1 cell line (a rat 
hepatoma cell line which is transfected with a construct containing human-Annexin V, h-A 
V) was employed for HBV infection. The effect of varying concentrations of DMSO and 
recombinant h-A V was assessed. Cells and culture supernatants were assayed at various 
times post infection by both IF microscopy (HBcAg staining in nucleus) and PCR of culture 
supernatants. Supernatants from these initially infected cells were then used to infect fresh 
FTO 9.1 cells with similar outcomes to primary infection. The virus has been further 
propagated in this manner in at least one further passage and can be reliably reproduced thus 
indicating the value of this cell line for in vitro studies of HBV.
5.2 Introduction
HBV displays a distinct hepatotropism and a narrow host range in vivo (Ganem et al., 1987, 
1994). However, very little is known about the interaction of HBV with its host cells, mainly 
because of difficulties in the development of suitable tissue culture system. In vitro studies of 
HBV infection system involve chromosomal replication of HBV DNA which does not 
include the early events of infection. Several studies using transfection and/or transgenic 
technology have suggested that the species barrier of HBV infection and replication may be 
located at the early step of viral adsorption (Gong et al., 1999; Paran et al., 2001). 
Transformed cell lines would be of interest for in vitro culture of HBV, however, they are 
also thought to lose some of their liver specific markers and functions, so losing 
susceptibility to HBV. The potential development of an in vitro culture system for HBV 
replication provided an opportunity to investigate molecular and cellular events in cloned
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cells (Roingeard et al., 1990b). However, attempts to establish a stable and reproducible in 
vitro system for production of HBV by infection of cells have not been successful.
5.2.1 Primary Human Hepatocyte Cells
Primary human hepatocytes are susceptible to viral infection as shown by de novo 
production of viral proteins, appearance of HBV DNA and DNA polymerase activity, and 
HBV-specific transcripts. However, with increasing time in tissue culture, such cells 
gradually lose the capability for production of viral proteins. Also, there is loss of the 
“hepatocyte-like “ morphology, presumably the result of a loss of differentiated functions of 
the hepatocytes in cell culture (Galle et al., 1994). A further problem is that primary human 
hepatocytes are very difficult to obtain. By adding chemicals (such as DMSO, PEG), 
infectivity can be stabilised and life and viability of the cells can be extended. However, as 
the addition of these artificial substances does not mimic the in vitro process and may be 
affecting the infection mechanism, it is desirable to find another system.
5.2.2 Human Liver Tumour Cell Lines
Hepatoma cell lines can be characterised by their expression of hepatocyte- and biliary- 
specific genes (Zvibel et al., 1998). It is possible to study HBV production in culture by 
transient transfection of human hepatoma cell lines (Shih et al., 1989): HepG2 (Roingeard et 
al., 1990b), Huh 6-cl5 (Tsurimoto et al., 1987), Huh-7 (Yaginuma et al., 1987) and Hepa RG 
(Gripon et al., 2002).
However these cell lines do not support stable HBV infection. It is postulated that human 
hepatoma cell lines do not have the receptor for virus attachment, penetration, and fusion 
leading to productive infection (Bchini et al., 1990). On the other hand, some infected 
HepG2 cell line have been achieved and reported to release HBV particle into the medium 
with the same antigenic, morphologic, and biologic properties as HBV virions (Bchini et al., 
1990; Paran et al., 2001).
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5.2.3 FTO Cell line and Annexin-V
Chapter 1.2A details the existence of a receptor-ligand relationship between hA-V and 
HBsAg. In this regard, transfection of hA-V into a non-susceptible rat hepatoma cell line, 
FT02B, resulted in conferred susceptibility to HBV infection. FTO 9.1 (Gong et al., 1999). 
It is interesting to note that rat Annexin V does not bind to HBsAg, although it has a 
sequence homology of more than 90% as compared with hA-V at the amino acid level (Gong 
et al., 1999). This cell line can therefore be considered both susceptible and permissive to 
HBV replication, although FTO-hA-V cells may lose expression of Annexin-V over time 
(Doman et al., unpublished results).
5.3 Objectives:
1-Which diagnostic procedure can be used to confirm true FTO 9.1 infection i.e., episomal, 
and not chromosomal, replication.
cccDNA specific PCR of cell extracts is a marker of internalization of virus by the cells, and 
confirms infection. HBcAg staining would also indicate expression of HBcAg by the cells.
2-How many viral passages can be achieved in this cell culture system?
3-What are the effects of chemical additives on the infectivity of FTO 9.1?
5.4 Methods
5.4.1 Cell Culture and Infection
FTO 9.1 cells (Innogenetics, Gent, Belgium) were grown at 37 C, 5% CO2 in Hams F12: 
Dulbeccos modified Eagles medium (1:1 v/v) containing 10% foetal bovine serum, 100 
IU/ml Penicillin, lOOug/ml Streptomycin and 2mM L-Glutamine (Life Technologies, 
Paisley, UK), and 600ug/ml G418 (The media for negative control did not contain G418). 
Cells were passaged every 3-4 days. Cos-7 cells were grown in DMEM with the same 
supplements as for the FTO 9.1 cells, except that G418 was not added to the medium. In our 
infection experiments the FTO-2B cell line (rat hepatoma without annexin V) was not
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available for study and for control cell lines, we used COS-7 cells which should not be 
permissive.
For infection, cells were plated at 3xl05 cells in 24 well plates. Infection was carried out for 
16 hrs with HBeAg positive serum containing ~5xl 06 genome equivalents (geq)/ml. HBV 
positive serum was diluted in FCS and media to give multiplicity of infection (MOI) of 100. 
At the time of infection either 2% DMSO or rAV (lOug/ml) added to the media. Cells were 
infected overnight at 37°C, then washed thoroughly (7 times) with PBS, and 200ul of the last 
wash was extracted (Figure 5.1, a), thus it is unlikely that the positivity of FTO cells seen at 
day 5 is a result of amplification of DNA from virions present in the original inoculum. For 
passage of the virus, supernatant of infected cells from day 5 was carefully removed to 
prevent contamination with cells and the supernatant added to fresh FCS and then added to 
fresh cells. Cells were examined for fluorescence under a Nikon Microphot-SA microscope. 
This experiment has been repeated twice with consistent results.
5.5 Results
5.5.1 Cell passage number and infection
Previously, our colleagues infected both early and late passage numbers of the FTO 9.1 cell 
line, and they found that the earlier passage number, 8 was more infectable than a later 
passage number, 20 (Table 5.1) (Doman, unpublished data). As a result of this, we used the 
cells only at passage number 18 or less.
5.5.2 HBV core gene PCR of cell culture supernatants from FT09.1 infected cells
Figure 5.1 shows the results of PCR on cell culture supernatants from cells infected with an 
HBeAg positive serum. A C-gene PCR was employed on the supernatant of infected cells 
from days 2 and 5 to confirm the infection (Figure 5.1, b, c). 200 ul of supernatant was 
extracted at day 5 and the supernatant became core PCR positive (Figure 5.1, d).
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0 1 2 3  4 5 6 7 8 9 0 1  2 3 4 5 6 7 8 9
a- 7'1' wash b- 2nd day
0 1  2 3 4 5 6 7 8 9
c- 5th day d- Transfer Experiment
Fig 5.1 Comparison o f PCR results obtained from  different time intervals during FTO 9.1 cell line 
infected with HBsAg positive sera. Lane 0, DNA m olecular weight marker; lane 1, H BV-contained media 
without DM SO/hAV; lane 2, HBV positive media plus rAV; lane 3, cells contained DM SO; lanes 4 and 5, 
DNA extraction positive and negative controls; lanes 6 to 9, 1st and 2"d PCR negative and positive 
controls, respectively.
The COS-7 cell line remained negative (results not shown). cccDNA-specific PCR had been 
carried out before (results not shown), using specific primers on each side o f the gap, to 
confirm internalisation o f the virus into the cells.
5.5.3 HBcAg staining
Cells grown on 13 mm coverslips in 24 well plates were analysed for the expression o f HB 
core antigen 5 days after infection. HBcAg staining can be clearly seen in the nuclei o f the 
cells (Figure 5.2, A).
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Fig 5.2 FTO 9.1 cell line expressing HBcAg using im m unofluorescene m icroscopy.
A) HBcAg staining of 5'1 day post infection with x40 m agnification. B) HBcAg staining of transfer 
experim ent, 5 days after supernatant transferring of previous H BV-infected FTOcells to the fresh cells 
with m agnification o f x75. (The poor quality of pictures is due to unavailability o f better images from  
the old files and early training on IF microscopy at the beginning of research course).
5.5.4 Effect of recombinant annexin V and DMSO on infectivity of FTO 9.1 cells
It was noted that the addition o f  lOug/ml recombinant annexin V to the cell culture medium 
resulted in more infection efficiency (Figure 5.1- lane 2; Table 5.2). As DMSO had been 
shown previously to improve infection efficiency, this was also added to the medium (Figure 
5.1, lane 3). In the absence o f rAV one o f  four wells proved positive by PCR at day 2 
whereas if  10 ug/ml rAV is present, three o f  four wells were positive (results not shown).
5.5.5 Transfer Experiment
Supernatant from the fifth day after priming infection was then used to inoculate fresh FTO
9.1 cells. Cells stained positive for HBcAg (Figure 5.2 B). This experiment was carried out 
at least twice by our colleagues, but Cat III became unavailable, we could not analyse further 
virus passages.
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Table 5.1: Effect of FTO-hAV cell passage number on infection in the presence of rAV and DMSO.
Cell Passage number Day 2 S gene PCR Day 5 S gene PCR
Passage 8 Negative Negative
Passage 8 Positive Positive
Passage 8 Positive Positive
Passage 20 Negative Negative
Passage 20 Positive Negative
Passage 20 Negative Negative
l- Effect of rAV and DMSO on infection of FTO cells
Additions Day 2 HBcAg PCR Day 5 HBcAg PCR
- Negative Negative
HBV Negative Positive
HBV + rAV Positive Positive
HBV + DMSO Positive Positive
HBV +rAV + DMSO Positive Positive
5.6 Discussion
Several cell lines retaining some of the hepatocyte markers are available that support HBV 
transcription and replication upon plasmid transfection. However, even these permissive cell 
lines are not susceptible to HBV infection. An inevitable conclusion is that the early steps of 
virus-cell attachment and entry determine the viral tropism and susceptibility. These results 
demonstrate the capacity of the rat hepatoma (FTO) cell line, transfected with human 
annexin V (FTO 9.1), to be fully infected by HBV. This cell line can therefore be considered 
both susceptible to and permissive for HBV. Using DMSO increased infectability, but its 
action is non-specific. It may be possible to increase infection efficiency with manipulation 
of the growth conditions.
Human annexin V presents itself as a likely candidate for the species specificity determining 
receptor for HBV, because of the ability of a non-susceptible cell line to become susceptible
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following transfection with DNA for this protein (Gong et al., 1999). The effect of rAV on 
infection may be explained by its competence for binding phospholipids, as HBsAg is 
extensively lipidated (Neurath et al., 1994). However, binding, and subsequent penetration of 
the hepatocyte membrane by HBV via HBsAg interacting with annexin V may not explain 
the hepatotropism of HBV. Clearly, since HBV virions can be produced after transfection of 
a rat cell line and also in transgenic mice (Farza et al., 1988; Shih et al., 1989; Guidotti et al., 
1995), the species barrier for HBV is not at the level of transcription/translation of HBV 
specific genes. Rat/mice nuclear or cytoplasmic factors may act on HBV 
promoters/enhancers to achieve replication, thus the species barrier is present at the initial 
stage of entry of the virus into the host cell. Since h A-V is expressed in most tissues 
(reviewed by Benz and Hofmann, 1997) this receptor does not account for the hepatotropism 
of HBV. It is possible that the tissue specificity results from downstream events and only 
liver specific factors will result in new virus after acting on the infecting DNA. These results 
should now allow the study of various aspects of the viral life cycle that could only be 
studied with the use of, e.g. primary hepatocytes, which are difficult to obtain and have 
limited growth characteristics, in term of retaining their hepatocyte specific functions. In 
future, further neutralisation assays should be carried out, using various monoclonal and 
polyclonal antibodies to assess their ability to block HBV infection.
In conclusion, this cell line does appear to be useful in the study of the early stages of HBV 
infection, and with continued investigation, should be available for the research for more 
information about HBV receptors and the development of new protective or preventive 
treatments.
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General Conclusion
In conclusion, the data presented in this thesis focused on several important issues. 
First, C gene variation relates to ethnic background; there are various genotypes 
associated with specific subtypes, which may have migrated with their human hosts. 
Peoples with related ethnicity, despite wide geographic location, have a set of 
common variants. Small changes (one or two substitutions) are selected, either 
negatively or positively, once there is little intermixing between these people (e.g. 
once they became a tribe). As more sequence data accumulate from different 
geographic origins, it is expected that HBV genomic classification will become 
refined, contributing to the finer mapping of the relation between diverse geographic 
origins and the distribution of HBV strains. Further, sequence analysis of core gene, 
particularly, in the CTL restricted regions, provides a useful tool for better 
understanding of biology of HBV strains, and finally, for design of 
immunomodulatory therapies upon vaccination.
Second, the dependence of the pattern of HBcAg localisation in vitro (in this 
thesis) on the sequence of variants and its correlation with the serology 
of chronic HBV infection, supports the hypothesis that such variants may 
have biological significance by influencing such things as antigenic 
expression. The effect of those variants on viral life cycle could be 
studied by applying a suitable cell culture system, such as the FT09.1 cell 
line. As it appears from this work, the data presented in chapters 4 and 5 are somehow 
speculative. Therefore, applying a suitable cell culture system for HBV infection 
would be useful in the study of biological behaviour of HBV variants in terms of new 
protective and preventive treatment.
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Appendix
A.I
Table A.I.1- Alignment of complete amino acid sequences of HBcAg which shows genotype/subtype 
identification and geographic origins of 91 sera.
Note: Amino acid residues are numbered from the beginning of the HBcAg using the single letter code. Apart 
from genotype A, which had 185 amino acids, all the other genotypes had 183 amino acids, therefore using 
Bioedit software (Clustal W alignment) 2 extra amino acids were added at positions 153 and 154 for a proper 
alignment.
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Appendix
Table A.I.2- Alignment of complete nucleotide sequences of HBcAg which shows genotype/subtype 
identification and geographic origins of 91 sera.
Note: Nucleotides are numbered from the beginning of the HBcAg. Genotype A had 6 insertions, 
therefore using Bioedit software (Clustal W alignment) 6 extra nucleotides were added at positions 2454 
to 2459 for a proper alignment.
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A.II Application of core gene sequencing data to an HBV incident
An elderly lady bom in the UK, underwent colostomy at the Royal London Hospital in 
04.02. She was found to be positive for HBsAg post-operatively (patient B). After an 
investigation, another HBsAg positive patient was identified. He had had renal 
transplantation in India in 2001 and underwent colonic surgery at two different London 
hospitals between 2001 and 2002 (patient A). These two patients had been in different 
wards; however, both patients were operated on at the same theatre and the same day by 
the same surgical team. The surgical team were suspected to be a source o f HBV in these 
two patients. However, all member of the team were negative for HBsAg. Stored sera from 
both patients were sent to the west o f Scotland special Virology Centre, Glasgow. DNA 
from sera was extracted manually (using QIAGEN kit) and a hemi-nested core gene PCR 
carried out on samples using standard primers (see table 2.1). Sequences were aligned 
using sequence Navigator program and Bioedit software. One o f the Indian core gene 
sequences (0123) obtained from our previous study (see chapter 3.1) was selected as a 
reference sequence. The two patient sequences were identical. Compared to the reference 
Indian sequence (0123) there was 100% homology at amino acid level, and there were only 
10 silent variations at the nucleotide level (Tables A.II.l and A.II.2). These two C gene 
sequences (Figure A.II.l, bold red sequences, A and B) localised within the Indian cluster 
in the tree (bold red sequences). Either patient A infected in India by the commonest kind 
(cluster) o f Indian genotype D or in Europe by a form o f genotype D that is rare in Europe. 
Since he was previously in India, the first possibility seems most likely; in which case the 
Western-derived isolates in the Indian cluster (155 and 8.25) may also have ultimately 
come from India (see chapter 3.3).
This HBV outbreak illustrates the value of generating databases of sequences from around 
the world. Just having the genotype would have been useful but databases o f sequences
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from this approach allowed us to confirm that the origin o f the virus was probably India. 
However the route o f transmission is not yet clear.
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Fig A.II.l. Neighbor joining phylogenetic tree of core gene sequences from chapter 3 as well as 2 HBV 
isolates, A and B (red, bold colour) rooted with one of Pacific sequences (3309). Genotype A, purple; 
Genotype B, blue; genotype C, green and genotype D, red colour. Indian sequences shown by bold red 
colour. Figure shows bootstrap value of 70% and scale donates present diversity.
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SUMMARY. There are eight genotypes and nine subtypes of 
HBV. Small differences in geographical origin are associated 
I with sequence changes in the surface gene. Here, we com- 
i pared core gene sequences from different genotypes and
1 geographical regions. Specific combinations of 24  amino
'i acid substitutions at nine residues allowed allocation of a
sequence to a subtype. Six of these nine residues were
located in different T cell epitopes depending on HBV geo­
graphical area and/or genotype. Thirty-four nucleotide 
changes were associated uniquely with specific genotypes 
and subtypes. Unique amino acid and nucleotide variants 
were found in a majority of sequences from specific coun-
1 tries as well as within subtype ayw2 and adr. Specific ^ ^Ssubtypes.
nucleotide motifs were defined for Korean, Indian, Chinese, 
Italian and Pacific region isolates. Finally, we observed 
amino acid motifs that were common to either South-east 
Asian or Western populations, irrespective of subtype. We 
believe that HBV strains spread within constrained ethnic 
groups, result in selection pressures that define sequence 
variability within each subtype. It suggests that particular T 
cell epitopes are specific for geographical regions, and thus 
ethnic groups: this may affect the design of immunomodu­
latory therapies.
Keywords; C gene variability, HBcAg, HBV genotypes, HBV
i INTRODUCTION
Hepatitis B virus (HBV) DNA contains four open reading 
frames. The core (C)-gene encodes the 1 8 3 -1 8 5  amino acid 
j  long nucleocapsid protein and is preceded by the precore
‘ region [1]. Hepatitis B core antigen (HBcAg) contains helper
T cell and humoural epitopes [2], and is an immunologic 
target of cytotoxic T lymphocytes (CTL) [1,3]. Different HLA- 
restricted HBcAg T cell epitopes have been proposed
throughout HBcAg [4-8], which might be different on 
account of the diverse distribution of HLA antigens in 
different countries [5 ,9 -10 ].
The HBV can be classified into at least eight genotypes 
(A-H) [1 1 -1 4 ]. One common antigenic determinant, a, and 
two pairs of mutually exclusive determinants, d/y and w/r, 
initially identified four HBsAg subtypes. Later research
defined nine subtypes in total: a y w l, ayw2, ayw3, ayw4,
I
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Correspondence: W illiam  F. C arm an, G artnavel General Hospital, 
PO Box 167 6 6 , Glasgow G12 OZA, Scotland. Tel.: + 4 4  (0) 141- 
2 1 1 0 0 8 5 ; E-mail: w .carm an@ vir.g la .ac.uk
© 20 0 4  Blackwell Publishing Ltd
ayr, adw2, adw3, adw4, adrq+ and adrq- [14,15]. The 
relationship of these nine subtypes to genotypes A-G has 
been established and some subtypes can be found in more 
than one genotype. HBV genotypes have a characteristic 
geographical distribution, largely in agreement with subtype 
distribution [16].
Although the amino acid sequence of the core region is 
relatively conserved (compared with surface gene), amino 
acid substitutions have been observed in several reports 
[1 -3 ,5 ,1 7 -2 1 ]. This is largely linked to the clinical or 
serological picture [1 -3 ,5 ,7 ,20 ]. However, in view of the 
heterogeneity of HBV strains, it can be difficult to determine 
whether substitutions recorded only once represent natur­
ally occurring variants or merely an immune-selected 
mutation in that patient. So far, no systematic study has 
been conducted to correlate HBcAg diversity with HBV 
subtypes and ethnic background. This background infor­
mation would not only be critical to the correct interpret­
ation of sequences observed in clinical studies, but may aid 
in the design of immunotherapies specific for persons of a 
particular ethnic origin.
Here, HBV DNA in 91 sera from nine diverse geographical 
origins was analysed by sequencing the core gene.
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Subtyping by additional S gene sequencing allowed defini­
tion of subtype-specific variants. Our sequences were then 
compared with those in international databases to add 
strength to the conclusions. We also found that nucleotide 
and/or amino acid variation can be correlated with geo­
graphical/ ethnic b ackground.
METHODS 
Sera
Sera from 91 HBsAg positive patients from nine countries, 
including 49 samples from California (39 from Asian origin 
living in California and 10 from Caucasians), 12 from Italy, 
and 10 each from Scotland, India, and the Pacific region 
were selected (Table 1). All were positive for HBsAg with a 
variety of clinical features and serological status for HBeAg/ 
anti-HBe. The Asian origin samples from California were 
previously sequenced for a precore variability study (results 
not shown). These findings then were compared with se­
quences of known geographical origin in the database to 
strengthen the associations.
Table 1 Origin of 91 HBsAg-positive sera that were used as 
the source for HBcAg sequencing
Country No. of samples
South-east Asia
China 20
Korea 8
Japan 5
Vietnam 6
Pacific 10
Caucasian
USA 10
Scotland 10
Italy 12
India 10
Total 91
DNA extraction
A 50 pL aliquot of serum was mixed with 150 pL of PBS, 
and then 200 pL binding buffer (High Pure Viral Nucleic 
Acid Kit, Roche, Germany) supplemented with poly A 
carrier RNA was added. The sample was digested with 
40 pL proteinase K and incubated at 72 °C for 10 min. 
After adding 100 pL of isopropanol, the mixture was ap­
plied to a filter tube containing fleece and washed twice 
with wash buffer. After centrifugation, 50 pL of elution 
buffer was added and the eluted DNA was stored at 
- 2 0  °C.
Polymerase chain reaction
Polymerase chain reaction (PCR) reactions were carried 
out in 50 pL of a mixture containing 5 pL of the extracted 
DNA, using standard methodology. The complete core 
gene was amplified using Cl, C3A and C4 primers 
(Table 2). In addition, the region of surface gene specifying 
HBV subtype (amino acid positions 122-160) was ampli­
fied using SI, S2Na, S6C and S7D primers (Table 2). First, 
round PCR was performed using 1 U of Taq DNA polym­
erase (Life Technologies, Paisley, UK), 1.4 of Taq start 
antibody (Clontech Laboratories Inc., Palo Alto, CA, USA), 
0.25 mM of each dNTP (Pharmacia, St Albans, UK), lOx 
reaction buffer, 25 pmol of Cl and C4 primers (for core 
gene) and 12.5 pmol of SI and S2 primers (for surface 
gene). For the second round PCR, 1 pL of first round PCR 
product was added to 49 pL of the reaction mixture with 
the same composition as the first round except that Cl 
was replaced by C3A, and Sl/S2Na, were replaced by 
S6C/S7D. A quantity of 5 pL of the second round PCR 
products were analysed by electrophoresis in 1% agarose 
gel, stained by ethidium bromide, and visualized under 
u.v. light.
The PCR products of the correct size were purified using 
the High Pure PCR Product Purification Kit (Roche Diag­
nostics, Penzberg, Germany), following the manufacturer's 
instruction.
Primer Gene Sequence 5' to 3' of oligonucleotide Base position
Cl Core CGG GAT CCG AGG AGT TGG GGG AGG 
AGA TT
1726-1754
C3A Core G(AG)T CTR TGT AWT AGG AGG CTG 1763-1783
C4 Core CCT TAT GAG TCC AAG G(AG)A TA 2478-2459
SI Surface CCT GCT GGT GGC TCC AGT TC 56-75
S2Na Surface CCA CAA TTC (K)TT GAC ATA CTT TCC A 1003-979
S6C Surface GCA CAC GGA ATT CCG AGG ACT GGG GAC 
CCT G
113-146
S7D Surface GAC ACC AAG CTT GGT TAG GGT TTA AAT 
GTA TAC C
857-823
Table 2 Oligonucleotide primers used for 
PCR and sequencing. Base positions 
numbered from the EcoRI site. W and K 
represent mixed base sites, A or T and G 
or T respectively
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Genotypes and core variation 3
DNA sequencing
The HBsAg subtype of the sequences was defined by substi- 
[ tutions in the ‘a’ determinant between codons 122 and 160 
; inclusive. Direct sequencing of core and surface genes was 
I carried out (Perkin Elmer ABI-PRISM™ 377 DNA Se- 
! quencer, Fostercity, CA, USA) using 2 pmol of appropriate 
primers: C3A and C4 for the core gene; S6C and S7D for 
surface gene. Because of unavailability of DNA materials, we 
did not sequence the S gene of Indian samples. The results 
were analysed using Sequence Navigator software.
Sequence analysis
)
'! After allocating a sequence to an HBV genotype by analysis 
of the S gene, the core gene amino acid/nucleotide variations 
that were found uniquely in that subtype or genotype were 
recorded. Variants found in a majority of HBcAg sequences 
f (>50%) from a particular geographical area were confirmed 
i with HBcAg sequences from the same area obtained from 
EMBL, GenBank and NCBI (Table 3). Sequences were only 
selected from databases if the subtype, country of origin and 
| serological picture were provided. Finally, geography-specific 
nucleotide and amino acid variations in each genotype were 
| identified. To qualify, they had to be both unique to a geo­
graphical region and found in a majority of sequences from 
that region. Sequences have been submitted to GenBank, 
numbered from AF323463 to AF323470 and from 
AF324066 to AF324148.
Phylogenetic analysis
Sequences of core and surface genes were aligned using the 
BioEdit Package version 5.0.9 [22], and a neighbour-joining 
phylogenetic tree constructed using the Treecon Package 
| [23] employing a Kimura distance matrix [24], Associationsk
I were tested by bootstrap re-sampling analysis using 100 
] replicates [25], Associations with a bootstrap value of 
greater than 70% were deemed significant.
RESULTS 
I  Phylogenetic analysis
| Figure la,b shows that sequences grouped into six major 
| clusters. Four of these were occupied by genotypes A-D.
| Pacific sequences composed two additional clusters (in both
C and S trees), one in genotypes C and one in D. Compared 
with the rest, the most homogeneous groups was the Pacific 
sequences. In genotype D strains, most of the Indian se­
quences comprised a subcluster in the C tree. Similarly, a 
majority of the strains found in Scotland and the USA 
(genotype A), were homogenous in both C and S trees. The
phylogenetic trees constructed based on S and C genes
revealed that the topological features of all strains except of 
A4, A5, 154 and 1113 in the phylogenetic trees were iden­
tical. The C gene of A5 grouped with genotype B sequences, 
whereas the S gene with genotype C ones (the Pacific adrq-). 
Similarly, strains 154 and 1113, based on core sequencing, 
grouped with genotype D, whereas, the S genes with geno­
type A.
Genotype/subtypespeciflc nucleotide substitution
At the nucleotide level, it was possible to identify unique 
variants for subtypes adw2 (belonging to genotypes A and 
B), ayw l, ayw2, adr and adrq- (there was no ayr subtype in 
our samples). Overall, 34 genotype-specific nucleotide sub­
stitutions in 20 positions were found (Table 4), of which 18 
were silent (synonymous) and 14 were missense (nonsyn- 
onymous). Of 34 variations, it was possible to define nine 
unique nucleotide variants for specific subtypes: C2121 and 
G2242 f°r ayw2; C2242 for ayw3 strains: Ti966, G1975 and 
£> 2 0 7 5  for adrq-; and C2i89 for adrq+. A23s4 was unique for 
adw2 and A2304 was unique for ayw l, both belonging to 
genotype B. Our results concurred with those of sequences in 
databases and we assume that some of the amino acid and/ 
or nucleotide differences between our results and other re­
ports could be related to the diversity in severity of chronic 
disease in specific patients.
Amino acid substitutions and genotype/subtype
The amino acid residues at nine codons (aa 27, 59, 67, 74, 
83, 87, 91, 97 and 116), and an insertion at amino acid 
position 152, allowed allocation of a specific subtype 
(Table 5). Of these nine residues, the following were unique 
for genotypes and their corresponding subtypes: N74 and 
N87 in genotype A (adw2); F97 and 1116 in genotype D; 
V59 and 191 in genotype C strains (for adrq-). All sequences 
which encoded adw2 (genotype A) had a 2-codon insertion 
corresponding to amino acid 153 and 154 in the core gene, 
independent of origin. The most divergent residues were 
amino acids 74 and 91 with five and three possible variant 
amino acids respectively. Table 6 shows alignment of all 
amino acid sequences between the countries studied. Most 
amino acid substitutions involved the HLA-restricted CTL 
[3], T helper and B cell [7] epitopes, irrespective of HBV 
subtype (Table 5).
Genotype A (adw2 subtype) and D (ayw2) sequences had 
five amino acid substitutions in common at residues 12, 27, 
67, 83 and 91, which were not present in other strains. 
Distinguishing adw2 (genotype A) and ayw2 (genotype D) 
was possible by examination of residues 74, 87, 97 and 116 
(Table 5). At the amino acid level, the core gene sequences 
belonging to adw2, aw yl (both belonging to genotype B) 
and adrq+ (genotype C) did not show any unique amino acid 
substitutions (however, see nucleotide results).
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Table 3 Identification of core sequences obtained from databases for comparison. Each sequence is listed under accession 
number
Accession no. Identification Origin Subtype Genotype Reference
M 57663 pFDW294 Philippines adw2 A [41]
X 02763 PHBV3200 USA adw2 A [42]
(X51970 HBV991 Germany adw2 A Koechel et al., unpublished data
X 70185 HBV-A938 Germany adw2 A [43]
AF297624 Isolate 656 Africa adw2 A [44]
V 00866 PHBV933 USA adw2 A [16]
Z35717 pHB614 Poland adw2 A Plucienniczak et al., unpublished data
X97850 Patint-4 Greece adw2 B [45]
X97851 Patint-6 Greece adw2 B [45]
AB033554 RTB299 Indonesia adw2 B [44]
AB033555 PAD744 Indonesia adw2 B [46]
AF121249 AF121249 Vietnam adw2 B [47]
A F282917 HBV-Bi China adw2 B Hou et al., unpublished data
AF282918 h b v -b 2 China adw2 B Hou et al., unpublished data
AB031261 HBV Vie A-2 Vietnam adw2 B [48]
AB031263 HBV Vie A-5 Vietnam adw2 B [48]
AB031264 HBV Vie F-l Vietnam adw2 B [48]
AB031262 HBV Vie A-3 Vietnam adr C [48]
AB031265 HBV Vie F-2 Vietnam adr C [48]
AB033553 SK619 Indonesia adw C [49]
D50489 HPBA11A Japan adr C [50]
L08805 HPBETNC Japan adr C [51]
D16666 HPBE88A Japan adr C [50]
S75184 S75184 Japan adr C [53]
AF241411 8290 Vietnam adr C [46]
AB031260 HBV VieA-1 Vietnam adr C [47]
X52939 HBV prex China adr C [53]
M 38454 pADR-1 China adr C [54]
M 38594 M 38594 Korea adr C [55]
M 38636 PHBV107 Korea adr C [56]
X04615 pYRB259 Japan adr C [18]
X14193 pADRm Korea adr C [57]
D12980 SRADR Japan adr C [58]
D00630 PHBV330 Japan adr C [17]
X01587 pHBVadr4 Japan adr C [59]
D00331 pAK66 Japan adr C [11]
X75656 HHVCCHA Polynesia adrq- C [60]
X75665 HHVBC New Caledonia adrq- C [60]
AB033557 pIWK146 Indonesia adw C [11]
AF121240 HBV/94-11066 Vietnam ayw D [46]
AF121242 HBV/98-1218 Vietnam ayw D [46]
AB033558 JYW796 Japan ayw D [11]
AB033559 JYW3I0 Papua New Guinea ayw D [11]
X65258 HBVAYWCI Italy ayw D Lai et al., unpublished data
X59795 HBVAYWMCG Italy ayw D [61]
X02496 pHBV320 Latvia ayw D [62]
AJ131956 AJ131956 Germany ayw D [63]
L27106 HPBMUT Israel ayw D [64]
X72702 HBVORFS Germany ayw D [65]
X85254 HBVPRESS12 Italy ayw D Lai et al., unpublished data
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H
Genotype D
Genotype D 
Pacific
 m
V Genotype A
Genotype C 
Pacific
^  Genotype B
LH
Genotype
Fig. 1 Neighbour-joining phylogenetic trees of core (a) and surface (b) gene sequences from 91 HBcAg, rooted with sample 
198 and U8 respectively. The figure shows bootstrap values of >70% and scale denotes percentage diversity. Coding numbers 
indicate samples that have been analysed in the figure.
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Fig. L Continued
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Table 4 Unique C-gene nucleotide dif­
ferences which permit subtype classifi­
cation. Nucleotides are represented by 
single letters and numbered from the 
beginning of EcoRI. Italicized bold letters 
represent missense mutations. Under­
lined numbers indicate the locations of 
the missense nucleotides
Nucleotide
Subtype (genotype)
position ad w2 (A) adw2(B) ayw 1(B) adr(C) adrq-(C) ayw2(D) ayw3(D)
1966 C C C C T C C
1975 T T T T G T T
1981 C T T T T A A
2059 T G G A A T T
20 74 C T T T T A A
2075 A A A A G A A
2080 C G G G G T T
2104 A A A G G A A
2121 A G G G G T/G/C T
2149 T A A A A C C
21 60 A G G G G G G
2189 A A A A/C A T T
2224 T T T T T C C
2242 T T T T T G/A C/A
2246 C C C C C A A
2290 A T T c c A A
2293 C A A T T T T
2296 T T T C C T T
2304 C C A c C C C
2354 C A C c C C C
2354-2359 CGGGAC - - - - - -
insertion
Table 5 The most frequent differences in HBc amino acid 
sequences between subtypes. Each was found in a majority 
of strains from each subtype and the combination was un­
ique for that subtype. Numbering of amino acid in bold is 
from the beginning of HBcAg. CD4 =  CD4 recognized epi­
tope. CD 8 =  CD 8 recognized epitope
Subtype/
genotype
CD8
27
CD4
74 83
CD8
11659 67 87 91 97
adw2/A V I T N D N T I L
adw2/B I I N S E S V I L
aywi/B I I N S E S V I L
adr/C I I N s E s V I L
adrq-/C I V N s E s V/I I L
ayw2/D V I T G/T/V D s T F L/I
ayw3/D V I T V D s T F I
Interestingly, with the exception of two samples, all 
strains with 9 7L (instead of I) were HBeAg negative or had 
the precore stop codon mutation, Ai 896.
Country-specific changes
A specific motif, consisting of S12, 127, N67, S74, E83 
and V91, was observed in a majority of samples from 
South-east Asia and the Pacific irrespective of HBV geno­
type, but not in core sequences from other regions studied 
(Table 6). Similarly, Western-derived sequences (USA- 
Caucasian, Scotland and Italy) shared a specific motif at 
the same residues, but with different amino acids: T12, 
V27, T67, N/V74, D83 and T91 (Table 6). This pattern 
seemed slightly different at amino acid position 74 in 
which all variation depended on genotype: N74 in geno­
type A and V74 in genotype D.
This finding was strengthened by analysis of the nucleo­
tide sequence. In both populations, 19 unique nucleotide 
changes were found, of which eight were missense changes 
for six amino acid residues (results not shown).
There were nine Indian and nine Italian strains of geno­
type D, subtype ayw2. One sequence (represented by six 
examples) dominated in each country: the remaining three 
sequences were represented by one example each (Table 6). 
Further, the five Scottish strains of genotype D, subtype 
ayw2 or ayw3, were identical to the majority strains in India 
or Italy, while all the Pacific-derived strains of genotype D 
were unique and identical.
Seven amino acid positions allowed definition of a par­
ticular country's sequence (Table 6). In the Pacific all se­
quences belonging to ayw2 contained A35, D40, V59 and 
T74; 191 was observed in all adrq-strains from that region. 
180 was seen in Indian sequences and G87 in Korea. The 
most heterogeneity was seen in ayw2 strains derived from 
Indian, Italian, Pacific island and Scottish patients. Residue 
74 showed the most discrepancy between countries in which
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Table 6 Alignment of complete amino acid sequences of HBcAg which shows genotype/subtype identification and geo­
graphical origins of 91 sera using Bioedit software (Clustal W). Amino acid residues are numbered from the beginning of the 
HBcAg using the single-letter code. Apart from genotype A, which had 185 amino acids, all the other genotypes had 183 
amino acids, therefore two extra amino acids at positions 153 and 154 were added for a proper alignment
Mo Cowry Sub/Geuhjp*
A-43 C lou dw 2 B 
A-34 C tna  d « 2  B 
A -3 IC h iu d v 2 B  
A-42 Chin adorZ B 
A-4S Chou qpwl B 
A-48 O n  odor! B 
A-4 K o ri dw 2 B 
A -ll V etnm iyw l B 
A -tfV rtu m q w l B 
A-14 V rk n o  iywl B 
A -l iV je tu n q w lB  
A - I K iru d rC  
A-2 Korco adr C 
A-3 Korea odr C 
A SK on oid rC  
A -S K a u a k C  
A-9 l o r n  d r  C 
A -IO K tra d rC  
A -l]V idsoD idrC  
A-ZO Japan tdr C 
A-21 J i f n td r C  
A-23 Jopon tik  C 
A-24 Jtpaa odr C 
A -32C b»adrC  
A-35 C lin  oik C 
A-30 Chin » k  C 
A-37 Q a i  oik C 
A A O C b u d rC  
A-41 C h n i l iC  
A -44 C hiu ikC  
A A lC to id r C  
A H  Chiu oikC 
A -51 C hiudrC  
A 5 2 0 » m k C  
A-53 Chiu d r  C 
A-54 Chiu d r  C 
A - J i d u m k C  
U3 USA d r  C 
0021 P io&  KkC 
2080 Pio&c d r  C 
3097 PidBc d r  C 
M IS P idB cd rC  
5017 Pidhc d r  C 
5072 Pidhc d r C
138 I t d r  i r « 2  D
139 IUty Ijw2 D 
H 4IU ly^w 2D  
154 Italy ijw 2D 
155Italy Ijw2 D
159 Italy Jjw2 D 
169 Italy tyw2 D 
1113 Italy ifir2  D 
lllSItilyijrrtD 
822Scodaa4iyw2D 
7.13 Scotiud iyw2 D 
7.29 Scodad iyw3 D 
8 .2 JS c a tb d iy w 2 D
8.32 S c d a d  iyw2 D 
00lB ln iiiyw 2D  
0052 buhl iyw2 D 
0062 t o i l  lyw l D 
0078 buhl ayw2 D 
OOSI India ajw2 D 
0013 buhl lywZ D
0094 bufia ayw2 D 
009! buhl iyw2D 
0123buhnyw2D 
Ul USA iyw3 D 
0026 Ptdbc tyw2 D 
2007 Pxific ayw2 D 
3414 Pidfic iy»2 D 
5029 Paafic iyw2 D 
A-16 V irtum d « 2  A 
A-19jipanaitw2 A
160 Italjr id»2 A 
168 Italy dw 2 A 
IS* Itd r orfw2 A
7.32 Scolfad dw 2 A 
8/19 Scodad dw 2 A 
8.21 Scadud ador2 A 
8.31 Scotkul d « 2  A
95 Scdand dw 2 A 
U2 USA d a r t  A 
U4 USA d « 2  A 
U5 USA dw 2 A 
U6 USA dw 2 A 
U7 USA d v 2  A 
U9 USA d a r t A 
U lOU SAdartA  
Ul USA aywl A 
0012 buho d » 2  A
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Table 6
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Continued
Nt Coney SubGootyi*
100 II I  13B 130 Ml UB
A -tiC tam h rtB  
A-34 Cbna M  B 
A-3J Claa adw2 B 
A-41 d m  M S  
A-45QaaiywlB 
A-41 Cbiu M  B 
A 4 I m i M I  
A 'llV ukaa  aywl B 
A 'lIV itto n  aywl B 
A-14 Vkkan ajrwl B 
A -lS V ie tan^v lB  
A-l K m  A C  
A -2 K m A C  
A-l Km a adr C 
A -5 K m A C  
A-l K r a A C  
A l  K m  A C  
A-IOKata A C  
A -lJV irtn o A C  
A fllJapa  A C  
A -B I J v a A C  
A D J a p a A C  
A-24 Jipao A  C 
A-32Cbna A C  
A -35C iaaA C  
A 36C bnaA C  
A-17Chu A C  
A A O C buA C  
A-41 C b u  A C  
A-44Cbna A C  
KAIOmtkC 
A-SOCba A C  
A -S IO a aA C  
A H C b o aA C  
A-S3Cbna A C  
A -i4 C b n A C  
A-SSQmAC 
W  USA A C  
OOTIPadb A C  
20S0Paafc A C  
W P A f ic A C
3413 Pacific A C  
5 0 I7 P A & A C  
5(72 Panic A C  
130 BAr *rir2 D 
mtyirrfD 
H4 Italy iy*2D 
l54Myap»2D 
155 Italy ay»2D 
1)9 Italy ayw2 D 
169 Italy ayw2D 
1113 Italy iyw2D 
HI8Italyiyw2D 
122 Scotland ayw2D 
713ScodacJ«yw2D 
7.29 Scodaod ay*3 D 
1.23 Scotland 9 * 2  D 
132 Scotland ayv2 D 
M il India ayv2D 
0052 lA a ayw2 D 
0062 India ayw2 D 
0076 InAa ayw2 D
0011 India ayw2D 
OOS31nAaayw2D 
0094b4aiyw2D 
0091 bda ay«2 D 
OI23bAaay»2D 
Ut USA aywl D 
0026 Panic ayw2 D 
2007 Panic ayw2D
3414 PaciSc ay«2 D 
5029 Pacific 9 * 2  D 
A-16 Vietnam adv2 A 
A-)9japaadv2A 
360 Italy adarl A 
16lltalyadw2A
191 Italy A r2 A  
732 Scodad ad*2 A 
VI9 Scotland »dw2 A 
121 Scodad ad*2 A 
t.31 ScAland adw2 A 
9.5 Scdand adw2 A 
U2USAadw2A 
U4USAadw2A 
V5VSAMA 
U6 USA ad*2 A 
U7USAadw2A 
U9 USA ad»2 A 
U10USAa6w2A 
Ul USA aywl A
0012 Inia adw2 A
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Table 6 Continued
No C ouibj Sub/Genotype
A-43 China dw 2 B  
A '3 4C t«a idw 2B  
A-3J Cbini ( M B  
A-42 China t iv 2  B 
A-45 Cbna aywl B 
A-41 China idw2 B 
A-4 Korea i4v2B  
A l l  V e ta n a y w lB  
A 12V irtM oayw lB  
A-14 V irtual aywl B 
A-15 V e tu n  aywl B 
A-l K oreiidrC  
A-2 Korea A C  
A-3 Korea A C  
A-5 Korea A C  
A -l Korea A C  
A-9 Korea A C  
A-1II Korea A C  
A-13 Vietnam A C  
A-20 Ja p s  A C  
A-21 Japan A C  
A-23 Japan A C  
A -24Japn A C  
A-32 China A C  
A-35 China A C  
A-36 China A  C 
A -3 7 C h o aA C  
A-40 China A C  
A-41 China A C  
A-44 China A C  
A-49 China A C  
A -JO Chia A C  
A-Sl China A C  
A-32Chba A C  
A -53ChoaadrC 
A-54 Cbna adr C 
A-55 China adrC 
U3USA A C  
0071 Pacific A C  
2010 PAfic A  C 
3097 Paafic A  C 
3415 PAfic A C  
5017Pacific A C  
5072 Pacific A C  
131 Italy ayw2 D 
139 Italy ayw2 D 
144 Italy ayw2D
154 Italy ayw2 D
155 Italy ayw2 D
159 Italy ayw2 D 
169 Italy ayw2 D 
1113 Italy ayw2D 
II I !  Italy ayw2D
1 22 Scotland ayw2D 
7.13 Scotland ayw2D 
7.29 Scotland ayw3D 
1.25 Scotland ayw2 D
1.32 Scotland ayw2D 
0011 India ayw2 D 
0052 Inifia ayw2 D 
0062 India ayw2 D 
0076 India ayw2 D
0011 India ayw2D 
0013 India ayw2 D 
0094 Indbayw2 D 
0098 Infia ayw2 D
0123 India ayw2D 
U lU SA ayw JD  
0026 Pacific ayw2 D 
2007 Pacific ayw2 D 
3414 Pacific ayw2D 
5029 Pacific ayw2 D 
A-16 Vietnam adw2 A 
A-19 japan adw2 A
160 Italy adw2 A
161 Italy adw2 A 
198 Italy adw2 A
7.32 Scotland ad*2 A 
8119 Scotland adw2 A 
8.21 Scotland adw2 A 
8.31 Scotland adw2 A 
9.5 Scotland adw2 A 
U2 USA adw2 A
U4 USA adw2 A 
US USA adw2 A 
U6 USA adw2 A 
U7 USA ad*2 A 
U9 USA adw2 A 
UI0USAadw2A 
U8 USA aywl A
0012 India adw2 A
ID  1R
 ■■■ 1 . . ■ ■ - a . i . I  • 1 • I
B l T P S P R R R R S Q S P R R R R S Q S R E S Q d
I:
■0 0
ayw2 is common: T in Pacific, V in Scottish and Italian, and 
G in Indian.
However, there were additional synonymous nucleotide 
substitutions that were unique for specific countries in our 
study (results not shown). For example, in a majority of 
samples from India, we observed T1912, C1955, T1957, A2on. 
G2 0 3 2 - A 2 i 3 8 , G2 i 55  and T2i91. In all strains belonging to 
ayw2 from the Pacific region, we observed T1966, G1975, 
G2 0 0 3 - G2oo5. T202o> A2o89> C2i2i and T 2i 5 5 . A2242 and 
C2i89 were unique for Italian and Korean sequences 
respectively.
Finally, subtype-related specific nucleotide variations were 
observed in a majority of samples from specific countries 
(results not shown). As for the amino acid sequence, ayw2 
subtype contained the most nucleotide divergence: 16 nuc­
leotide substitutions were unique in ayw2 sequences from 
India, 10 from Pacific, and two from Italy. Much less het­
erogeneity was observed in adr strains: only A2i58 and C2i 89 
were unique in adr strains from Chinese and Korean se­
quences respectively (results not shown).
DISCUSSION
HBcAg contains helper T cell [26] and CTL epitopes [3,5,27]. 
Different HLA-restricted CTL/T helper epitopes have been 
identified within the core gene which are capable of inducing 
significant T-cell responses in HBV-infected patients [2 -  
3,19]. Previous studies have suggested that epitopes for CTL/ 
Th recognition might be different on account of the diverse 
distribution of HLA antigens in different geographical re­
gions [28-30], Since the worldwide distribution of HBV 
follows a geographical pattern [16], there may be a strong 
influence of ethnic background, perhaps driven by T-cell 
selection, on this distribution, reflected by divergence of 
amino acid substitutions within certain regions of the core 
gene [4,31].
The aim of this study was to characterize the core antigen 
variability in diverse geographical regions and ethnic 
groups, and to determine genotype- and subtype-specific 
variants. Our comparison of 91 new complete core genes 
and those in databases verified that amino acid/nucleotide- 
specific substitutions correlate with both ethnicity and HBV 
genotypes/subtypes. Motifs and specific individual mutations 
were observed that correlated with broad ethnic back­
ground, country, genotype and subtype. Our finding that 
HBcAg variability was distributed geographically was 
entirely consistent with Norder’s study of S genes [16], 
Moreover, construction of phylogenetic trees (Fig. 1), of C 
and S genes, showed an almost identical pattern of HBV 
genotype distribution. Some samples had discrepant geno­
type allocation based on analysis of two genes: in C gene 
samples 154 and 1113 were in D, but A in S gene: similarly, 
sample A-5 was genotype B in C gene and C in surface gene. 
These discrepancies were not surprising, as recombination 
events between different genotypes have been described
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previously [32]; between A and C from Vietnam [33], 
between C and D from Tibet [34] and between B and C from 
different countries of South-east Asia (with exception of 
Japan) [35]. Of interest is that A-5 came from Korea, where 
HBV genomes have been reported with recombination 
between genotypes B and C, designated as genotype Ba (a for 
Asia). This is in keeping with Suguachi’s study [35]. Inter- 
; estingly, in this study recombination between A and D was 
found in two of Italian sequences (154 and 1113). The 
validity of our data was strengthened by subsequent com­
parisons with international databases (Table 3). Below, we 
briefly discuss three aspects of our findings.
I The HBV antigenic subtypes generally reflect the country 
or regions of origin [36]. However, there are a number of 
confounding factors. First, some subtypes are not geo- 
, graphically localized but are worldwide. Secondly, there are 
differences in HBV strains between native and foreign car­
riers in different geographical areas [36]; this means that 
genetically homogeneous HBV strains cannot simply be 
presumed to be linked epidemiologically. Thirdly, some 
subtypes are genetically heterogeneous and belong to more 
than one genotype [12]. Knowing the degree of HBV vari­
ation to be expected in a certain community could be useful 
in epidemiological investigations [37].
Comparisons of our data with HBcAg sequences in dat­
abases (except ayw l strains, of which there were no exam­
ples) were almost entirely consistent. In previous reports, 
i codon 97 showed the highest variation [38,39]; however,
! here, codon 74 contained the most discrepancy between 
: sequences. Of nine variable residues observed throughout 
i  the C gene, seven were unique for genotypes A and D, and 
I two residues were unique for the adrq- subtype. As some 
I subtypes belong to more than one genotype, these variants 
; may also be found in more than one genotype. Further
i
identical variants allowed correct subtype categorization.
The findings at the amino acid level were mirrored at the 
nucleotide level. At the nucleotide level (Table 4), the best 
correlation between our data and those obtained from dat­
abases was found in genotypes A (adw2 subtype) and D 
strains. Because six of eight adw2 (genotype B) sequences in 
our study were derived from Chinese patients, we compared 
these with other Chinese adw sequences in the database [5]. 
These were almost identical. adrq+ strains in the databases 
were also very similar to ours, but adrq- strains did not 
contain T1975. Tables 4 and 5 propose amino acid and 
, nucleotide substitutions that are critical sites for defining 
genotypes and their corresponding subtypes.
It is interesting that peoples of a broad ethnic background 
(Asian or Western) share amino acid substitutions in the 
core gene despite having different subtypes. This was par­
ticularly true of samples from the South-east Asian regions. 
It would appear that there are shared host-factors, most 
likely immunological, which act on these sequences despite 
their background subtype. One of our hypotheses was 
that specific ethnic groups would maintain the virus that
originated in their home country. The hypothesized migra­
tion of South-east Asian peoples out into the Pacific corre­
lates with their commonality of HBV sequences; similar to 
Norder’ study [16], six adrq- strains in genotype C as well as 
four ayw2 in genotype D formed a separate cluster that be­
longed only to the Pacific area (Fig. 1). Thus, the divergence 
of HBV genomes in this area is limited, in keeping with the 
known low variability between genotypes B and C. Another 
novel finding is that a majority of Indian genotype D strains 
almost composed a separate branch in the core phylogenetic 
tree (Fig. la). Further, we were able to distinguish strains 
that were observed only in Korea (Table 6). Asian immi­
grants to the USA shared identical sequences to those from 
their home country. It thus appears that there are no sig­
nature sequences in the USA, probably because of long-term, 
widespread importation of sequences. Immigration to the 
USA had no effect on Asian sequences, in keeping with cir­
culation of HBV amongst ethnic minorities or the likelihood 
that, in an intra-ethnic sexual partnership, it is the Asian 
partner who is more likely to be the primary infecting 
source. Nevertheless, genotype/subtype-specific variants 
were identical whatever the geographical origin.
The pattern in Western-derived sequences (including from 
US-Caucasians, Scotland and Italy) was slightly different, as 
there was no specific substitution that correlated with indi­
vidual countries (Table 6). Nevertheless, a clear motif was 
identified that was common to Western populations. We did 
not study genotype F, which is native to the Americas.
Core variation was most likely to occur at positions within 
known epitopes which can tolerate naturally occurring 
variants [2 ,4 ,6 ,20-21,38-39], i.e. residues 12, 27, 67, 74, 
83, 87, 91, 97 and 116 (Table 5). Most changes were 
synonymous. This might be due to a lack of a positive 
selection advantage or a strong bias towards maintaining 
that amino acid. The similarity in amino acid/nucleotide 
distribution in adw2 (genotype A) and ayw2 (genotype D) 
strains found in Western countries (USA-Caucasian, Italy, 
and Scotland), showed that considerable constraints must 
exist against HBV variability in a particular genotype 
infecting a person of a particular background. In addition, 
the ‘South-east Asian’ and ‘Western’ motifs suggest either 
that there is positive selection on specific variants or that 
genetic drift in HBV is relatively slow [40]. According to the 
almost unique amino acid variation in residues 35, 40, 59, 
74, 80, 87 and 91 in particular countries (Table 6), we 
hypothesize that differences in distribution of HLA antigens, 
or other immune genes between diverse geographical areas 
[6], probably contributed to the selection of amino acid 
variation. However, primary data need to be accumulated to 
investigate this issue.
In conclusion, it appears from this work that there are 
three levels at which C gene variation relates to ethnic 
background. First is that there are various genotypes 
associated with specific subtypes, which may have migrated 
with their human hosts. Next, peoples with related ethni­
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city, despite wide geographical location, have a set of 
common variants. Finally, small changes (one or two 
substitutions) are selected, either negatively or positively, 
once there is little intermixing between these people (e.g. 
once they became a tribe). As more sequence data accu­
mulate from different geographical origins, it is expected 
that HBV genomic classification will become refined, con­
tributing to the finer mapping of the relation between di­
verse geographical origins and the distribution of HBV 
strains. Further, sequence analysis of core gene, partic­
ularly, in the CTL-restricted regions, provides a useful tool 
for better understanding the biology of HBV strains, and 
finally, for design of immunomodulatory therapies upon 
vaccination.
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Intracellular Distribution of Hepatitis B Virus Core 
Protein Expressed In Vitro Depends on the Sequence 
of the Isolate and the Serologic Pattern
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Intracellular localization of hepatitis B core antigen (HBcAg) in vivo varies with liver cell damage. By use of 
confocal microscopy, in vitro localization of HBcAg was studied using transfection of cloned HBcAg variants 
in Cos-7 cells, by use of the pRK5 expression vector. Twenty-six samples were obtained from 14 patients with 
liver disease; 10 of the samples were hepatitis B e antigen (HBeAg) positive, and 16 were anti-hepatitis B e 
(HBe) positive. In HBeAg-positive patients, HBcAg predominantly localized in the nucleus; in anti-HBe- 
positive patients, it accumulated mainly in the cytoplasm. This finding also applied to patients who either 
experienced seroconversion to anti-HBe or remained anti-HBe positive and developed mutations. Of the 13 
samples with nuclear localization, 9 were HBeAg positive; 5 had C-terminus and/or B cell epitope mutations. 
All but 1 of the 13 samples with predominantly cytoplasmic localization were anti-HBe positive; all 13 had 
mutations. Using site-directed mutagenesis to revert C-terminus and B cell epitope m utant sequences with 
cytoplasmic expression back to the wild type led to the shifting of HBcAg distribution back to a predominantly 
nuclear distribution. Thus, the pattern of HBcAg localization in vitro depends on sequence and the serologic 
pattern of chronic infection, paralleling the situation in vivo.
The hepatitis B nucleocapsid protein consists of 2 struc­
turally and functionally separate domains; the sequence 
from the N-terminus to approximately amino-acid (aa) 
position 149 is, by itself, sufficient for assembly, whereas 
the C-terminus is involved in pregenomic encapsida- 
tion. Hepatitis B core antigen (HBcAg) is a major im­
mune target [1, 2] that can function as a T cell-de­
pendent and T cell-independent antigen [3]. Hepatitis 
B e antigen (HBeAg), on the other hand, is a nones­
sential secreted variant of the core protein, and it is 
believed to be an immune modulator that somehow 
suppresses cytotoxic T lymphocyte (CTL) responses. 
Once an immune response against HBeAg has devel-
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oped, it is advantageous for the virus to suppress pro­
duction of HBeAg. Pathogenicity results from the in­
ability to avoid reinfection of hepatocytes and from the 
incomplete suppression of replication by T cells. Al­
though HBcAg and HBeAg are serologically distinct, 
the primary amino-acid sequence is identical over a 
large stretch. Three shared binding sites for anti-HBe 
and anti-HBe have been mapped to core aa positions 
74-89, 107-118, and 128-135 of HBcAg (table 1). An 
additional antigenic site has been proposed within the 
arginine-rich C-terminus domain of HBcAg that, un­
like the other epitopes, faces the interior of the nu­
cleocapsid [4] (table 1). These 2 proteins are also highly 
cross-reactive at the T helper (Th) and CTL levels. In 
chronic carriers, seroconversion from HBeAg to anti­
hepatitis B e (HBe) can lead to either ongoing, often 
severe, disease or remission of hepatitis. Among pa­
tients who experienced seroconversion from HBeAg to 
anti-HBe, there exists supportive indirect evidence for 
the proposed immunomodulatory role of HBeAg [5- 
7]. In patients whose disease went into remission, mu-
q9
q10
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Table 1. Antigenic sites proposed within hepatitis B core an­
tigen (HBcAg).
Reference, year
Epitope/HBcAg 
amino acid
Immune
effector
No. of 
mutations3
Penna, 1992 1-20 Th 8
Bertoletti, 1991 18-27 CTL 5
Ferrari, 1991 50-69 Th 32
Salfeld, 1989 74-89 B 21
Ehata, 1992 84-101 CTL 4
Colucci, 1988 107-118 B 3
Ferarri, 1991 117-131 Th 1
Salfeld, 1989 128-135 B 9
Missale, 1993 141-151 CTL 2
Machida, 1989 148-160 B 13
NOTE. Nos. denote amino-acid residues within the core protein. B, B cell 
epitope; CTL, cytotoxic T lymphocyte epitope; Th, T helper epitope.
3 For all patients in the present study.
tations tended to cluster in CD4-Th epitopes, whereas, in pa­
tients with ongoing disease, mutations clustered in B cell epi­
topes [8-9], although not in CTL epitopes [10-12]. Nearly all 
those selections occurred at the time of, or soon after, emer­
gence of the precore stop codon. One interpretation of this 
finding is that the loss of HBeAg led to increased immune 
activity. Samples that were obtained later during the anti-HBe- 
positive phase, during peaks in hepatic activity, showed few 
additional changes, and such changes did not occur within 
epitopes. These and other results have led to a conundrum 
concerning the pathogenesis of disease in this group. If hepatitis 
B virus (HBV) disease is immune mediated, as is believed, then 
why should viruses, which appear to have escaped the immune 
response, still cause disease? One suggestion is that there may 
be immune targets in other regions of the genome, in which 
case one might predict that selection would occur sequentially 
in these other proteins. Alternatively, the mutated viruses may 
be directly cytopathic or may become novel targets for other 
relatively unstudied arms of the immune response, such as NK 
cells [13-15].
Several histologic studies o f the association between expres­
sion of HBcAg and liver cell damage have been performed. 
However, little is known about cellular localization of HBcAg 
variants. For HBeAg-positive patients [16-20] and for anti- 
HBe-positive patients whose disease is in remission [18, 21, 
22], staining for HBcAg in liver biopsy specimens tends to be 
nuclear; however, for anti-HBe-positive patients with ongoing 
disease [17, 23-26], staining tends to be both nuclear and cy­
toplasmic. This cannot be related only to a high level of rep­
lication, because HBeAg-positive patients usually are highly vi- 
remic. In vitro, the cellular localization of HBcAg is dependent 
on the stage of the cell cycle [27]. HBcAg is usually confined 
to the nucleus when cells are blocked in the Gl/S stage. This
may explain, in part, the in vivo observations that core protein 
is expressed more predominantly in the cytoplasm during pe­
riods of active disease when liver cells are dividing. Conversely, 
during periods of clinical remission of disease, when hepato- 
cytes are quiescent, core protein is mainly confined to the nu­
cleus. If sequence could be shown to correlate with distribution 
of HBcAg— especially if distribution changes with selection of qi4 
mutations in individual patients—this would provide impor­
tant clues regarding the potential mechanisms o f liver damage.
In the present study, we examined the distribution of HBcAg qis
in transfected cells from samples successively obtained from 
patients with chronic hepatitis B disease. The distribution of 
HBcAg was correlated with sequence variation within B cell 
epitopes and the C-terminus. Next, using mutagenesis, we di­
rectly investigated the influence of these mutations with regard 
to intracellular trafficking.
PATIENTS, MATERIALS, AND METHODS
Patients. All 14 patients who participated in the study were qi6
Greek or Italian, had known HBV genotypes, and were under 
the care of the authors of the present study. The patients were 
selected for inclusion in the study, on the basis of previous 
characterization of their sequential HBV precore/core se- qi7
quences [28], Twenty-six samples were studied and were cat­
egorized as belonging to 1 o f 3 groups (table 2). Group 1 qis
comprised all samples obtained from 6 patients. Group 1-A 
included only the samples that were obtained from these 6 
patients when they were HBeAg positive (including 2 initial 
samples [1A1 and 1A2] obtained from the first patient). Group qi9
1-B included a second set of samples from the same 6 patients, 
all of which were obtained after the patients underwent anti- 
HBe seroconversion. Group 2 included all samples obtained 
from 5 patients who had active disease and who were found 
to be continuously anti-HBe positive. Group 2-A included the 
samples obtained from these 5 patients during an early period 
when few mutations were apparent in HBcAg. Group 2-B in­
cluded a second set o f samples obtained from the same 5 pa­
tients after selection of either a precore stop codon and/or at 
3s 1 HBcAg mutation. Group 3 included all samples obtained, 
at a single point in time, from HBeAg-positive patients.
Polymerase chain reaction (PCR), cloning, and mutagen­
esis. DNA was extracted from 50 /xL of serum, by use a 
QIAamp blood kit (Qiagen). Nested PCR was performed on 5 
/xL of extracted DNA, by use of primers to the core region of 
HBV, as described elsewhere [8]. One microliter of first-round 
PCR products was nested using primers that contained the 
restriction enzyme sites £coRI and Hindm, respectively. The 
second-round PCR products were purified using Geneclean 
(BIO 101), according to the manufacturer’s instructions. Ten q2o 
microliters of the products purified using Geneclean were used
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Table 2. Serologic, clinical, and sequence data correlated with hepatitis B core antigen (HBcAg) localization 
in vitro.
Group,3 sample Genotype
HBeAg/
anti-HBe
Clinical
outcome
HBcAg
distribution
B cell 
epitopeb
Mutation
C-terminus
Precore 
stop codon0
Group 1
1 A1 
1 A2
A + / -
+ / -
N
C + + :
1B - / + Remission C + + -
2A D + / - N - - -
2B - /+ Remission C - + +
3A D + / - N - - +
3B - / + Remission C + + +
4A D + / - N - - -
4B - / + Active C + + +
5A D + / - N + - -
5B - /+ Active C + + +
6A D + / - N + + +
6B - /+ Active C + + +
Group 2
7A D - /+ NC + + -
7B - / + Remission NC + + +
8A D - /+ N - + +
8B - /+ Active C + + +
9A D - / + N + - -
9B - / + Active NC + + +
10A D - /+ C + - +
10B - /+ Active N - - -
11A D - / + N + + +
11B - / + Active C + + +
Group 3
12A D + / - Acute disease N - - -
13A A + / - Acute disease N - - -
14A D + / - Acute disease N - - -
NOTE. C, Predominantly cytoplasmic distribution; HBe, hepatitis B e; HBeAg, hepatitis B e antigen; N, predominantly nuclear 
distribution; NC, mixed nuclear and cytoplasmic distribution; +, positive; - ,  negative.
a Group 1 included samples obtained from patients who had seroconversion from HBeAg to anti-HBe, group 2 included samples 
obtained from patients who were continuously anti-HBe positive, and group 3 included single samples obtained from patients who 
were HBeAg positive. Two initial samples were obtained from patient 1 (samples 1A1 and 1A2). 
b B cell epitopes were those shown in table 1. 
c Mutation A 1B96.
j in a restriction digest with 10 U each of EcoRI and HindHI 
j (Life Technologies), were run on a 1% agarose gel, and were 
purified using Geneclean. These fragments were ligated into the 
multiple-cloning site of the eukaryotic expression vector pRK5 
(a gift from H. Will, Hamburg, Germany), which contained a 
cytomegalovirus promoter. Competent Escherichia coli strain 
DH5a was transformed with the ligation reactions, colonies 
were picked, and clones that contained inserts were identified 
by restriction digests o f minipreparations of DNA. Large-scale 
preparations of DNA for transfection were prepared over 2 CsCl
density gradients. The constructs were sequenced to confirm 
the presence of mutations.
Site-directed mutagenesis was performed with a PCR method 
that used oligonucleotides to revert mutated sequences back to 
the wild-type sequence (according to original sequences in the 
early phase and/or normal variations in the corresponding ge­
notype, as obtained from a database), according to the man­
ufacturer’s instructions (Stratagene). Sequencing of the plasmid 
confirmed the presence of mutations. All relevant sequence 
information is found in table 3.
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Table 3. In vitro mutation of cytoplasmically distributed 
sequences.
Mutated
virus
Mutagenesis position® HBcAg localization
B cell epitope 
HBc-1b HBc-2c C-terminus N NC C
2B T160A +++ +
3B N74A +++ +
3B S181P ++ ++
3B N74A S181P + +++
4B E77D, A79Q, S80P + +++
4B S181P +++ +
4B E77D, A79Q, S80P S181P +++ +
5B Q177K +++ +
5B A81T Q177K +++ +
10A V74A ++ ++
10A A131P ++ ++
10A N74A A131P + +++
11B P135Q + +++
NOTE. Confocal microscopy was used to study the distribution of hepatitis 
B core antigen (HBcAg) after mutation was confirmed by sequencing. C, Pre­
dominantly cytoplasmic distribution; N, predominantly nuclear distribution; NC, 
mixed nuclear and cytoplasmic localization; +, 25% of stained cells; ++, 50% 
of stained cells; +++, 75% of stained cells.
a The mutations generated are listed according to their amino-acid position 
within an epitope. Letters appearing before each no. denote the mutated se­
quence to wild type, and letters appearing after each no. denote the original 
sequence before mutagenesis. 
b Residues between aa positions 74-89. 
c Residues between aa positions 128-135.
Cell culture, transfection, and immunofluorescence. It is
known that the distribution of expressed HBcAg is cell cycle 
dependent. Sequential thymidine- and aphidicolin-blocking 
steps produced monolayers of synchronized Cos-7 cells (data 
not shown). Twelve hours before treatment with cell cycle- 
blocking agents, Cos-7 cells were seeded at a density of 
3 X 104 cells/well, in a 24-well plate, in growth medium. Me­
dium that contained 2 mmol/L thymidine replaced the afore­
mentioned medium, and, 12 h later, cells were washed twice 
with PBS and refed with normal medium. Transfections were 
done after thymidine withdrawal and cell release, by use of 
FuGENE-6 and/or Lipofectamine Plus transfection reagent (In- 
vitrogen), according to the manufacturer’s instructions. After 
an additional 13 h, the cells were washed twice with PBS, me­
dium that contained 2.5 /ig/mL aphidicolin was added, and the 
cells then were incubated for an additional 36 h. Aphidicolin 
blocks cells in the Gl/S phase of the cell cycle, in which ex­
pression of HBcAg is predominantly nuclear [27]. This inhibits 
movement of HBcAg into the cytoplasm because of dissolution 
of the nuclear membrane, implying that any cytoplasmic ex­
pression is more likely to be the result o f active transport.
FACS analysis. The cell-cycle status of cultured cells was 
determined by flow cytometric analysis of permeabilized cells
that were stained with propidium iodide. Cos-7 cells were dis­
sociated with EDTA at the appropriate time after transfection 
and were resuspended in PBS. Cells underwent centrifugation 
at 1500 g for 2 min and then were fixed with 70% ethanol on 
ice. After 20 min, the cells underwent centrifugation, were 
washed once with PBS, and then underwent centrifugation 
again. Pelleted cells were resuspended in 1 mL of a solution 
that contained 0.5% Triton X-100, propidium iodide, and RN- q26
ase. After incubation for 30 min at room temperature, the total 
DNA content was analyzed in the FL3-H channel of a FACS 
flow cytometer (Beckton Dickinson).
Immunofluorescence and confocal microscopy. Localiza­
tion of core protein was studied using immunofluorescence 
and confocal microscopy. Cells were fixed with ice-cold meth­
anol. After permeabilization with 0.5% Triton X-100, rabbit 
anti-core polyclonal Ig G (Zymed) and fluorescein isothiocy- 
anate-conjugated goat anti-rabbit IgG (Sigma) were used as 
primary and secondary antibodies, respectively. Then, cell sam­
ples were examined using a Zeiss LSM510 confocal microscope 
with laser excitation at 488 nm. The intracellular distribution 
and quantitative expression of HBcAg were determined by ran­
dom evaluation of S*100 cells with either a 40 X or a 63 X oil- q27
immersion objective lens. Cells had either predominantly nu­
clear distribution or predominandy cytoplasmic distribution if 
>70%-80% of cells showed nuclear or cytoplasmic HBcAg, 
respectively. If a similar proportion of cells expressed HBcAg q28
in both the nucleus and the cytoplasm, they were considered 
to have nuclear and cytoplasmic localization. Data sets were 
processed using LSM510 software.
RESULTS
Synchronization of Cos-7 Cells by Thymidine-Aphidicolin
To study the influence of the cell cycle on the subcellular dis­
tribution of HBcAg, Cos-7 cells were synchronized by the use 
of 2 blocking agents. In initial experiments (data not shown), 
aphidicolin, when used alone soon after transfection, yielded 
low transfection efficiencies. Consequently, a 2-step cell-cycle q29
synchronization was used. As a first step, cells were incubated 
in the presence of thymidine for 12 h, to enter the G0/G1 phase 
of the cell cycle (figure 1A). Afterward, cells were withdrawn q30
from thymidine and were permitted to progress out of the GO/
G1 phase and into the S, G2, and then M phases of the cell 
cycle for 12 h (figure IB). After cell-cycle release, the cells were 
washed twice with PBS, and transfection was done using 
FuGENE-6 and/or Lipofectamin Plus transfection reagent 
methods. As a second step, 12 h after transfection, the cells 
were treated with 2.5 /tg/mL aphidicolin for 30 h. Synchroni- q3i
zation achieved by use of aphidicolin resulted in 94% of the 
cells remaining in the Gl/S phase (figure ID and IB).
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Figure 1. A nalysis of Cos-7 cells by FACS flow cytometry. The peak to  th e  left corresponds to  cells in th e  G1 phase  of the  cell cycle; th e  peak 
to  th e  right co rresponds to  cells in th e  G2 phase. The shoulder betw een  the  2 peaks co rresponds to  th e  S phase . D ifferent cell cycles sho w  variable 
fea tu res , according to  th e  tre a tm e n t described  in P atien ts, M aterials, and  M ethods. A synchronously grow ing cells w ere  given a characteristic  trim odel 
profile (A); th e  thym id ine-treated  cells (B) w ith  84%  of cells w ere  in th e  GO/1 phase. The re lease  period in w hich cells w e re  thym idine free  (C) is 
show n, a s  are  aphid ico lin-treated  cells 12 h (D) and 30 h (E) a fte r adm inistration  of aphidicolin. A to ta l of 88%  and 94%  of Cos-7 cells a rre sted  in 
th e  G1-S phase  of th e  cell cycle a fte r incubation w ith  aphidicolin for 12 h and 30 h, respectively.
Distribution of Mutations in the Core Gene B Cell Epitopes 
and the C-Terminus Region
Overall, 34 mutations were distributed in different known B 
cell epitope regions within the core gene (table 1). Twenty-one 
mutations (62%) occurred in residues 74-89, whereas 3 mu­
tations (8%) occurred in residues 107-118 and 9 mutations 
(30%) occurred in residues 128-135 (table 4). Of 21 mutations 
in the first B cell epitope (aa residues 74-89), 8 mutations
occurred at aa position 80, Thirteen (59%) of 22 C-terminus 
mutations occurred within aa residues 148-160 (table 4).
Cellular Distribution of Core Protein
Expression of HBcAg was predominandy nuclear in 13 samples, 
both nuclear and cytoplasmic in 3 samples, and predominandy 
cytoplasmic in 10 samples. Of the 13 samples that showed q35
predominandy nuclear expression of HBcAg, 9 were HBeAg
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Table 4. Correlation between sequence and hepatitis B core antigen (HBcAg) localization.
T helper T helper
Patient HBcAg Clinical
code localization status3
20  21
12 13 26 27  29  35 38 40
T V  S V D S Y E
51 55 56 57 58 59 63 64 66 67 68
H L R Q A I G E M T L
1 A1 N
1 A2 C S M D T N F
1B C Remission s D V D I F
2A N
2B C Remission H V D
3A N
3B C Remission D I s
4A N A
4B C Active s D
5A N D I s
5B C Active D I S
6A N
6B C Active D
7A NC s T
7B NC Remission s A E
8A N T Q F D I
8B C Active T L F D I N
9A N D
9B NC Active S L D V D
10A C D V D
10B N Active A D H V V D
11A N D I
11B C Active D I
12A N
13A N
14A N
NOTE. B cell and T helper epitopes and C-terminus areas, with their boundaries and wild-type variants. Amino acids are denoted by a
single-letter code and are numbered from the beginning of HBcAg. Only positions at which changes occurred are shown, so the relative 
proportion of epitopic to nonepitopic areas is skewed in favor of regions where substitutions occurred. C, predominantly cytoplasmic 
distribution; N, predominantly nuclear distribution; NC, mixed nuclear and cytoplasmic localization.
8 Status of 11 samples obtained from patients who were anti-hepatitis B e positive during a later phase of the study, according to whether 
the samples were obtained during the remission phase or the active-disease phase.
positive and 4 were anti-HBe positive (i.e., samples 8A, 9A, 
11A, and 10B; (note that 3 of the samples that showed nuclear 
expression were initial samples) (see below). Only 1 patient 
whose sample (sample 1A1) showed a predominantly cyto­
plasmic distribution o f HBcAg was HBeAg positive; in other 
words, 9 patients were anti-HBe positive. In keeping with this 
finding, none of the patients whose samples had both nuclear 
and cytoplasmic distribution of HBcAg were HBeAg positive; 
in other words, all o f these patients were anti-HBe positive. 
Also, we observed a form of nuclear expression associated with 
the membrane, by use of standard microscopy (results not 
shown). Figure 2 and tables 2 and 4 detail the patterns of core 
localization in 3 patient-derived HBV core genes cloned into 
pRK5 and transfected into GO/1-arrested Cos-7 cells. Conse­
quently, the first finding of the present study is that cytoplasmic 
distribution of HBcAg is closely associated with HBeAg neg- 
ativity/anti-HBe positivity.
Core gene sequences from the initial samples showed nu­
clear distribution. Tables 2 and 4 show the results o f core 
gene substitutions in 11 initial samples (either HBeAg-positive
or anti-HBe-positive samples) and in 3 HBeAg-positive sam­
ples obtained at a single point in time. Twelve of these 14 
samples shown predominandy nuclear distribution (only 1 of q39
the samples obtained later during the anti-HBe-positive phase 
[sample 10B] had nuclear localization; a total o f 13 samples 
had predominandy nuclear localization). Eight of 13 samples 
(all but 1 of which were from HBeAg-positive patients) did not 
have any mutation. The remaining 5 samples (3 of which were 
anti-HBe positive) had mutations in either the C-terminal re­
gion and/or the B cell epitopes. Two of these samples (samples 
9A and 5A) had mutations only in B cell epitopes (A74V/G [2 
possible variants for genotype D] and T80A, respectively). An 
additional 2 samples contained mutations in both regions; sam­
ple 6A showed mutations T80A, Q130P, C153G, and T155S, 
and sample 11A showed mutations S135P, Q151R, and T155S.
Only 1 sample (sample 8A) with a C-terminus mutation alone 
(C153G) was observed. As noted below, a second set o f samples q40
that were obtained from the same 5 patients later during the 
anti-HBe-positive phase developed further mutations and 
shifted to the cytoplasm. Finally, HBcAg from the remaining 2 q4i
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Table 4. (Continued.)
B cell B cell B cell C-terminus
70 73 74 89 90 106  107 118 119  127  128 135 136  150 183
77 79 80 81 87 92 93 96 97 109 113 130 131 151 153 155 156 160 177 179 180 181
T G V/G E P A S S  N M K  T E  R P A P  R G S P T Q R E S
initial samples (samples 10A and 7A) showed either predom­
inantly cytoplasmic distribution or both nuclear and cytoplas­
mic distribution, respectively (figure 2, sample 10A). Therefore, 
all but 2 of the initial samples that were obtained showed pre­
dominandy nuclear expression. It was unusual to observe C- 
terminus and/or B cell epitope mutations and nuclear locali­
zation of samples that were HBeAg positive.
Accumulation of B cell epitope/C-terminus mutations and 
HBcAg localization. For the 5 patients with initial samples 
that contained B cell epitope and/or C-terminus mutations and 
predominandy nuclear localization (samples 5A, 6A, 8A, 9A, 
and 11 A) (table 2), there was a shift, over time, both in cellular 
distribution and sequence. Samples that were obtained later 
during the anti-HBe-positive phase (samples 5B, 6B, 8B, 9B, 
and 1 IB) (table 2) had predominandy cytoplasmic distribution 
(see below): all sequences in the latter group contained addi­
tional mutations in the same and/or other regions (table 4). 
Thus, it appears that there is an association between accu­
mulation of additional mutations and a shift to cytoplasmic 
distribution.
A shift in cellular distribution to the cytoplasm is linked to 
substitutions in the carboxy terminal and/or B cell epitopes.
Of the 10 samples with predominantly cytoplasmic distribution 
that were obtained later in the study, 8 contained both C- 
terminus and B cell epitope mutations (tables 2 and 4). Sample
2B contained only a C-terminus mutation (A160T), whereas 
sample 10A only had mutations in 2 B cell epitopes (A74V/G 
and P131A). Sample 10B, although obtained later during the q42 
anti-HBe-positive phase, shifted back to the nucleus: in keeping 
with this finding, all the mutations in sample 10A (the first 
sample obtained) reverted back to the wild type (i.e., there were 
no mutations) in sample 10B (figure 2 and table 4). Sample 
8A, which was obtained during the initial phase and which had 
a C-terminus mutation (C153G) (see above), reverted back, 
and an L156P mutation arose during the anti-HBe-positive 
phase (table 4, sample 8B). An additional aa variation (V74G) 
occurred in the sample obtained during the later phase (sample 
8B). Both of these variants in aa position 74 are specific for 
genotype D (M.S.J. et al., in press). Both the samples that q43
showed nuclear and cytoplasmic distribution (samples 7B and 
9B) contained mutations in both the C-terminus and the B cell 
epitope regions (table 4). In sequences with mutations, there 
were no differences in the distribution of those mutations be­
tween the 2 clinical groups (i.e., patients with seroconversion 
from HBeAg to anti-HBe and patients who were continuously 
anti-HBe positive). Thus, all samples obtained during the later 
phase showed predominantly cytoplasmic distribution (includ- q44
ing both nuclear and cytoplasmic distribution) and contained 
B cell epitope and/or C-terminus mutations. All but 1 of the 
samples were anti-HBe positive. As a result, cytoplasmic dis-
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Negative Control
Initial sample Later Sample After Mutagenesis
Predominantly nuclear 
Anti-HBe positive 
No mutation
4B
Clinical sta tus: Active 
Predominantly cytoplasmic 
Anti-HBe positive 
E77Q, Q79P and P80A
Predominantly nuclear 
Mutated positions: 
S181P
5A
Predominantly nuclear
HBeAg-positive
T80A
4
*
10A
Predominantly cytoplasmic 
Anti-HBe positive 
A74V/G- P131A
11A
Predominantly nuclear 
Anti-H Be positive 
S135P- Q151-T156
SB
Clinical status: Active 
Predominantly cytoplasmic 
Anti-HBe positive 
T80 A-P131A-K177Q
10B
Clinical status: Active 
Predominantly nuclear 
Anti-HBe positive 
No mutation
11B
Clinical status: active 
Predominately cytoplasmic 
Anti-HBe positive 
V80 A-G89V-Q135P-Q151R-7
5B
Predominantly nuclear 
Mutated position: Q177K
#
10B
Nuclear and cytoplasmic 
Mutated positions: 
N74A-A131P
wJ**' ■P1
11B
Nuclear and cytoplasmic 
Mutated position: P135Q
Figure 2. In trace llu la r loca liza tion  o f hepa titis  B core antigen (HBcAg), by use of confocal m icroscopy. Im m unofluorescence sta in ing  of HBcAg in 
Cos-7 ce lls  transfected  w ith  constructs  th a t conta ined clones o f in itia l sam ples (sam ples 4A, 5A, 10A, and 11 A), and " la te r"  sam ples (i.e., sam ples 
obta ined la ter during the  a n t i-h e p a t it is  B e [HBe]— positive  phase) (sam ples 4B, 5B, 10B, and 11B), and m uta ted  sequences in the  B cell epitope and 
C-term inus o f patien ts w ith  chron ic h epa titis  B virus in fection , as described in the  tex t. Cos-7 ce lls show ed various patte rns o f p redom inan tly  nuclear 
d is trib u tio n , p redom inantly  cytop lasm ic d is trib u tio n , and both nuclear and cytop lasm ic d is tribu tion . Note th a t only B cell ep itope and C-term inus 
m uta tions are ind icated as va ria tions . The c lin ica l sta tus of la ter sam ples is shown. No ce lls show ed predom inan tly  cytop lasm ic loca lization a fte r 
m utagenesis, ind ica ting  th a t sequence is c ritica l to  in trace llu la r d is tribu tion . HBeAg, hepa titis  B e antigen.
tribution of HBcAg was strongly correlated with the presence 
of mutations in B cell epitopes and/or the C-terminus region 
of the C gene as well as with anti-HBe positive status.
Correlation of HBcAg Localization with Clinical Outcome
Of the 11 samples obtained during the later phase, 4 were 
obtained from patients whose disease was in clinical remission 
and 7 were obtained from patients who had active disease. 
Samples from the 4 patients whose disease was in clinical re­
mission showed a shift in the distribution of HBcAg from the 
nucleus to the cytoplasm after seroconversion to anti-HBe. All 
but 1 of samples (sample 10B) from the 7 patients who had 
active disease showed a shift from nuclear to cytoplasmic ex­
pression, in a comparison of samples obtained during the earlier 
and later phases (table 2). Of interest, with the exception of 
sample 10B, all samples obtained during the active-disease 
phase and the remission phase contained B cell epitope and/ 
or C-terminus mutations. Consequently, in 10 of 11 samples 
obtained later during the study, either from patients with active 
disease or from patients whose disease was in remission, there 
was a shift from predominandy nuclear to predominandy cy­
toplasmic distribution, a finding that indicates that there was 
no clear difference between different clinical outcomes and 
HBcAg localization.
Cellular Distribution of the Core Protein is Dependent 
on the Sequence
Some of the shifter samples (table 2) were chosen for site- 
directed mutagenesis (table 3). Samples 3B, 4B, and 5B had 
double mutagenesis, at the same time, on both the C-terminus 
and B cell epitopes. Because sample 10A did not contain a C- 
terminus mutation but contained mutations in 2 different B 
cell epitopes (table 4), it was selected for double mutagenesis 
on these epitopes. All experiments were designed to revert the 
mutated amino acid to the expected amino acid variant for 
each genotype, which was also that observed in the first sample 
of the pair obtained (or the second sample, as in the case of 
patient 10). All clones were sequenced to confirm reversion. 
After the sequence in the C-terminal and/or B cell epitopes of 
the later sample was reverted back to the original sequence, a 
shift back to the original nuclear distribution and/or both nu­
clear and cytoplasmic distribution was observed. After single 
amino acids in B cell epitopes underwent mutation, 4 of 5 
samples shifted back partially (i.e., they localized to both the 
nucleus and the cytoplasm) (figure 2, sample 11B). In contrast, 
mutagenesis of C-terminus mutations resulted in predomi­
nantly nuclear localization in all cases (figure 2, samples 4B and 
5B; table 3). In keeping with these findings, all double-mutated 
samples shifted back to either nuclear distribution (results not 
shown) or nuclear and cytoplasmic distribution (figure 2, sam­
ple 10B). Consequently, reversion of C-terminus mutations
leads to shifting of HBcAg back to the nucleus. Reversion of 
B cell epitope mutations leads to a mixed nuclear and cyto­
plasmic distribution. The effect of dual mutations is the same 
as that of C-terminus mutations.
Precore Variants
The precore stop codon mutation was found at aa position 28 q48
of the precore region in 8 of 13 samples with predominantly 
cytoplasmic localization; it was found in 3 of 13 samples with 
predominandy nuclear distribution. Consequently, the precore 
region did not appear to influence the effect o f C gene local­
ization. Note that the pre-C region was not within the cloned 
product (table 2), so it did not directiy affect localization.
DISCUSSION
The entire HBV genome is extremely stable in the early high- 
replicative HBeAg-positive phase, when the immune response 
is considered to be weak [29]. However, after seroconversion 
of HBeAg to anti-HBe, multiple clusters of mutations appear 
in different regions of HBcAg— in particular, in immunodom- q49
inant epitopes (table 1). Several studies have shown that the 
amino-acid variability of HBcAg is related to the severity of 
liver disease, both in the HBeAg and the anti-HBe phases [7- 
8, 10-11, 28, 30]. Previous studies have reported HBcAg dis­
tribution in the cytoplasm, nucleus, or both, of infected or 
transfected cells [17-20, 22-24, 26, 30-34], but none of the 
studies evaluated naturally mutated sequences. Recently, Kawai 
et al. [35] found that hepatocytes that exhibited cytoplasmic 
expression of HBcAg contained more core promoter double 
mutations (T1762 and A1764) than did hepatocytes that ex­
hibited nuclear expression. Studies o f liver biopsy specimens 
have suggested that the intracellular distribution of HBcAg cor­
relates with disease activity, with cytoplasmic expression being 
associated with more severe disease [17, 19, 25, 34, 36]. The 
cell membrane of HBV-infected hepatocytes may also express 
HBcAg during chronic infection [1, 37], However, whether 
intracellular distribution of HBcAg is associated with liver dam­
age is unclear.
Previous studies have evaluated biopsy specimens for which 
the additional influence of host factors has made it difficult to 
delineate the mechanisms responsible for intracellular distri­
bution of HBcAg. The present study has confirmed previous 
observations that there is a close association between the top­
ographic distribution of HBcAg in vitro and the inflammatory 
status of the liver in vivo (figure 2 and table 2). For the first 
time, it has been shown that the distribution of expressed 
HBcAg is strongly associated with the viral sequence (tables 2 
and 4). The presence of cytoplasmic expression of HBcAg cor­
related with the existence of mutations in the B cell epitopes 
and/or the carboxy terminus of the protein. These experiments
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were performed in the presence of aphidicolin, to block cells 
in the Gl/S phase; consequently, any shift to cytoplasmic ex­
pression of HBcAg was not a result of dissolution of the nuclear 
membrane. However, to prove that sequence was critical in 
HBcAg localization, reversion of C-terminus and/or B cell epi­
tope mutations back to the wild type was performed; in most 
cases, reversion shifted HBcAg localization back to the nucleus 
(table 3). Some possible explanations for this shifting are pre­
sented below.
Machida and et al. [4, 38] reported an antigenic site within 
the C-terminus region, known as “HBicAg” (hepatitis B inner 
cAg; aa residues 148-160), to be a potential B cell antigenic 
determinant [39]. In the present study, 13 of 22 C-terminus 
mutations occurred within aa residues 148-160 (table 4). If the 
arginine-rich C-terminus is a B cell epitope, that might explain 
the mutations that occurred in this region. Because this region 
is also known to affect nuclear localization, mutations would 
explain the shift o f HBcAg to the cytoplasm. This is in line 
with observations that escape mutations appeared in the B cell 
epitopes of patients with ongoing disease [8] (tables 2 and 4), 
because double mutagenesis o f both a B cell epitope and C- 
terminus residue led samples shifted back to both nuclear and 
cytoplasmic distribution and/or predominantly nuclear distri­
bution (results not shown).
Although B cell epitope mutations tended to shift HBcAg to 
the cytoplasm, they was not as effective as C-terminus muta­
tions, which probably direct HBcAg intracellular trafficking by 
a different mechanism(s). A majority of samples with B cell 
mutagenesis had localization in both the nucleus and the cy­
toplasm (figure 2, sample 11B), whereas all samples with C- 
terminus mutations showed predominantly nuclear distribu­
tion (figure 2, samples 4B and 5B). This was also observed in 
2 of 3 samples with double mutations (figure 2, sample 10B). 
The reason underlying this phenomenon is unclear and de­
serves more investigation.
In the present study, we clearly showed that, in samples with 
both nuclear and cytoplasmic localization, HBcAg could be 
associated with the nuclear membrane (results not shown). This 
unusual pattern has been reported elsewhere [40]. Because there 
is no sharp boundary between the G1 and S phases, transport 
of HBcAg to the nuclear membrane may occur during the 
transition between phases. It may be that nuclear/cytoplasmic 
localization may be a transition step between the 2 compart­
ments [19]. Alternatively, there may have been high levels of 
nuclear HBV DNA with inefficient transportation from the 
nucleus. However, there is no strict division between predom­
inantly nuclear and predominantly cytoplasmic localizations of 
core protein in vivo, because core particles usually are present 
in both compartments [30, 26].
For a majority of patients, a predominantly cytoplasmic dis­
tribution in vitro was found in samples obtained during the 
active-disease phase and the remission phase (table 2). These 
samples (samples 1A1,1A2,2B, and 3B) selected more mutations 
in Th epitopes than in the C-terminus region and/or B cell 
epitopes (table 4). Of the samples obtained from 7 patients 
who had active disease, 6 showed a shift from nuclear to cy­
toplasmic expression in a comparison of samples obtained in 
the early and later phases (table 2); of these 6 samples, 4 (sam­
ples 4B, 6B, 8B, and 1 IB) had a higher proportion of mutations 
in B cell epitopes than in other regions (table 4). All samples 
with active disease were anti-HBe positive; 4 had predominantly 
nuclear distribution (see above). In keeping with this finding, 
all 4 samples that had predominantly nuclear localization and 
were obtained from patients who were continuously anti-HBe 
positive were obtained from patients with active disease. The 
only apparent correlation of HBcAg sequences in samples 8A,
9A, 10B, and 11A with those in samples from other anti-HBe- 
positive patients with predominantly cytoplasmic distribution 
was that fewer mutations were found in these samples, com­
pared with later samples with predominantly cytoplasmic ex­
pression (table 4). Although this unusual expression has been 
reported elsewhere [35, 40—41], it is likely that, after serocon­
version o f HBeAg to anti-HBe, there is coexistence of both 
antigen and antibody for some time [42], with concurrent per­
sistence of a low concentration of integrated HBV DNA in the 
liver after the disappearance of HBeAg [40]. Nevertheless, var- q55
ious studies reported continued liver disease activity after cer­
tain patients experienced seroconversion to anti-HBe status that 
might be related to continued viral replication and secretion 
with the presence of HBcAg in the nuclei. Even in some patients 
with cirrhosis and severe chronic hepatitis, distribution of 
HBcAg has been reported to be predominantly nuclear. The 
reason underlying this pattern is not clear, but it might be 
related to the specific patient population studied [16].
In summary, we have shown that subcellular expression of 
HBcAg is related to serologic patterns and that it depends on q56
the HBcAg sequence, even in samples successively obtained 
from individual patients. C-terminus and/or B cell epitope mu­
tations are involved in the shifting of HBcAg between the nu­
cleus and the cytoplasm. These results were generated by trans­
fection. Because there is no susceptible cell line that can be 
truly infected by HBV, the biological importance of such var­
iants, with regard to the viral life cycle and cell behavior, are 
still unclear.
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Abstract
Background/Aims: The world-wide distribution o f HBV genotypes follows a geographic 
pattern under the influence o f ethnic background. Methods: 48 core genes from four Pacific 
islands were compared with the following findings. Results: First, island-specific variant 
substitutions were found for only two out o f  four islands. Second, 11 amino acid and 90 
nucleotide changes specific for Pacific genotypes C and D were defined. Third, the 
nucleotide diversity o f  genotype C (all but one were silent) was greater than that o f  genotype
D. Conclusions: These results suggest an early appearance o f  genotype C in the Pacific with 
few subsequent amino acid changes because o f  shared immunological responses across the 
region followed by random silent changes, some o f which reflect isolation o f individual 
island populations. Genotype D appeared later.
Keywords: HBcAg variability, HBV adrq- subtype, Pacific-specific core gene sequences.
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Introduction
HBV genomes can be classified into at least eight genotypes (A to H) based on nucleotide 
divergence between the strains (1-4). Subtypes are based on antigenic typing, but correlate 
broadly with genotypes. Some subtypes can be found in more than one genotype; hence, 
these confer additional heterogeneity within the genotypes. Subdeterminants o f  w (w l to w4) 
have allowed the further characterisation o f  ayw and adw subtypes into a total o f 10 subtypes: 
ayw l, ayw2, ayw3, ayw4, ayr, adw2, adw4, adw4q-, adrq+ and adrq-. The q determinants 
were found to be absent from adr strains in the Pacific region, thus, defining adr and adw as 
either q+ or q- (5). Between strains, ayw and adw subtypes demonstrate considerable genetic 
heterogeneity (2). Genotypes and subtypes probably evolved in ethnic backgrounds over 
centuries (6) and the relationship o f these ten subtypes to genomic groups A to H has been 
established.
HBV genotypes have a characteristic geographic distribution, largely in agreement with 
subtype distribution (7). Genotype A is widely distributed in Western Europe, USA and Sub- 
Sahara Africa as well as Asia as far as east as the Philippines. Genotypes B and C belong to 
the indigenous population o f South East Asia (1, 8). In addition, genotype C is found in the 
populations o f  the Pacific Islands, and can be sub-differentiated geographically by subtype in 
this region. As compared to strains from South East Asia, two adrq- strains formed a distinct 
cluster within the Pacific area (7). Genotype D has been found worldwide with its highest 
prevalence in the Mediterranean area, the Middle East, and South Asia (7). Genotype E is 
found in West and South Africa. Genotype F is found in South and Central America. 
Genotype G has been found in France and the USA (3). The distribution o f  genotype H seems 
to be restricted so far to the Northern part o f Latin America including Central America and 
Mexico (4).
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It has been proposed that HBV diverged into genotypes according to the distribution o f  
humans among the different continents (9). Well-known waves o f  migration have occurred 
over time: the prevalence o f  different HBV genotypes reflects the origin o f the immigrants 
and other patterns o f  migration (10). The presence o f  genotype D in Central America reflects 
the westward immigration o f  Spanish in whom genotypes A and D are common (11). 
Yamashita et al, (12). analysed the geographical interface o f  adr (genotype C) and adw 
(genotypes A and/or B) strains from Japan. They found an apparent south-to-north gradient o f  
the r determinant and concluded that Japan may have been originally inhabited by people 
infected with adw (Philippines and Indonesia), and later, by people from the Asian continent 
infected with adr (South East Asia). In keeping, the HBV type in populations living on 
Pacific Islands correlates with immigration from South East Asia (genotype C) (13-15). An 
alternative hypothesis, because o f  the great diversity o f genotype C in the Pacific (Basuni et 
al, unpublished) is that genotype C migrated from the Pacific to South-East Asia.
The hypothesis that the outcome o f  HBV infection is influenced by HLA-associated immune 
response genes has been evaluated in many studies (16-20). There is an association between a 
self-limited course o f  acute infection and the presence o f  certain HLA alleles: HLA-DR B l-  
1302 in West Africa (21); DR Bl-1301 and 1302 among Caucasians (22); and DR13A in 
Asians (23). In keeping, immunodominant CTL epitopes restricted by HLA-A2404 have been 
identified in East Asia (24). Collectively, these results suggest that the epitopes for CTL/Th 
recognition might be different on account o f the diverse distribution o f  HLA antigens in 
different geographic regions. Analysis o f patients with different HLA haplotypes revealed 
that several sequences within the HBV proteins, in particular core, could induce significant 
levels o f T cell response. Consequently, it is o f relevance to sequence geographically 
divergent HBV genomes to describe the extent o f  natural variation (25).
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Abstract
Background/Aims: The world-wide distribution o f HBV genotypes follows a geographic 
pattern under the influence o f ethnic background. Methods: 48 core genes from four Pacific 
islands were compared with the following findings. Results: First, island-specific variant 
substitutions were found for only two out o f four islands. Second, 11 amino acid and 90 
nucleotide changes specific for Pacific genotypes C and D were defined. Third, the 
nucleotide diversity of genotype C (all but one were silent) was greater than that o f genotype 
D. Conclusions: These results suggest an early appearance o f genotype C in the Pacific with 
few subsequent amino acid changes because o f shared immunological responses across the 
region followed by random silent changes, some of which reflect isolation of individual 
island populations. Genotype D appeared later.
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Introduction
HBV genomes can be classified into at least eight genotypes (A to H) based on nucleotide 
divergence between the strains (1-4). Subtypes are based on antigenic typing, but correlate 
broadly with genotypes. Some subtypes can be found in more than one genotype; hence, 
these confer additional heterogeneity within the genotypes. Subdeterminants of w (w l to w4) 
have allowed the further characterisation of ayw and adw subtypes into a total of 1 0  subtypes: 
aywl, ayw2, ayw3, ayw4, ayr, adw2, adw4, adw4q-, adrq+ and adrq-. The q determinants 
were found to be absent from adr strains in the Pacific region, thus, defining adr and adw as 
either q+ or q- (5). Between strains, ayw and adw subtypes demonstrate considerable genetic 
heterogeneity (2). Genotypes and subtypes probably evolved in ethnic backgrounds over 
centuries (6 ) and the relationship o f these ten subtypes to genomic groups A to H has been 
established.
HBV genotypes have a characteristic geographic distribution, largely in agreement with 
subtype distribution (7). Genotype A is widely distributed in Western Europe, USA and Sub- 
Sahara Africa as well as Asia as far as east as the Philippines. Genotypes B and C belong to 
the indigenous population o f South East Asia (1, 8 ). In addition, genotype C is found in the 
populations o f the Pacific Islands, and can be sub-differentiated geographically by subtype in 
this region. As compared to strains from South East Asia, two adrq- strains formed a distinct 
cluster within the Pacific area (7). Genotype D has been found worldwide with its highest 
prevalence in the Mediterranean area, the Middle East, and South Asia (7). Genotype E is 
found in West and South Africa. Genotype F is found in South and Central America. 
Genotype G has been found in France and the USA (3). The distribution o f genotype H seems 
to be restricted so far to the Northern part of Latin America including Central America and 
Mexico (4).
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It has been proposed that HBV diverged into genotypes according to the distribution o f  
humans among the different continents (9). Well-known waves of migration have occurred 
over time: the prevalence o f different HBV genotypes reflects the origin of the immigrants 
and other patterns o f migration (10). The presence of genotype D in Central America reflects 
the westward immigration o f Spanish in whom genotypes A and D are common (11). 
Yamashita et al, (12). analysed the geographical interface o f adr (genotype C) and adw 
(genotypes A and/or B) strains from Japan. They found an apparent south-to-north gradient o f  
the r determinant and concluded that Japan may have been originally inhabited by people 
infected with adw (Philippines and Indonesia), and later, by people from the Asian continent 
infected with adr (South East Asia). In keeping, the HBV type in populations living on 
Pacific Islands correlates with immigration from South East Asia (genotype C) (13-15). An 
alternative hypothesis, because o f the great diversity o f genotype C in the Pacific (Basuni et 
al, unpublished) is that genotype C migrated from the Pacific to South-East Asia.
The hypothesis that the outcome of HBV infection is influenced by HLA-associated immune 
response genes has been evaluated in many studies (16-20). There is an association between a 
self-limited course o f acute infection and the presence of certain HLA alleles: HLA-DR B l-  
1302 in West Africa (21); DR Bl-1301 and 1302 among Caucasians (22); and DR13A in 
Asians (23). In keeping, immunodominant CTL epitopes restricted by HLA-A2404 have been 
identified in East Asia (24). Collectively, these results suggest that the epitopes for CTL/Th 
recognition might be different on account of the diverse distribution of HLA antigens in 
different geographic regions. Analysis of patients with different HLA haplotypes revealed 
that several sequences within the HBV proteins, in particular core, could induce significant 
levels o f T cell response. Consequently, it is o f relevance to sequence geographically 
divergent HBV genomes to describe the extent o f natural variation (25).
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In a pilot analysis, we showed that specific core gene motifs (amino acid and nucleotide) 
could be defined for the Pacific regions in both genotypes C and D (Jazayeri et al., in press). 
Here, a further 48 sequences have been analysed. We have confirmed our previous results 
and defined further specific variants that are unique for particular islands, genotypes and 
subtypes.
Materials and Methods
HBsAg positive samples were collected from four Pacific islands (Fig 1, table 1): Kiribati 
(14), Vanuatu (14), Fiji (15) and Tonga (15). They were chosen from a previous study of 
surface variability based on known migration patterns (Basuni, PhD thesis, 2001).
DNA Extraction and PCR
DNA extraction and PCR were done as have been described previously (Jazayeri et al., in 
press). Briefly, DNA was extracted from the serum samples, then, the 1st round PCR reaction 
was carried out in 50 pi o f a mixture containing 5 pi o f the extracted DNA, using standard 
methodology. The complete core gene was amplified using Cl and C4 primers. The region 
of the surface gene specifying HBV subtype (amino acid positions 122-160) was amplified 
using SI, S2Na primers (Jazayeri et al., in press) to allow an allocation o f the virus to 
subtype. For the second round PCR, 1 pi of first round PCR products was added to 49 pi of 
the reaction mixture with the same composition as the first round except that Cl was replaced 
by C3A, and Sl/S2Na, were replaced by S6C/S7D. PCRs were analyzed by electrophoresis in 
1% agarose gel, stained by ethidium bromide, and visualized under UV light.
DNA Sequencing
After PCR product purification, direct sequencing o f core and surface genes was done as 
described previously (Jazayeri et al., in press) and results were analysed using Sequence 
Navigator software (Applied Biosystems).
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Sequence Analysis
After allocating a sequence to an HBV genotype by analysis o f the S gene, the core gene 
amino acid/nucleotide variations that were found in a majority (> 50%) o f HBcAg sequences 
from a particular island were recorded and compared with HBcAg sequences obtained from 
databases. The adrq- subtype is rarely found in Genbank; o f eight available, six were 
submitted as part o f our studies (Jazayeri et al., in press). These, and two isolates (HMA and 
Cha) published by Norder et al., (7), constituted our reference sequences. No Pacific ayw 
sequence (excluding this study) has been reported in Genbank. Finally, genotype/subtype- 
specific nucleotide and amino acid variations were identified. Sequences have been submitted 
to GenBank, numbered from AY269035 to AY269047, from AY269050 to AY269061 and 
from AY269064 to AY269086. The accession numbers for the previous 10 samples from the 
pilot study were AF324097 to AF3224106. After construction o f simple Neighbour-joining 
Trees based on core and surface proteins, further phylogenetic trees were constructed using 
sequences from the database and from a previous study (Jazayeri et al., in press) for 
comparison.
Phylogenetic Analysis:
Sequences of core and surface genes were aligned using the BioEdit Package version 5.0.9 
(26), and a neighbor joining phylogenetic tree constructed using the Treecon Package (27) 
employing a Kimura distance matrix (28). Associations were tested by bootstrap re-sampling 
analysis using 100 replicates (29). Branches with a bootstrap value o f greater than 70% were 
deemed well-supported by the data.
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Results
Genotype and subtype prevalence in Pacific islands
Table 1 shows the distribution o f genotypes and subtypes o f strains studied from individual 
islands. The following preparations were genotype D: in Kiribati, 13 out of 14; in Fiji, 5 out 
o f 15; in Vanuatu, 1 out of 14; and in Tonga, 2 out of 15. The remaining sequences were 
genotype C. Subtype adrq- was the main subtype in genotype C-occupied islands while ayw2 
was the prevalent one in Kiribati.
Genotype/subtype-specific substitutions common to Pacific region
Comparing genotypes C and D, there were 11 aa variations at 10 positions (table 2): S/T12, 
I/V27, A/S35, D/E40, I/V59, N/T67, S/T74, D/E83, I/V/T91 and F/I97. These variants were 
not island-specific with the exception of V91 found only in Vanuatu.
It was also possible to identify nucleotide variants for genotypes C and D, subtypes adrq- and 
ayw2. Overall, 90 genotype/subtype-specific nucleotide substitutions in 45 positions were 
found (table 3), o f which 67 were silent. 23 were missense (genotype specific) in the 10 
positions detailed above. Interestingly, a majority of adrq- strains derived from Vanuatu (but 
not other islands) contained nucleotide variants identical to ayw (genotype D) in 4 positions: 
78, 138, 234 and 255.
Substitutions that distinguish specific islands
Island-specific nucleotide variants were identified which increased or decreased in frequency 
from West to East (from Vanuatu to Fiji and on to Tonga) (figure 1, table 4). Nucleotide 
changes at positions C36, T109, Cm, G255 and T267 were found in a majority of strains from 
Tonga. On the other hand, changes including C78, T234 A 246> A 255, G271, C354, C366, A454 and 
G510 were predominant in Vanuatu. However, no island-specific nucleotide variants were 
detected in Fiji and Kiribati. All nucleotide changes that were specific to an island group, 
except G271 (which corresponded to residue V91 in Vanuatu), were silent mutations.
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There were six strains from Tonga (3309, 3415, 3417, 3419, 3428 and 3629) and four from 
Vanuatu (5017, 5022, 5230 and 5072) o f genotype C, adrq- subtype, which showed high 
variability at the nucleotide level compared to other Pacific strains (results not shown). 
However, in genotype D-studied strains, the only major heterogeneity was seen in isolate 
2143 from Kiribati. All these strains originated from different cities in each island with 
various HBeAg/anti-HBe status.
Comparison with international database
Choosing the correct reference sequence is mandatory, especially in cross-sectional studies, 
otherwise over- and/or under-estimations can occur. The adrq- subtype is rarely found in 
Genbank; o f eight available, six were submitted as part o f our previous study (Jazayeri et al, 
in press) and two isolates (HMA and Cha), published by Norder et al., (7), constituted our 
reference sequences. No ayw sequence from Pacific (excluding this study) has been reported 
in Genbank. We chose one genotype C from a Chinese (A3 5) and one Indian genotype D 
(0123), both from our pilot study for comparison between corresponding Pacific strains. For 
genotype C, there were 2 amino acid and 12 nucleotide variations between our predominant 
Pacific genotype C sequence and A35 (Chinese reference) (table 5). However, in genotype D, 
we found 5 amino acids and 30 nucleotides different between our Pacific D and 0123 (table 
6).
Phylogenetic Analysis 
Genotype C Tree
Figure 2 shows that all the genotype C sequences, from the pilot study (bold codes), database 
(bold italic codes) and adrq- strains (from this study, italics), grouped into two major clusters. 
The first is completely occupied by Pacific adrq-, including one o f the database sequences, 
X75656 (7); a majority o f strains belonging to Vanuatu composed a major sub-cluster. The
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second cluster contains adrq+ sequences (including from the database) derived mainly from 
S.E Asian populations, which are heterogeneous.
Genotype D Tree
Figure 3 shows alignment of all genotype D sequences. They grouped into 2 major clusters. 
The first, similar to the genotype C tree, was entirely made up of Pacific strains (italic codes). 
The second cluster contained two sub-clusters: the first had those from Western populations 
(a majority from Europe); the second had a combination of Asian and a few European 
sequences. Inside the Euro-Asian cluster, there was an Indian sub-cluster. Unlike genotype C, 
the Pacific genotype D shows relative homogeneity with only a few nucleotide mutations, 
indicating that genotype D arrived recently in the Pacific as a relatively homogenous 
population. We have been unable to identify a likely some of this migration in this study. 
Discussion
The prevalence o f hepatitis B in the South Pacific is amongst the highest in the world. This 
geographic area comprises a unique region of admixing two HBV genotypes, C and D, with 
specific identities which have not been identified in other regions. In a pilot study, analysis of 
ten HBV sequences from 4 Pacific islands showed unique changes in both genotypes C and D 
(Jazayeri et al., in press). This provoked us to investigate another 48 sequences which 
confirmed those.
The intra- and inter-Pacific island nucleotide variations showed that a majority o f such 
variants, despite being silent, were within the known HBcAg immune epitopes, mainly CD4. 
Phylogenetic analysis revealed that both genotypes belonged to a separate Pacific cluster 
(figures 2-3). Comparison with databases samples supported our conclusions. Adrq+ is the 
prevalent subtype in South-East Asia, while adrq- is only found in Oceania. Geographical 
transition from Asian adrq+ to South American adw4q- has been suggested to be via the 
adrq- subtype in Oceania (5). The gradient o f nucleotide and aa variations from west to east
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in our study (shared sequences between Tonga and Fiji and, on the other hand, variations 
between Tonga and Vanuatu), are most consistent with the hypothesis o f migration of 
Polynesian people from Southern China through Melanesia and Fiji and their radiation across 
the Pacific to fill the Polynesian triangle in different times (13, 15, 30-31). In contrast, back 
migration from Polynesia to Melanesia could also be responsible for this variation gradient 
(see below). Of interest is that 10 strains from Vanuatu, all genotype C isolates, constitute a 
subcluster in genotype C tree (figure 2, cluster B). However, two isolates from Vanuatu were 
extremely divergent and found within subcluster A. On the other hand, within the subcluster 
A, 6 strains from Tonga constitute a separate branch (see results). The presence o f different 
strains from all islands (in particular Fiji and Tonga) in cluster A may indicate admixture of 
isolates in Fiji due to its geographical location between other 3 islands (fig 1). The gradient of 
nucleotide substitutions between 3 islands in table 3 showed commonality between Fiji and 
Tonga, rather than Vanuatu. This is in keeping with the history of an isolated Vanuatu.
The contrast between the silent mutations that predominate within Pacific genotype C 
sequences and non-synonymous changes that separate Pacific from the S.E Asian sequences 
is suggestive of an interaction with human genetic variants, especially HLA, in the evolution 
of geographically separated HBV lineages. Once in the Pacific, no further immune mediated 
amino acid selection seems to have occurred, probably because there are only a few Pacific 
HLA types. On the other hand, the significant nucleotide variability is in keeping with 
random mutation in isolated island population.
In contrast, genotype D strains including those from databases showed that the Pacific 
islands contain a unique homogenous cluster separated from other genotype D groups. The 
few D sequences on other islands show a similar homogeneity, indicating recent contact 
between Kiribati (which is almost an isolated island in Micronesia with limited transfer of 
virus-see figure 1) and the genotype C-dominated islands. This suggests that genotype D
1 0
arrived in the Pacific as a relatively homogenous population and has been distributed by 
admixing with stable human populations (Basuni, unpublished data). As Indian immigrants 
usually have genotype D, one might expect Indians to be the origin of genotype D strains in 
this region. However, our results did not show such an acquisition of these new strains by 
migration, there was substantial variability between these two ethnic groups. This is best seen 
as the two separate clusters in figure 3. The study on S genes by Basuni et al, also revealed no 
strong evidence for Indian admixture in Pacific genotype D populations. In fact, results from 
our previous pilot study showed that at the nucleotide level the Pacific genotype D sequences 
were closer to Caucasian strains rather than Indian (results not shown). Thus, a Pacific origin 
for genotype D cannot be ruled out.
Using phylogenetic network analysis (Basuni, unpublished data), Pacific sequences can be 
shown to shared an ancestral lineage most closely related to Japan and China, suggesting an 
immediate Asian origin for genotype C (while, the Pacific genotype D sequences contained a 
completely separate cluster from India). The hypothesized migration of South-East Asian 
peoples out into the Pacific correlates with their commonality of HBV sequences similar to 
the study by Norder et al (7): 37 adrq- strains in genotype C as well as 21 ayw2 in genotype 
D formed a separate cluster that belonged only to the Pacific area (figures 2-3). Thus, the 
divergence of HBV genomes in this area is limited, in keeping with the known low variability 
between genotypes B and C.
To the best of our knowledge, the HBV C genes of Pacific peoples has never been studied. 
There may be implications for the design o f therapeutic vaccines, but, at a minimum, these 
studies reveal that both C and S genes o f HBV have evolved in similar ways in the Pacific. 
Overall, the high diversity for genotype C (including silent mutations) and the island-specific 
sequences, suggest a long history o f evolution and isolation for genotype C-islands. In
1 1
contrast, the low diversity o f genotype D indicates a recent, limited, spread over the rest of 
the Pacific with a single lineage.
1 2
Fig 1- Pacific map showing boundaries o f the Pacific islands and surrounding countries. Fiji 
and Vanuatu located in Melanesia, Tonga and Kiribati located in Polynesia and Micronesia, 
respectively.
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Table 1- Origin and Distribution of HBsAg positive sera that were used in this study as 
well as genomic/subgenomic identification o f Pacific islands strains.
Island Sample
Code
Genotype Subtype Island Sample
Code
Genotype Subtype
Fiji Vanuatu
0142 C adrq- 5022 C adrq-
0143 C adrq- 5072 C adrq-
0314 C adrq- 5073 c adrq-
0349 C adrq- 5075 c adrq-
0480 C adrq- 5081 c adrq-
0550 C adrq- 5093 c adrq-
0800 C adrq- 5114 c adrq-
0880 C adrq- 5311 c adrq-
0026 C adrq- 5186 c adrq-
0075 C adrq- 5230 c adrq-
0078 D ayw2 5264 c adrq-
0079 D ayw2 5265 c adrq-
0092 D ayw2 5017 c adrq-
0456 D ayw2 5029 D ayw2
0470 D ayw2
Tonga Kiribati
3415 C adrq- 2080 c adrq-
3417 C adrq- 2006 D ayw2
3097 C adrq- 2007 D ayw2
3419 C adrq- 2019 D ayw2
3428 C adrq- 2119 D ayw2
3629 C adrq- 2127 D ayw2
3099 C adrq- 2317 D ayw2
3221 C adrq- 2483 D ayw2
3365 C adrq- 2109 D ayw2
3369 C adrq- 2 1 1 0 D ayw2
3519 C adrq- 2117 D ayw2
3309 C adrq- 2143 D ayw2
3509 C adrq- 2039 D ayw2
3414 D ayw2 2084 D ayw2
3343 D ayw2
Table 2. The most frequent differences in core gene amino acid sequences between 
genotypes/subtypes o f the Pacific region.
Amino acid Genotype D Genotype C
Position Subtype ayw Subtype adrq-
12 T S
27 V I
35 A s
40 D E
59 I V
67 T N
74 T S
83 D E
91 T I/V*
97 F I
Each specific amino acid was found in a majority o f strains from each 
genotype/subtype and the combination was unique for that genotype/subtype. Amino 
acids are represented by single letters and are numbered from the beginning o f the core 
gene.
V* was only seen in adrq- strains from Vanuatu.
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Table 3- Unique C-gene nucleotide differences which permit genotypes C and D 
classification.
Nucleotide
Position
Genotype D 
Subtype ayw
Genotype C 
Subtype adrq-
Nucleotide
Position
Genotype D 
Subtype ayw
Genotype C 
Subtype adrq-
34 A T 2 0 0 C A
51 G T 204 A G
6 6 C T 219 T A
75 T G 2 2 1 C G
*
78 C T 228 A G
79 G A 234* T C
81 A - 243 T C
90 T C 249 C A
93 A C 250 C T
96 T c 255* A G/T
103 G T 272 C T
105 G A 288 G A
1 2 0 T G 289 T A
135 T G 308 T C
138° G A 324 C T
159 T A 342 G T
174 A T 348 A T
175 A G 387 C T
180 T G 390 A C
183 C T 396 T C
189 A T 418 C T
192
193
A
C
G
T
435 G A
1 6
Note: Nucleotides represented by single letters and numbered from the beginning of the core 
gene. Dash lines represent no variant specified for that position. Bold numbers and letters 
indicate amino acid altered positions (missense mutations).
*: A majority o f adrq- strains from Vanuatu had C78.
0  A majority o f adrq- strains from Vanuatu had C138. 
adrq- strains from Vanuatu contained T234.
A255 seen in a majority of samples from Vanuatu despite belonging to adrq- subtype.
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Table 4. Nucleotide differences between prevalent strains in Fiji, Tonga and Vanuatu.
Nucleotide Vanuatu Fiji Tonga
Positions/Changes
C36T 1 2 6
C78T 9 6 3
T109C 1 2 6
C114T 0 4 12
A138G 3 9 12
T234C 11 0 3
A246G 10 1 1
G255T 0 2 6
A255T 9 6 2
T267C 0 2 6
G271A 11 1 0
C354T 10 2 0
C366T 10 1 0
A454C 7 2 0
G501A 3 6 12
G510A 11 7 2
1 8
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Table 6- HBcAg nucleotide differences between Pacific genotype D and Indian samples. 
Nucleotide Position Pacific Indian
12 C T
55 T C
57 G T
75 T A
78 C A
103 G T
105 G A
111 G A
120 T A
132 T G
138 G A
189 A G
207 T C
220 A G
221 C G
228 A G
238 G A
239 C T
243 T C
255 A G
267 C T
288 G A
291 C T
294 A G
298 T C
345 T C
346 C A
366 T C
387 C T
418 C T
501 A G
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Fig 2. Neighbour joining phylogenetic tree of core gene sequences o f genotype C from 
Pacific adrq- strains (italic), adr subtypes from the pilot study (bold) and database (bold 
italic). Sequences belonged to Pacific island shown by first island name letter after their 
sample code; F, Fiji; K, Kiribati; T, Tonga and V for Vanuatu. Strains rooted with sample 
198. Figure shows bootstrap value o f >70% and scale denotes percent diversity. Viet= 
Vietnam. Sequence variations of Pacific strains grouped into two sub-clusters, A and B.
24
0 . 1
100
r- 3419 T
----------- 0075 F
3415 T  
3428 T  
L- 0314 F  
—  3417 T 
------------- 3629 T
3097 T 
L- 5017 V
j— 0 8 0 0 F
n 0 4 8 0 F
— 5230 V 
3221 T
—  X 7 5 6 5 6
0550 F
3099 T
0078 F
3309 T
3519 T 
3369 T 
3365 T
3509 T
92 r 0349 F  
—n83,— 0143 F  
L 0142 F  
— 2080 K
88, 50 73 V 
93] i 5022 V 
J L_ 5186 V
!----- 5114 V
 5311
5075 V 
— 5081 V
V
0880 F  
-  5093  
5265 V 
5264 V
V
J
91
A  B 033553
A-50 China 
-------------A B 0 3 3 5 5 7
-  A-36 China 
A-35 China
D 00630
A B 0 1 4 3 7 6
A-23 Japan
88
7 0
- A-9 Korea  
A-55 China 
A-13 Viet 
A-44 China 
A-10 Korea
A-20 Japan
- D 1 2 9 8 0
r A-8 Korea
rL A-2 Korea 
-------------------- A-3 Korea
A -l Korea
A-5 Korea  
-  A  F 241411
A-24 Japan
A-54 China
A-21 Japan
U3 USA
A-53 China 
A-32 China
A B 0 3 1 2 6 5  
----------- A B 0 3 1 2 6 2
L d Z
- 5072 V 
X 75665
A-37 China 
A-51 China
A-41 China
-  A-49 China 
 A-52 China
A-40 China
198
2 5
Fig 3. Neighbour joining phylogenetic tree of core gene sequences o f genotype D from the 
Pacific (italic), pilot study (bold) and database (bold italic) ayw strains, rooted with samples 
198. Sequences belonged to Pacific island shown by first island name letter after their sample 
code; F, Fiji; K, Kiribati; T, Tonga and V for Vanuatu. Strains rooted with sample 198. 
Figure shows bootstrap value of >70% and scale denotes percent diversity. Indi=India, Scot= 
Scotland.
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